

Natural Pathogens of Laboratory Mice, Rats, and Rabbits and Their Effects on Research

DAVID G. BAKER*

*Division of Laboratory Animal Medicine, School of Veterinary Medicine,
Louisiana State University, Baton Rouge, Louisiana 70810*

INTRODUCTION	233
Historical Perspective	233
Infection versus Disease	233
Scope of the Review	233
MICE AND RATS	234
Respiratory System	234
Viruses	234
(i) <i>Pneumonia virus of mice</i>	234
(ii) <i>Sendai virus</i>	234
Bacteria	234
(i) <i>CAR bacillus</i>	234
(ii) <i>Klebsiella pneumoniae</i>	235
(iii) <i>Mycoplasma pulmonis</i>	235
(iv) <i>Streptococcus pneumoniae</i>	235
Fungi	236
(i) <i>Pneumocystis carinii</i>	236
Digestive System	236
Viruses	236
(i) <i>Cytomegalovirus</i>	236
(ii) <i>Mouse parvovirus type 1</i>	236
(iii) <i>Mouse rotavirus</i>	237
(iv) <i>Rat rotavirus-like agent</i>	237
(v) <i>Mouse thymic virus</i>	237
(vi) <i>Reovirus type 3</i>	237
Bacteria	238
(i) <i>Helicobacter</i> spp.	238
(ii) <i>Citrobacter rodentium</i>	238
(iii) <i>Clostridium piliforme</i>	238
(iv) <i>Pseudomonas aeruginosa</i>	239
(v) <i>Salmonella enteritidis</i>	239
Parasites	240
(i) <i>Giardia muris</i>	240
(ii) <i>Spironucleus muris</i>	240
(iii) <i>Oxyuriasis</i> (pinworms).....	240
Dermal System	241
Viruses	241
(i) <i>Mouse mammary tumor virus</i>	241
Bacteria	241
(i) <i>Pasteurella pneumotropica</i>	241
(ii) <i>Staphylococcus aureus</i>	241
(iii) <i>Corynebacterium</i> spp. in athymic mice.....	241
Parasites	242
(i) <i>Acariasis</i> (mite infestation).....	242
Hematopoietic System	242
Viruses	242
(i) <i>Lymphocytic choriomeningitis virus</i>	242
(ii) <i>Lactate dehydrogenase-elevating virus</i>	242
Central Nervous System	243
Viruses	243

* Mailing address: Division of Laboratory Animal Medicine, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70810. Phone: (504) 346-3145. Fax: (504) 346-5705. E-mail: baker_d@vt8200.vetmed.lsu.edu.

(i) Theiler's murine encephalomyelitis virus	243
Multiple and Miscellaneous Systems.....	243
Viruses	243
(i) Adenoviruses	243
(ii) Ectromelia virus	243
(iii) H-1 virus	244
(iv) Kilham rat virus	244
(v) Minute virus of mice	244
(vi) Mouse hepatitis virus	244
(vii) Sialodacryoadenitis virus	245
Bacteria	245
(i) <i>Corynebacterium kutscheri</i>	245
Parasites.....	246
(i) <i>Encephalitozoon cuniculi</i>	246
RABBITS.....	246
Respiratory System.....	246
Bacteria	246
(i) <i>Bordetella bronchiseptica</i>	246
(ii) CAR bacillus	246
(iii) <i>Pasteurella multocida</i>	246
Digestive System	247
Viruses	247
(i) Adenovirus.....	247
(ii) Rabbit enteric coronavirus	247
(iii) Lapine parvovirus	247
(iv) Rabbit oral papillomavirus	247
(v) Rotavirus.....	247
Bacteria	248
(i) <i>Clostridium piliforme</i>	248
(ii) <i>Clostridium spiroforme</i>	248
Parasites.....	248
(i) <i>Cryptosporidium parvum</i>	248
(ii) <i>Eimeria stiedae</i>	248
(iii) Intestinal coccidiosis	249
(iv) <i>Passalurus ambiguus</i>	249
Dermal System	249
Viruses	249
(i) Cottontail rabbit (Shope) papillomavirus	249
Bacteria	249
(i) <i>Staphylococcus aureus</i>	249
(ii) <i>Treponema cuniculi</i>	249
Parasites.....	250
(i) <i>Cheyletiella parasitivorax</i>	250
(ii) <i>Psoroptes cuniculi</i>	250
(iii) <i>Sarcoptes scabiei</i>	250
Fungi.....	250
(i) Dermatophytes	250
Genitourinary System.....	250
Viruses	250
(i) Rabbit hemorrhagic disease virus	250
Parasites.....	250
(i) <i>Encephalitozoon cuniculi</i>	250
Multiple Systems.....	251
Viruses	251
(i) Coronavirus (pleural effusion disease/infectious cardiomyopathy virus).....	251
(ii) Myxoma virus	251
Bacteria	251
(i) <i>Listeria monocytogenes</i>	251
(ii) <i>Francisella tularensis</i>	252
ANIMAL HOUSING FOR PATHOGEN EXCLUSION OR CONTAINMENT	252
HEALTH-MONITORING PROGRAMS	252
FUTURE TRENDS	252
REFERENCES	252

INTRODUCTION

Historical Perspective

Weisbroth (714), in an excellent review of the historical struggle against pathogens of laboratory rodents, divides the last 100 years of research involving laboratory animals roughly into three periods. The first, from 1880 to 1950, was the period of domestication, during which many rodent species became much-used research subjects. Many of these original stocks harbored a variety of natural, or indigenous, pathogens. However, during this period, many improvements were made in sanitation, nutrition, environmental control, and other aspects of animal husbandry. The result was a great reduction in the range and prevalence of pathogens found in laboratory animals. The second period, from 1960 to 1985, was the period of gnotobiotic derivation, when cesarean rederivation was exploited as a means of replacing infected stock with uninfected offspring. In this procedure, full-term fetuses are removed from an infected dam and transferred to a germ-free environment and foster care. This procedure was very successful in eliminating pathogens not transmitted in utero. Weisbroth has described the third period, from 1980 to 1996, as the period of eradication of the indigenous murine viruses. In this period, additional pathogens dropped from the scene or were found less and less often. These reductions were accomplished through serologic testing of animals for antibodies to specific pathogens and subsequent elimination or cesarean rederivation of antibody-positive colonies, in addition to continued advances in animal husbandry methods. Pathogen prevalence studies have been (475) and continue to be (234) conducted. Examination of several of these reports from past decades as well as the present one will confirm the steady decline in the range and extent of microbiological contamination in laboratory colonies.

To put things another way, someone has summarized the advances in laboratory animal disease control in the following way: At the turn of the century, an investigator might have said, "I can't do my experiment today because my rats are all dead"; at the midpoint of the current century, an investigator might have said, "I can't do my experiment today because my rats are all sick"; while today, an investigator might say, "I can't do my experiment today because my rats are antibody positive." Surely there has been a steady increase in the awareness of the varied and generally unwanted effects of natural pathogens in laboratory animals and there have been ever-greater efforts to exclude pathogens from research animals. Only when laboratory animals are free of pathogens which alter host physiology can valid experimental data be generated and interpreted.

Infection versus Disease

In interpreting the microbiologic status of laboratory animals, it must be understood that infection is not synonymous with disease (475). Infection simply indicates the presence of microbes, which may be pathogens, opportunists, or commensals, of which the last two are most numerous (475). Few agents found in laboratory animals today cause overt, clinical disease. It is hoped that investigators will appreciate that overt disease need not be present for microorganisms to affect their research. Animals that appear normal and healthy may be unsuitable as research subjects due to the unobservable but significant local or systemic effects of viruses, bacteria, and parasites with which they may be infected. Microbiology and serology reports should be interpreted with the assistance of a veterinarian trained in laboratory animal medicine. Such a

professional can assist the investigator in determining the significance of organisms reported.

As accrediting and funding bodies increase their scrutiny of pathogen status and, by inference, the experimental suitability of the animals used in sponsored research, investigators will also want to work with a laboratory animal veterinarian or animal facility manager to ensure that laboratory animals are obtained from reputable, pathogen-free sources and are maintained under conditions that preclude, as much as possible, the introduction of pathogens. It is far better to prevent the introduction of pathogens than to have to account for their presence when interpreting experimental results. At this point, it is appropriate to mention another valid reason for preventing pathogen entry into an animal facility: in some cases, the drugs used to clear pathogens will themselves alter the host physiology and interfere with research. For example, parasiticides with proven immune system-modulating activity include ivermectin (53), levamisole (82), and thiabendazole (676). Additionally, chlorpyrifos, an organophosphate occasionally used to treat mite infestations, has been reported to decrease brain acetylcholinesterase activity in mice (515).

Scope of the Review

This review is intended to inform clinical and other research scientists, laboratory animal veterinarians, and students of laboratory animal medicine of the known or potential effects of natural pathogens of laboratory mice, rats, and rabbits, on host physiology and subsequently on research efforts involving those laboratory animal species. I have tried to include what I consider the most important infectious agents currently found in laboratory animals. The review is not intended to include pathogens that were historically prevalent and important but are no longer so or are only very rarely found in modern animal facilities. Additionally, efforts have been made to include as much information as possible from natural outbreaks of disease. However, a considerable amount of information has also been included from experimental infections when the conditions of infection, e.g., the route and dose, were compatible with those of natural infections. Some information from *in vitro* studies has been included when that information seemed relevant. Information from infections induced by abnormal routes has been, for the most part, excluded.

This review is intended to add current information to the excellent body of literature previously published by others, for example Lussier (409) and, more recently, the National Research Council (475). In this regard, special recognition is due the many authors who contributed to the latter publication; it is an outstanding reference on the subject of infectious diseases of mice and rats. I have drawn heavily from that resource and wish to acknowledge this fact. The interested reader is directed there for additional information about the history, biology, and pathophysiology of specific pathogens, as well as for specific references pertaining to the effects of pathogens on mice and rats.

The reader may notice that considerably more information is presented on the effects of natural pathogens of mice and rats than on those of rabbits. This reflects the disparity between what is known about the pathogens of these species. Mice and rats have achieved a level of use in biomedical research unparalleled by other species, including rabbits. Consequently, far greater efforts have been made to identify the effects of pathogens in mice and rats. In addition, many of these infections serve as useful models of human infections or disease mechanisms and have therefore been more extensively studied than those of rabbits.

The review is organized first by the host species, then by the body system affected, and lastly by the pathogen. This organization of material best facilitates the finding of information concerning the pathogens that affect specific body systems, as well as information on specific pathogens.

MICE AND RATS

Respiratory System

Viruses. (i) Pneumonia virus of mice. Pneumonia virus of mice is a single-stranded RNA (ssRNA) virus of the family *Paramyxoviridae*, genus *Pneumovirus*. Transmission is via aerosol and contact exposure to the respiratory tract (450). Active infections are short-lived and generally without clinical signs in euthymic mice and rats, and there is no carrier state (61, 475). In contrast, athymic (*nu/nu*) mice develop chronic pneumonia and wasting and die (550). Pathologic lesions have not been reported in naturally infected mice or rats. Experimental intranasal infections of mice have resulted in mild rhinitis and interstitial pneumonia (91). The susceptibility of mice and rats may be increased by a variety of local and systemic stressors (475), and immune responsiveness is strain dependent (584). Experimentally infected athymic mice develop persistent interstitial pneumonia (92). While natural infections appear to be of little consequence in immunocompetent rodents, pneumonia virus of mice infection could alter the pulmonary architecture and interfere with immunological studies (409). Natural infection of athymic mice results in death and would therefore confound studies with such animals.

(ii) Sendai virus. Sendai virus (SV) is one of the most important pathogens of mice and rats (475). Hamsters may also be infected, although their infection is asymptomatic. SV is an ssRNA virus of the family *Paramyxoviridae*, genus *Paramyxovirus*, and species parainfluenza 1. Multiple strains have been described (565). SV is extremely contagious, and transmission is via contact and aerosol infection of the respiratory tract (302, 475). Natural infection of rats with SV is generally asymptomatic, with only minor effects on reproduction and growth of pups (415). Natural infections of mice present as enzootic or epizootic infections. Enzootic infections are those endemic to a colony, where the constant supply of susceptible animals maintains the infection. Mice are infected shortly after weaning as maternal antibody levels wane, and they show few clinical signs. Since there is no carrier state, cessation of breeding eventually results in elimination of the infection, although antibody titers remain in previously infected animals. Epizootic infections occur upon first introduction of the virus to a colony. Clinical signs may include teeth chattering, dyspnea, prolonged gestation, poor growth, and death of young mice (475). Where breeding is occurring, the enzootic pattern eventually takes over.

SV contains HN protein, with hemagglutinating and neuraminidase activities, and F glycoprotein, with cell fusion, cell entry, and hemolytic activities (475, 641). Conversion of the F glycoprotein to the active form is dependent on host proteases and is inhibited by pulmonary surfactant (643). However, there are considerable differences in susceptibility to SV among both rat and mouse strains. Among rat strains, LEW and Brown Norway (BN) rats are more susceptible than F344 rats (400, 606). Among mouse strains, 129/J and DBA strains are among the most susceptible and SJL/J and C57BL/6J are among the most resistant (322, 452, 453, 475). Because of these strain differences in susceptibility, pathologic lesions vary in severity. The hallmark of SV infection is transient hypertrophy, necrosis, and repair of airway epithelium as the virus descends the

respiratory tract. Repair of airway epithelium results in epithelial hyperplasia, squamous metaplasia, and syncytial cell formation (475). Upon reaching the lungs, focal interstitial pneumonia occurs, with inflammatory and hyperplastic changes being most severe around terminal bronchioles, in contrast to infection with *Mycoplasma pulmonis*, which affects more proximal airways. The lungs appear focally reddened. Viral replication occurs in the respiratory tract for only about 1 week postinfection, so lesions resolve quickly and eventually consist only of loose peribronchiolar and perivascular lymphocyte cuffing. Lesions are more severe and varied when additional pathogens such as *M. pulmonis* are present. Aged (329) and immunodeficient mice and rats infected with SV develop a severe form of pneumonia, with delayed viral clearance (475, 516).

There is a considerable volume of literature on immune responses to SV (113, 194, 223, 238, 304–308, 310, 313, 452, 453, 492, 516, 657, 658). Immunity to SV is both cell and antibody mediated. Natural infection with SV could profoundly interfere with a wide variety of research efforts involving mice and rats, since SV has been shown to affect rodents in many ways. Reported effects include interference with early embryonic development and fetal growth (390); alterations of macrophage, natural killer (NK) cell, and T- and B-cell function (77, 108, 205, 223, 227, 332, 333, 347, 552); cytokine and chemokine production (123, 310); bronchiolar mast cell populations (606); pulmonary hypersensitivity (122, 607); isograft rejection (625); airway physiology (566, 737, 743); response to transplantable tumors (427) and lung allografts (728); neoplastic response to carcinogens (513); apoptosis rates (658); and wound healing (348). Recently, SV has been used experimentally as a gene vector (654, 741). Natural infection would, of course, interfere with such studies.

Bacteria. (i) CAR bacillus. Cilia-associated respiratory (CAR) bacillus is a relatively recently identified pathogen of wild (73) and laboratory rats and, to a lesser extent, mice and rabbits; it has been used in experimental infections of guinea pigs and hamsters (598). CAR bacillus is a gram-negative, filamentous rod of uncertain classification. Analyses of small-subunit rRNA sequences indicate that rat-origin CAR bacillus may be closely related to *Flavobacterium ferrugineum* and *Flexibacter sancti* (711). Recent studies suggest that CAR bacillus isolates of rat and rabbit origins may be distinct strains and suggest that, in mice, isolates of rat origin may be more virulent than those of rabbit origin (136). Transmission is probably via contact exposure to the respiratory system (323, 426). Current information suggests that CAR bacillus is usually a copathogen (135), most prominently of *M. pulmonis* in rats, and that it exacerbates lesions of murine respiratory mycoplasmosis (MRM) (254). However, primary infection of rats with CAR bacillus has been recently reported (439). The clinical signs following natural CAR bacillus infection that have been reported for rats are similar to those of severe murine respiratory mycoplasmosis (see the discussion of *M. pulmonis*, below) and include hunched posture, lethargy, rough coat, and periocular porphyrin staining (425, 475). Lesions of CAR bacillus infection are similar to those of MRM, and the reader is referred to that section for a full description. In addition, CAR bacillus infection produces severe bronchiolectasis, pulmonary abscesses, and atelectasis of entire lung lobes (425, 475). These lesions are due mainly to accumulation of pus in the airways. Large numbers of CAR bacilli can be observed between cilia on respiratory epithelial surfaces and cause the ciliated border to appear dense. Lesions may also be found on epithelial surfaces in nasal passages, larynx, trachea, and middle ears (475). Lesions have been observed in mice of the ICR strain

experimentally infected with CAR bacillus (598), and lesions compatible with CAR bacillus infection have been reported in C57BL/6J-*ob/ob* mice, although these latter mice may have also been infected with SV and/or PVM (254). Information is lacking concerning effects of natural CAR bacillus infection on rats and mice. However, one might expect that CAR bacillus infection could contribute to the morbidity and mortality associated with MRM and could compromise studies of the respiratory system.

(ii) *Klebsiella pneumoniae*. *Klebsiella pneumoniae* is a gram-negative bacterium normally inhabiting the intestinal tract of rats, mice, and numerous other animals. Reports of clinical disease in immunocompetent rodents are rare (208, 275, 325, 579), and *K. pneumoniae* is therefore considered an opportunistic pathogen (475). The prevalence in rodent colonies is high and may increase with antibiotic treatment which eliminates other bacteria (272). Transmission is primarily fecal-oral; aerosol transmission is effective (58). Clinical signs in mice most commonly include dyspnea, sneezing, cervical lymphadenopathy, inappetence, hunched posture, and rough coat (208, 579), and those in rats include cervical and inguinal abscesses (275, 325). Following hematogenous spread, focal abscess formation can occur in any organ. In the lungs of mice, this results in granulomatous pneumonia. Clinical signs in immunocompromised rodents are generally more severe.

The majority of clinical *K. pneumoniae* isolates produce a high-molecular-weight capsular polysaccharide, which is one of the dominant virulence factors (289). Immunity is age related (708); is directed against lipopolysaccharide (LPS) and related antigens (542); involves interleukin-1 (IL-1) (693), IL-8 (692), IL-12 (250), leukotrienes (19), chemokines (613), tumor necrosis factor (TNF) (381), TNF- α -mediated mast cell chemoattraction (417) (which may be influenced by macrophage inflammatory protein type 2 [252]), neutrophil activity (315), and production of defensins (357); and may be inhibited by IL-10 (251). Rats and/or mice infected with or exposed to products from *K. pneumoniae* serve as models of pneumonia (106, 290), endotoxemia (480, 686), sepsis (163, 293), cystitis and pyelonephritis (87), antibiotic pharmacokinetics (174, 265), host resistance (418), riboflavin metabolism (72, 537), and human phacoantigenic uveitis (738). In addition, infection has been shown to lower thyroxine levels in plasma (72). Natural primary or opportunistic infection of laboratory mice and rats would interfere with such studies.

(iii) *Mycoplasma pulmonis*. *M. pulmonis* is, without question, one of the most important pathogens infecting laboratory rats and mice, and is the cause of MRM. *M. pulmonis* lacks a cell wall and has membrane-associated hemolytic activity (447). Prevalence rates can be high within animal facilities. Transmission is primarily intrauterine and by aerosol (302, 475, 618). The organism readily establishes infection by colonizing the nasopharynx and middle ears (145). Infection is usually asymptomatic, causing some researchers to consider *M. pulmonis* a commensal under ideal conditions (475). Its pathologic effects vary, depending on a variety of host, organismal, and environmental factors (314, 475, 580), including concurrent infection with copathogens (582). Levels of susceptibility differ according to host stock and strain (94, 96, 198, 380, 433). In this regard, the most resistant mouse strains include C57BR/cdJ, C57BL/6Ncr, C57BL/10ScNcr, and C57BL/6J (93). Clinical signs typically follow chronic infection and include "snuffling" in rats and "chattering" in mice, dyspnea, weight loss, hunched posture, lethargy, and, in rats, periocular and perinasal porphyrin staining (475). Mice may be asymptomatic. *M. pulmonis* preferentially colonizes the luminal surfaces of respiratory epithelium lining the proximal airways. This characteristic gave

rise to the earlier designation of "proximal airway disease" (475).

Grossly, the lungs appear focally consolidated and airways contain a highly viscous exudate. Microscopically, the spectrum of pathologic changes may include rhinitis, otitis media, laryngitis, tracheitis, suppurative bronchitis, bronchiectasis, pulmonary abscesses, and alveolitis (475, 517). *M. pulmonis* is a mitogen for rat lymphocytes and induces the hyperplasia of bronchus-associated lymphoid tissue (472, 473) which is a histologic hallmark of MRM in rats. The severity of airway disease may be influenced by profiles of cytokine production (199), by interactions with sensory nerve fibers (68), and by alveolar macrophage viability (147). Immunodeficient mice are equally susceptible to pneumonia and death compared to immunocompetent mice and may develop severe arthritis following infection with *M. pulmonis* (96, 192). Genital mycoplasmosis also occurs, particularly in LEW rats (85, 96). A recent study demonstrated that the time of infection plays a major role in determination of pregnancy outcome and spread of infection from the genital tract to the respiratory tract (75).

In mice, humoral responses contribute to but do not guarantee protection from systemic infection (94) while in rats, cellular immunity is more important (96). Immune system responsiveness is age related (617). *M. pulmonis* may disseminate widely throughout the host and therefore may alter the experimental results in numerous ways. The effects thus far reported include alteration of (i) pulmonary carcinogen and immune responses, ciliary function, and cell kinetics; (ii) reproductive efficiency; (iii) adjuvant- and collagen-induced arthritis; and (iv) systemic immune responses (199, 475, 557). *M. pulmonis* infection in mice is an invaluable model for the study of host defenses against respiratory mycoplasmas *in vivo*, including those of *M. pneumoniae*, an important worldwide cause of human death and disability (94, 146). Natural infection of laboratory rats and mice could seriously impair research efforts investigating a variety of body systems, primarily the respiratory, reproductive, and immune systems.

(iv) *Streptococcus pneumoniae*. *Streptococcus pneumoniae* is a gram-positive diplococcus commonly found in laboratory rodent colonies. More than 80 strains, grouped by capsular type, have been reported. Transmission is primarily via aerosol from infected humans. The organism is considered a commensal under most conditions, although host strain susceptibility differences have been reported (638). Typically, a carrier state is established in the nasal passages and middle ears. Clinical signs are uncommon, although natural outbreaks of disease have been reported (475). When present, clinical signs are nonspecific and may include dyspnea, weight loss, hunched posture, and snuffling (475). Virulence is related to several bacterial components, most prominently pneumolysin, a multifunctional toxin with distinct cytolytic and complement-activating activities (156, 561, 709). Infection begins in a bronchopulmonary segment and spreads centrifugally (475). The infection spreads from the lung to the pleura, pericardium, and, via septicemic spread, to the rest of the body. The affected lung is first edematous, then becomes consolidated and eventually is cleared of cellular debris (733). There may be suppurative or fibrinous lesions throughout the respiratory tract and adjacent structures. These most commonly include suppurative rhinitis and otitis media (475) but may also include similar changes in and around the deeper tissues of the respiratory tract. Septicemia may result in suppurative lesion establishment in virtually any organ, with death being a common sequela. Athymic mice are not more susceptible to disease (727). Host immunity is primarily humoral (16, 563, 677), with considerable help from the complement and mononuclear phagocytic systems (475), C-re-

active protein (633, 634), TNF- α (637), and pulmonary surfactant (651). IL-10 production is induced following *S. pneumoniae* infection and attenuates the proinflammatory cytokine response within the lungs, hampers effective clearance of the infection, and shortens survival (678). Rats and mice experimentally infected with *S. pneumoniae* serve as models of respiratory tract infection (638), peritonitis (220), meningitis (624), otitis media (410), and the effects of exercise on the course of bacterial infections (318). Natural infections of laboratory rats and mice with *S. pneumoniae* have been shown to alter hepatic metabolism, levels of biochemicals in serum, blood pH and electrolytes, thyroid function, and respiratory parameters (475) and could be expected to interfere with a variety of studies depending on the bacterial distribution following septicemic spread. The cost of eliminating the organism from colonies must be evaluated in light of the intended use of the animals.

Fungi. (i) *Pneumocystis carinii*. *Pneumocystis carinii*, recently classified as a fungus (626), inhabits the respiratory tracts of laboratory mice and rats. It is a pathogen only under conditions of induced or inherent immunodeficiency. Transmission is via inhalation of infective cysts (608). Placental transmission does not occur (321). Recent studies have demonstrated differences in host specificity (38, 589, 712) and susceptibility (366). Clinical signs are absent in immunocompetent animals. Infection has been detected and clinical signs have been induced following several weeks of corticosteroid administration (629). Clinical signs in immunosuppressed or immunodeficient mice and rats include wasting, rough coat, dyspnea, cyanosis, and death (475). The lungs are enlarged, dark, and rubbery. Microscopic changes include alveolar septal thickening and alveolar filling with foamy, eosinophilic material consisting of organisms, dead host cells, serum protein, and pulmonary surfactant (104, 150, 186, 446). Pneumonia may be exacerbated by the presence of coinfecting pneumotropic pathogens (29, 559). The attachment of *P. carinii* to lung cells may play a role in the pathophysiology of *P. carinii* pneumonia (5) and may be enhanced by surfactant-associated protein A (725).

Immunity is age related (229) and occurs via both humoral and cell-mediated mechanisms, with macrophages and neutrophils playing major roles in killing organisms (41, 249, 270, 361, 388, 420). Glycoprotein A is the immunodominant antigen of *P. carinii* (232). *P. carinii* has been demonstrated to alter alveolar capillary membrane permeability (740) and uptake of tracheally administered compounds (455) and to elevate TNF (361), IL-1 (103), IL-6 (102), arachidonic acid metabolite (97), and surfactant-associated protein A (524) levels. Mice and rats have been used as models of opportunistic human *P. carinii* pneumonia (15, 373, 531, 536). Infected mice and rats are likely to develop severe pneumocystosis following immunosuppression and will be rendered unsuitable for most experimental purposes.

Digestive System

Viruses. (i) Cytomegalovirus. Cytomegaloviruses (CMVs) are dsDNA viruses of the family *Herpesviridae*, subfamily *Betaherpesvirinae*. Mouse cytomegalovirus (MCMV) is commonly found in wild mice, principally in the submandibular salivary glands (475). Its prevalence in laboratory colonies is thought to be much lower, although survey results are affected by the screening method. Because the salivary glands are persistently infected, transmission is via contact with infectious saliva. Vertical transmission may also occur (662). Aside from the salivary glands, latent infections can occur in the kidneys, prostate, pancreas, testicles, heart, liver, lungs, spleen, neurons of the cerebral cortex and hippocampus, and cells of the myeloid

lineage and are directly correlated with the extent of viral replication during acute infection (117, 448, 502, 532, 662). Natural infections of immunocompetent mice with MCMV are subclinical. Pathologic changes are limited to finding intranuclear inclusions in enlarged (cytomegalic) salivary gland cells (502). In addition, experimental infection results in adrenalitis without compromise of adrenal function (538). The effects of experimental infection are dependent on a variety of host factors, with newborn and immunocompromised mice being more susceptible than adult immunocompetent mice (176, 475). Lathbury et al. (387) reported that BALB/c and A/J mice are more susceptible to infection than are C57BL/10 and CBA/CaH mouse strains, whereas Dangler et al. (141) reported that C57BL/6 mice infected with MCMV develop inflammatory lesions affecting the ascending aorta and pulmonary artery more readily than do BALB/c mice. In addition, multiple natural and experimental strains of MCMV differing in virulence have been reported (63, 224). Immunity is primarily cell mediated, with CD8⁺ T cells and NK cells playing critical roles in controlling MCMV replication (387, 500). Monoclonal antibodies against MCMV antigens have been shown to cross-react with host proteins, suggesting a potential autoimmune component to immunity analogous to that described in humans (391). CMVs have recently been recognized as having superantigen activity (312). Natural MCMV infection has not been shown to interfere with research results. However, experimental infection may alter a variety of host physiologic functions, including depression of antibody and interferon production, major histocompatibility complex (MHC) class I-restricted antigen presentation, CD4⁺ lymphocyte numbers in bronchoalveolar lavage fluid, lymphocyte proliferation, cytotoxic lymphocyte responses, and allogeneic skin graft rejection; decreased fecundity; thrombocytopenia; exacerbation of normal cardiac calcification in BALB/c mice; formation of anticardiac autoantibodies; increased susceptibility to opportunistic infections; and induced reactivation of dormant *Toxoplasma gondii* infection (241, 475, 491, 534, 644).

Natural cases of rat cytomegalovirus (RCMV) have been reported in wild but not laboratory rats (81, 475). The biology and pathophysiology of experimental RCMV infection is similar to that of MCMV infection, and the reader is referred to the above description of MCMV for that information. Experimental RCMV infection has been reported to alter macrophage function, the response to sheep erythrocytes, and peripheral lymphocyte subsets; exacerbate the development of collagen-induced arthritis; induce vascular wall inflammation; enhance smooth muscle cell proliferation and intimal thickening of rat aortic allografts; and induce interstitial lung disease in allogeneic bone marrow transplant recipient rats independent of acute graft-versus-host response (255, 256, 364, 397, 475, 610, 612). Mice and rats are commonly used as models of human CMV infection (228, 349, 454, 593, 661), and CMV particles and promoters have recently been used in gene vector research (271, 595). Natural infection of these and other laboratory mice and rats could confound research through alteration of a variety of immunological and other functions.

(ii) Mouse parvovirus type 1. Mouse parvovirus type 1 (MPV-1), formerly known as orphan parvovirus, is a recently recognized and very important pathogen of laboratory mice. The prevalence of infection appears to be high within and among rodent facilities, although many colonies have yet to be screened. Three isolates (MPV-1a, MPV-1b, and MPV-1c) of one serotype have been reported (328). MPV-1 is an ssDNA virus of the family *Parvoviridae*. Like other parvoviruses, MPV-1 requires actively dividing or differentiating cells for survival. The virus is shed via urinary, fecal, and perhaps re-

spiratory routes (605). Transmission is therefore most probably primarily direct, although extensive transmission studies have yet to be conducted (605). Transmission may also occur following experimental exposure to selected, infected T-cell lines (434). Natural infections of mice are generally asymptomatic and apathogenic, even for neonatal and immunocompromised mice (605). In immunocompetent mice, viral replication occurs in the pancreas, small intestine, lymphoid organs, and liver and may persist for several weeks (331, 605). Viral replication is more widespread in immunodeficient mice (605). MPV-1 has some antigenic cross-reactivity with minute virus of mice, another rodent parvovirus, due to two highly conserved nonstructural proteins (23, 49, 328). MPV-1 affects processes linked to cell proliferation. Reported effects include direct modulation and dysfunction of T lymphocytes and altered patterns of rejection of tumor and skin allografts (435). It is anticipated that additional effects will be reported as more studies are conducted on this important virus. Recently, a new parvovirus of rats, designated RPV-1, has been identified (327). To date, little is known about the virus. However, RPV-1 may suppress the development of lymphoid tumors (327).

(iii) Mouse rotavirus. The disease caused by mouse rotavirus, formerly known as epizootic diarrhea of infant mice, is commonly diagnosed in young laboratory mice with diarrhea. Rotaviruses are dsRNA viruses of the family *Reoviridae*. Mouse rotavirus is a member of the group A rotaviruses, which are known to infect a variety of vertebrate hosts, including humans. Multiple strains of mouse rotavirus have been identified (84, 316). Infection is highly contagious and is acquired through exposure to contaminated airborne dust and bedding and through contact with infected mice. There is no evidence of transplacental transmission (475). Mice are most susceptible from birth to about 2 weeks of age, possibly due to transient features of intestinal enterocytes (475). Virus is shed in the feces for up to about 10 days postinfection. It remains uncertain whether a carrier state, with persistent, low-level fecal virus shedding exists.

Clinical signs generally are seen only in mice infected within the first 2 weeks of life and include watery, mustard-colored stool; lethargy; and distended abdomen. Infection and pathologic changes progress from the proximal to distal intestine. Apical villous enterocytes are primarily affected, while crypt cells are largely spared (404). Affected enterocytes may be vacuolated and contain pyknotic nuclei. Malabsorption and osmotic diarrhea with overgrowth of *Escherichia coli* may contribute to the clinicopathologic pattern (517). Athymic (*nu/nu*) mice are no more susceptible to rotavirus disease than are normal mice (183). In contrast, mice with severe combined immunodeficiency (*scid/scid* mice) are more severely affected (551). Rotavirus may bind to mouse intestinal cells via a subset of sialylated glycoconjugates, i.e., glycoproteins containing O-linked sialic acid moieties (726). This conclusion is consistent with the observation that intestinal mucins inhibit rotavirus infection and may represent a barrier to infection (101).

Immunity to rotavirus infection in mice occurs through the activities of several effector components, including antibodies, antigen-presenting cells, and T lymphocytes (80, 84, 436, 438, 707). Protection may be related to the intestinal replication properties of the virus rather than to specific immunogenic properties of specific viral proteins (437). Rotavirus alters host physiology in many ways and may therefore confound research. Infected mice are more susceptible to the pathologic effects of copathogens (481) and have alterations in intestinal physiology (116, 317). In addition, rotavirus infection may alter results of dietary and nutritional studies (463, 488, 564). The rotavirus-infected mouse serves as a model of human rotavirus diarrhea,

which is responsible for the deaths of approximately 800,000 children per year (217). Natural infection of laboratory mice with rotavirus would confound such research efforts and may interfere with other studies involving the gastrointestinal system.

(iv) Rat rotavirus-like agent. Rat rotavirus-like agent (RVLA), like mouse rotavirus, is a dsRNA virus in the family *Reoviridae*. Unlike mouse rotavirus, however, RVLA has been tentatively classified as a group B rotavirus (696). The natural hosts of RVLA include rats and humans. It has yet to be grown in culture. Transmission is probably via direct contact with contaminated feces, fomite transmission, human contact, and possibly airborne spread of contaminated dust and bedding (475). Clinical signs are seen in rats 1 to 11 days of age and consist of poor growth, diarrhea, and perianal dermatitis (695). These signs led to the designation "infectious diarrhea of infant rats." Pathologic changes include watery, discolored proximal small-intestinal contents; villous atrophy and epithelial necrosis; increased crypt depth; and syncytial cell formation (569, 695). RVLA infection results in a net secretory state for water and in impaired sodium absorption (568, 569). Relatively little is known about immune mechanisms in RVLA infection, but it is likely that there are similarities to immunity to mouse rotavirus infection. In addition to acquired immunity, intestinal mucins may inhibit rotavirus replication and may be dependent on specific mucin-virus interactions (739). Natural infection of rats with RVLA would probably confound studies involving the intestinal system.

(v) Mouse thymic virus. Relatively little is known of mouse thymic virus (MTV) due to the inability to culture the virus in vitro. MTV is considered a member of the *Herpesviridae*, which are dsDNA viruses. Transmission appears to be via direct contact (623) and possibly via transmammary passage (464). Natural infections are subclinical. Pathologic changes are limited to transient lymphoid necrosis of the thymus, lymph nodes, and spleen of neonatal mice, followed by a diffuse granulomatous response with giant cells, which eventually resolves (732). The thymus is most severely affected, especially lymphocytes, epithelial reticular cells, macrophages, and lymphoepithelial cell complexes (thymic nurse cells). CD4⁺ CD8⁺ and CD4⁺ CD8⁻ lymphocytes are selectively lysed by MTV (17). Both T-helper and T-cytotoxic lymphocytes may be involved (112). The virus also infects and persists in salivary glands. MTV infection has been shown to reduce T-cell responsiveness to concanavalin A and phytohemagglutinin and to reduce the graft-versus-host response (132). Natural infection of laboratory mice might therefore temporarily interfere with immune competence.

(vi) Reovirus type 3. Mammalian reoviruses are grouped into serotypes 1, 2, and 3. Reovirus type 3 is the most pathogenic reovirus of laboratory rodents (36). The primary importance of reovirus type 3 is as a contaminant of transplantable tumors and cell lines (475, 484). Reovirus type 3 is a dsRNA virus in the family *Reoviridae*. Transmission is thought to be primarily via direct contact. However, Barthold et al. (36) demonstrated that transmission of virus to cagemates or mothers of infected infants did not occur, indicating low contagiousness. The preponderance of the literature on the effects of reovirus type 3 reports on experimental infections. The effects of natural infections as well as relevant findings from experimental infections are reviewed here. Natural infection with reovirus-3 is nearly always asymptomatic. Cook (120) reported the following clinical signs in first litters of mice infected with reovirus type 3: stunting, diarrhea, oily coats, abdominal alopecia, and jaundice. Pathologic changes consisted of enlarged, black gallbladders; hepatic necrosis; and yellow kidneys (120).

Experimentally inoculated mice have a wider scope of organ involvement (36, 475, 507).

Immunity to reovirus type 3 infection is primarily humoral (26, 133, 665) but also involves T lymphocytes (133, 134, 689). Protective antibodies may act at least partially by inhibiting internalization and intracellular proteolytic uncoating of the virion (688). Athymic (*nu/nu*) mice are no more susceptible to disease than are immunocompetent mice (594). The reported effects of natural infection with reovirus type 3 are limited to lysis of transplantable ascites tumors (46, 479). Experimentally, reovirus type 3 has also been shown to reduce the pulmonary clearance of *Staphylococcus aureus* (354); suppress pulmonary carcinogenesis (645); inhibit cellular DNA synthesis and induce apoptosis (296); cause pulmonary neutrophil influx, increased levels of chemokine mRNA expression (196), and acute myocarditis (597); induce murine NK cell cytotoxicity (7) and TNF- α levels (197); synergize with chemotherapeutic agents to cause the rejection of various murine tumors (615); and enhance tumor-specific immunity (360, 570). Mice and, to a lesser extent, rats infected with reovirus type 3 are commonly used as models of human acute and chronic hepatitis, chronic biliary obstruction, extrahepatic biliary atresia, pancreatitis, lymphoma, and pneumonia (459, 614). Natural infection of laboratory rodents could alter intestinal studies and multiple immune response functions.

Bacteria. (i) *Helicobacter* spp. The genus *Helicobacter* contains an ever-increasing number of recently identified, gram-negative, spiral, microaerophilic, gastrointestinal system pathogens that are known to infect mammals (127, 212). Species naturally infecting mice and/or rats include *H. hepaticus*, *H. bilis*, *H. muridarum*, *H. trogontum*, *H. rodentium*, and “*Flexispira rappini*,” a *Helicobacter* sp. based on 16S rRNA analysis (212). Among these, *H. hepaticus*, a pathogen of mice, is most prominent. The prevalence of *H. hepaticus* is currently unknown but may be quite high (591). Rats, guinea pigs, and hamsters are not susceptible to infection (706). Transmission is via direct fecal-oral contact or fomites. Clinical signs are absent in immunocompetent mice but include rectal prolapse in immunodeficient mice (704). *H. hepaticus* selectively and persistently colonizes the bile canaliculi and cecal and colonic mucosae (211, 706). Pathologic changes include chronic, active hepatitis, possibly of autoimmune etiology (705); occasional enterocolitis; and hepatocellular neoplasms induced by as yet undelineated nongenotoxic mechanisms (88, 213, 706). Other, lesser known *Helicobacter* spp. include *H. bilis*, associated with multifocal chronic hepatitis and isolated from the liver, bile, and lower intestine of aged, inbred mice (214); *H. muridarum*, from the intestinal mucosa of rats and mice (394); *H. rodentium* and *F. rappini*, from the colons and ceca of mice (212, 576); and, lastly, *H. trogontum*, recently isolated from the colonic mucosa of Wistar and Holtzman rats (440). *H. hepaticus* has been associated with hepatic carcinomas and elevated levels of alanine aminotransferase in serum (215, 706). *H. hepaticus* serves as a model for *H. pylori*-induced chronic gastritis, gastric ulcers, and gastric adenocarcinoma (213). Natural infection of laboratory mice with *H. hepaticus*, and possibly other *Helicobacter* spp., could confound carcinogenicity research and research involving the gastrointestinal system. It is certain that much additional information concerning these and yet unknown murine *Helicobacter* pathogens will be published in the scientific literature in the near future.

(ii) *Citrobacter rodentium*. *Citrobacter rodentium* (577), formerly *Citrobacter freundii* biotype 4280, is the etiologic agent of transmissible murine colonic hyperplasia (31). *C. rodentium* is a gram-negative, facultatively anaerobic rod. Rats are not susceptible to infection (37). Transmission is via direct contact

(71) or via contaminated food or bedding. *C. rodentium* is generally considered an opportunistic pathogen. For example, the use of antibiotics effective primarily against gram-negative rods may allow an overgrowth of *C. rodentium* in the mouse intestine (681). Clinical signs, when present, are nonspecific and may include ruffled coat, weight loss, depression, stunting, perianal fecal staining, and rectal prolapse (475). Nursing mice are most susceptible. Strain differences in susceptibility exist, with C3H/HeJ mice more susceptible than DBA/2J, NIH3 (Swiss), or C57BL/6J mice (37). Infection is transient, and there is no carrier state. The hallmark pathologic lesion of *C. rodentium* infection is colonic hyperplasia. Generally, the descending colon is most affected. However, the entire colon and cecum may be involved, with crypt elongation, variable mucosal inflammation, crypt abscesses, occasional erosions and ulcers, and, with healing, goblet cell hyperplasia (32, 475). Transient colonization of the mouse small intestinal mucosa, followed by colonization of the large bowel, is dependent on the presence of the chromosomal *cae* gene (575). Once colonization has occurred, *C. rodentium* causes the formation of attaching and effacing (A/E) lesions. Outer membrane proteins, known as intimins, are required for formation of the A/E lesions (218). Immunity appears to be humoral and may be directed at least partially toward intimin antigens (218). Reported effects on research are few, but they include acceleration of carcinogenesis by 1,2-dimethylhydrazine (34). *C. rodentium* is used as a model of A/E lesions in vivo and in intestinal disease of humans. Natural infection of laboratory mice might severely, if only transiently, alter intestinal cytokinetics.

(iii) *Clostridium piliforme*. *Clostridium piliforme* (177), formerly *Bacillus piliformis*, is the causative agent of Tyzzer's disease. *C. piliforme* is a gram-negative, filamentous, endospore-forming bacterium. Prevalence remains high in laboratory rodent colonies (475). Possible explanations for this include the moderately contagious nature of the organism (61) and the wide range of susceptible and naturally infected host species (475). However, concerning the latter, Franklin et al. (219) have suggested that both cross-infective isolates and more host-specific isolates may exist. With this in mind, transmission is thought to be via ingestion of infectious endospores in contaminated food or bedding. Inadequate sterilization of feed or bedding components may facilitate the entry of the pathogen into an otherwise well-managed rodent colony.

Most infections are subclinical. Various host and environmental stressors may precipitate clinical disease. Clinical signs occur most commonly in suckling and weanling rodents and include sudden death, watery diarrhea, lethargy, and ruffled fur (475). Pathologic changes involve three main phases. These include the establishment of infection in the ileum and cecum, the ascension of the pathogen to the liver via the portal circulation, and hematogenous spread to other tissues such as the myocardium (475). This triad of organ involvement is the hallmark of Tyzzer's disease. In mice, the affected intestine is thickened, edematous, and hyperemic. Necrotic foci develop in the affected intestine, liver, and myocardium. Lesions are similar in rats, except that megaloleitis is a common finding (273). Waggle et al. (697) demonstrated that B-cell- but not T-cell-deficient mice were more susceptible and concluded that immunity to *C. piliforme* was therefore primarily humoral. More recently, others have demonstrated increased susceptibility to a toxigenic isolate of *C. piliforme* in nude mice and have concluded that T cells may also play a role in immunity to Tyzzer's disease (405). Those authors acknowledge that the cytotoxin produced by the isolate may have contributed to the severity of clinical disease and lesions. Athymic (*nu/nu*) rats have also been shown to be highly susceptible (650). Effects on research

include increased mortality, alteration of the pharmacokinetics of warfarin and trimethoprim, and alteration of the activity of hepatic transaminases (475). In addition, experimental manipulations have been reported to provoke or exacerbate clinical disease caused by *C. piliforme* (475). Natural infection of laboratory mice and rats could severely alter the findings of studies involving the gastrointestinal and cardiopulmonary systems.

(iv) *Pseudomonas aeruginosa*. *Pseudomonas aeruginosa* is a gram-negative rod that normally inhabits the nasopharynx, oropharynx, and lower digestive tract of many vertebrate species. The primary importance of *P. aeruginosa* is as an opportunistic pathogen (475). *P. aeruginosa* is commonly found in soil and organic waste and as a normal skin inhabitant, and it is frequently cultured from facility water systems. Active exclusion of the organism from the animal facility is achievable but costly. Transmission is via contact with contaminated water, feed, bedding, and infected rodents and humans (670).

Clinical signs are generally not observed in immunocompetent hosts, although the host response to *P. aeruginosa* infection varies among inbred mouse strains. For example, mice of the BALB/c strain are resistant to *P. aeruginosa* lung infection whereas mice of the DBA/2 strain are susceptible (460). Some immunocompromised mice and rats may develop hunched posture, apathy, dullness, shortness of breath, ruffled coat, emaciation, circling movements around their longitudinal axis, and oblique head posture, and some of them will die (167, 335, 475). Clinical disease is due to invasion of deep tissues, resulting in hematogenous spread of the bacteria to multiple organs. Entry into the vascular system may be facilitated by pseudomonal proteases and bradykinin generated in infectious foci (567). Pathologic lesions are found in affected tissues and consist of multifocal necrosis, abscess formation, and suppuration (517). Lesions are often most severe in the lungs (517). Vegetative lesions may be found on heart valves of animals with infected indwelling vascular catheters (517).

Much of what is known of the cell biology of *P. aeruginosa* infections comes from experimentally induced infections. Studies of immune responses to *P. aeruginosa* present evidence of both humoral (525) and cellular (178, 621) contributions to immunity, which is enhanced by vitamin B₂ (13) and IL-1 (691). Type 1 T-helper (Th1) cells may participate in part by triggering TNF- α -mediated hypersensitivity to *P. aeruginosa* (221). Macrophages and neutrophils are important effector cells (471), with neutrophil accumulation mediated through CD11 and CD18 cells (539). Also, inbred mouse strains differ in susceptibility (461). Susceptible mice have been shown to have a defect in TNF- α production (245, 460). In addition, strains of *P. aeruginosa* differ widely in virulence (225). Bacterial flagella (412), pyoverdinin (which may compete directly with transferrin for iron [443]), pyocyanin (596), elastase (640), and potent exotoxins (263, 294, 490, 642) play major roles in determining virulence. Most prominent among the exotoxins is exotoxin A, a superantigen (451, 528).

Numerous publications have reported on the effects of *P. aeruginosa* on research involving immunocompromised mice and rats. Most reports are from experimental infections. Effects include early death following exposure to radiation, cyclophosphamide treatment, CMV infection, or cold stress; increased severity of infection following airway trauma; depressed contact sensitivity to oxazolone; stimulation of T-cell proliferation within splenocytes of nude mice; induction of thymic atrophy via apoptosis; inhibition of wound healing; inactivation of cytokines by bacterial proteases; possible T-cell-dependent immune system suppression mediated by the polysaccharide fraction of LPS; altered fluid transport across the lung epithelium; suppression of delayed hypersensitivity responsiveness;

increase in cardiac excitability and enhanced vulnerability to hypoxic insults; inhibition of macrophage function by bacterial rhamnolipids; and altered behavioral and clinical pathologic parameters following experimental infection of surgical wounds (69, 173, 277, 287, 376, 423, 433, 475, 508, 528, 701, 736). In addition, rodents with streptozotocin-induced diabetes mellitus are more susceptible to *P. aeruginosa* infection (353). Rodent-*P. aeruginosa* systems have been developed as models for numerous human diseases and conditions, including indwelling-catheter infections (350), pyelonephritis (659), burn trauma (478, 620), chronic mucosal colonization (526), immunization strategies (131), and infection accompanying cystic fibrosis (336, 411). From these reports, it is apparent that natural infection of immunocompromised mice and rats could affect a variety of research projects, depending upon the organ systems affected.

(v) *Salmonella enteritidis*. *Salmonella enteritidis* and the roughly 1,500 serotypes of that species are gram-negative, non-endospore-forming bacteria that colonize the intestinal tracts of a wide variety of animal hosts. The primary importance of *Salmonella* spp. is as zoonotic agents and as pathogens in immunocompromised mice and rats. *S. enteritidis* serotype typhimurium is the most common serotype infecting laboratory rodents, although the prevalence of asymptomatic carriers is unknown but probably low. Transmission is via ingestion of contaminated feed ingredients and water and by contact with contaminated bedding and animal facility personnel (475). Reports of natural outbreaks of disease are rare in the literature (475), probably because most infections are asymptomatic in normal hosts. When clinical effects are observed, reproduction is most prominently affected, while other signs are nonspecific (398). Diarrhea is an uncommon finding (475). Many host, pathogen, and environmental factors determine the pathologic findings and severity of infection, including host age and genotype; makeup of the intestinal flora; nutritional state; immune status; presence of concurrent infections; bacterial serotype; and environmental stressors such as food and water deprivation, temperature, iron deficiency, and experimental manipulations (475). Inbred mouse strains have a wide range of susceptibility to *S. enteritidis*. Susceptible strains include DBA/1, BALB/c, C57BL/6, and C3H/HeJ. Relatively resistant strains include C3H/HeN, A/J, and DBA/2 (475). Susceptibility is determined by three distinct genetic loci (475).

Following ingestion, the mucosa and Peyer's patches in the distal ileum are initial sites of invasion. From those sites the organism reaches the mesenteric lymph nodes and gains access to the vascular system, to be distributed throughout the body. Lesion development depends upon the distribution of the pathogen. The organs most commonly infected include the terminal small intestine and the large intestine, lymph nodes, liver, and spleen. Hallmarks of the infection include local hyperemia, focal necrosis, and pyogranulomatous inflammation, consistent with septicemic disease; they also include crypt epithelial hyperplasia in the intestine (475, 517). Immunodeficient rodents are more severely affected. Numerous virulence factors have been identified, each of which contributes to the pathogenic potential of various *S. enteritidis* isolates (622, 630, 646).

A combination of humoral and cellular immune mechanisms control infection with *S. enteritidis*, while gamma interferon (IFN- γ) may contribute to pathology in septic shock (288). Cellular mechanisms participating in immunity include L3T4⁺ and Lyt-2⁺ T cells (535, 571) and T lymphocytes that express a γ/δ T-cell antigen receptor (449). Reported interference of *Salmonella* spp. with research includes induced resistance or increased mortality to copathogens, suppression of growth of

transplantable tumors, reduced glucose levels and hepatic enzyme levels in blood, reduced intestinal enzyme levels (475), and increased rates of crypt cell proliferation, resulting in substantial growth of the small intestine (476). In addition to the changes observed with infection, there is a large body of literature concerning the effects of *Salmonella* LPS on mouse and/or rat systems under experimental and often in vitro conditions. These effects include mitogenic activity (631); stimulation of cytokine production (111); lung damage and decreased circulating leukocyte counts (556); recruitment of neutrophils to the lung, probably due to the chemoattractant properties of macrophage inflammatory protein type 2 (262); induction of vasodilation of isolated rat skeletal muscle arterioles (236); decreased amino acid incorporation into proteins (298); altered guanine nucleotide regulatory (G) protein function (414); activation of the nuclear transcription factor kappa B and expression of E-selectin mRNA in hepatocytes, Kupffer cells, and endothelial cells (189); mortality in neonates and stimulation of adherent splenic cell thromboxane B2, IL-6, and nitrite production (110); altered development of the hypothalamic-pituitary-adrenal axis with long-term effects on stress responses (592); altered glucose metabolism (248); increased expression of Mac-1 (CD11b/CD18) adhesion glycoproteins on neutrophils (730); increased calcitonin gene-related peptide and neuropeptide Y levels in plasma (702); and altered liver levels of 1,2-diacylglycerol and ceramide (664). It remains to be discerned which of these observations extend to the mouse or rat infected with *S. enteritidis*. Mice and/or rats infected with *S. enteritidis* serve as models of enteritis (477), typhoid fever, and other septicemic diseases (231).

Parasites. (i) *Giardia muris*. *Giardia muris* is a flagellated intestinal protozoan. Infections are occasionally detected in laboratory rodent colonies. Strains of *G. muris*-infected mice and rats may be host specific (372). The life cycle is direct. Environmentally resistant and infectious cysts are passed in the feces. Excystation occurs following ingestion. The minimum infectious dose for a mouse is approximately 10 cysts (611). Shortly after excystation, trophozoites divide longitudinally and colonize the mucosal surface of the proximal small intestine, adhering to columnar cells near the bases of intestinal villi and moving within the mucus layer on the mucosa (475). Most infections are asymptomatic. When apparent, clinical signs are nonspecific and include weight loss, stunted growth, rough coat, and enlarged abdomen. In athymic or otherwise immunocompromised hosts, clinical signs may be more severe and may include diarrhea and death; and cyst shedding may be prolonged (60, 555). Pathologic changes include villous blunting; increased numbers of intraepithelial lymphocytes, goblet cells, and mast cells; and alterations in intestinal disaccharidase content (685).

Strain differences in susceptibility have been observed. Resistant mouse strains include DBA/2, B10.A, C57BL/6, and SJL/2; the relatively more susceptible strains include BALB/c, C3H/He, A/J, and Crl:ICR (475, 684, 685). The bases for these differences are unknown, although both MHC and non-MHC genes appear to influence the outcome of primary *G. muris* infections (683). In addition, male mice shed cysts in their feces longer than females do and trophozoites are present in their intestines for a longer period than in females (143).

Protective immunity is dependent upon both cellular and humoral mechanisms (291, 522, 553), with IFN- γ somehow playing a role in clearance of trophozoites (685). The mechanisms responsible for elimination of a primary infection may not be identical to those required to resist a secondary challenge infection (600). Reported effects of *G. muris* include alterations in intestinal disaccharidase levels (142, 144) and

mucosal immune responses (406), transient reduction in immunoresponsiveness to sheep erythrocytes (43), and increased severity of concurrent infections in athymic (*nu/nu*) mice (60). Natural infection of laboratory mice and rats with *G. muris* could interfere with studies involving the gastrointestinal and immune systems.

(ii) *Spiroucleus muris*. *Spiroucleus muris* (formerly *Hexamita muris*) is a second flagellated protozoan commonly infecting laboratory mice and rats. Host-specific strains of *S. muris* have been identified (574). The biology of *S. muris* appears to be much like that of *G. muris*; however, due to the inability to culture *S. muris*, considerably less is known about this organism. Infectious cysts are passed in the feces. The minimum infective dose for a mouse is 1 cyst (611). Following ingestion, excystation occurs and trophozoites colonize the crypts of Lieberkühn in the small intestine. Infections with *S. muris* are asymptomatic in immunocompetent, adult mice and rats. However, weanling and immunodeficient mice may develop clinical disease. It has been reported by several investigators that young mice may develop diarrhea, dehydration, weight loss, rough coat, lethargy, abdominal distension, and hunched posture and may die (475, 720), although in none of the reported cases were other potential causes of the clinical signs excluded. In athymic (*nu/nu*) and lethally irradiated mice, *S. muris* causes severe chronic enteritis and weight loss (371, 441). In severe infections, the intestine is reddened and filled with fluid and gas. The crypts are hyperplastic and may be distended with trophozoites, microvilli and villi may be shortened, and enterocyte turnover is increased; inflammation is minimal (475, 720). *S. muris* has been shown to interfere with research in several ways, including increasing the severity of copathogen infection; increasing the mortality associated with cadmium treatment; and altering macrophage function and lymphocyte responsiveness to sheep erythrocytes, mitogens, and tetanus toxoid (475).

(iii) *Oxyuriasis* (pinworms). Pinworms commonly infecting laboratory rodents include the rat pinworm *Syphacia muris* and, in mice, *Syphacia obvelata* and *Aspicularis tetraptera*. *S. obvelata* has also been reported to infect humans (475). Life cycles are direct, with adult worms inhabiting the cecum and colon. Eggs are deposited in the perianal region of the host (*Syphacia* spp.) or are excreted with the feces (*A. tetraptera*). The eggs are very light and will aerosolize, resulting in widespread environmental contamination. Embryonated eggs are infective to another rodent and can survive for extended periods at room temperature. The prevalence of infection remains high (475, 527), even in well-managed animal colonies. Pinworm burden in an infected rodent population is a function of age, sex, and host immune status. In enzootically infected colonies, weanling animals develop the greatest parasite loads, males are more heavily parasitized than females, and pinworm numbers diminish with increasing age of the host. While infections are usually subclinical, rectal prolapse, intussusception, fecal impaction, poor weight gain, and rough coat have been reported in heavily infected rodents, although generally without adequate exclusion of other pathogens (475). Very heavy parasite loads may lead to catarrhal enteritis, liver granulomas, and perianal irritation. Athymic (*nu/nu*) mice are reportedly more susceptible to infection (326). Immunity is probably mostly humoral, as for many other helminthiases. In this regard, *Syphacia*-specific antibodies have been demonstrated in pinworm-infected mice (573). There are a few reports documenting the effects of pinworms on research. Pinworm infection resulted in significantly higher antibody production to sheep erythrocytes (573), reduced the occurrence of adjuvant-induced arthritis (512), and impaired intestinal electrolyte transport (408). While many consider pinworm infection irrel-

evant in laboratory rodents, specific research goals may justify the eradication of pinworms from an animal colony.

Dermal System

Viruses. (i) Mouse mammary tumor virus. Mouse mammary tumor virus (MMTV) is a ssRNA type B retrovirus of the family *Retroviridae*. At least four major variants of the virus have been identified in laboratory mice, including MMTV-S ("standard"), MMTV-L ("low oncogenic"), MMTV-P ("pregnancy"), and MMTV-O ("overlooked") (428, 475). More recently, additional variants, including MMTV-SW and MMTV-C4, have been described (590). Mechanisms of transmission differ among the major variants. MMTV-O is endogenous to the genome of most mice, MMTV-S is transmitted via milk, MMTV-L is transmitted via germ cells, and MMTV-P is transmitted through both milk and germ cells (475). T cells are needed for transmission of milk-borne MMTV from the gut to the mammary gland (734). The variants also differ in oncogenicity, with MMTV-S and MMTV-P being highly oncogenic and MMTV-L and MMTV-O being less so (475). Depending upon the mouse strain and virus variant, MMTV may be expressed in mammary and many other tissues (698), including lymphoid tissues (345, 468, 663), or may exist as a provirus in the DNA of the host (680). Clinical signs of infection are generally limited to mammary tumors, which may arise several months after infection, although distant metastases can also occur with subsequent organ compromise. Most virus-induced tumors are adenocarcinomas (475). While the mechanism of tumor induction is unknown, it is thought that MMTV induces hyperplastic nodules which eventually become neoplastic (475). MMTV may integrate into and disrupt the *Tpl-2/cot* proto-oncogene (188). Various hormones (57), carcinogens (475), diet (204), and transforming growth factor α (467) may accelerate the development of tumors. Mouse strains differ in their susceptibility to MMTV to the point that mouse strain selection can be used as a control measure (475). Immunity involves both cellular and humoral components (47, 428). B cells are the primary targets of infection for MMTV. However, for productive retroviral infection, T-cell stimulation through the virally encoded superantigen (SAg) is necessary. SAg is expressed on lymphocytes (735); binds MHC class II molecules; stimulates T cells via interaction with the V β domain of the T-cell receptor (3); activates B cells, leading to cell division and differentiation (99, 290); is involved in the transmission of milk-borne MMTV from virus-infected milk in the gut to the target mammary gland tissue (735); may initiate or aggravate graft-versus-host disease (444); and has the ability to destroy a large portion of CD4⁺ T cells (744). In addition, MMTV affects T-cell (392, 744) and B-cell (99) responses, activates NK cells through superantigen-dependent and -independent pathways (233), and lowers the amount of prolactin required to elicit α -lactalbumin production from mammary epithelial cells (56). MMTV is used as a model for viral carcinogenesis. Natural infection of laboratory mice with MMTV will interfere with carcinogenesis studies and result in a shortened life span.

Bacteria. (i) *Pasteurella pneumotropica*. *P. pneumotropica* is a gram-negative, nonhemolytic bacterium. Multiple biotypes have been reported (62). While most species of rodents may harbor the organism (445, 475), reports of natural outbreaks are rare and are generally limited to rats and immunocompromised mice (61). McGinn et al. (432) reported otitis media in CBA/J mice used in hearing research. *P. pneumotropica* was isolated from infected otic bullae. However, in that report the primary pathogen was not clearly established. *P. pneumotropica* is frequently isolated from several sites on and within

healthy rats and mice and is therefore considered an opportunistic pathogen (475). Transmission is probably via direct contact and fomites (475). Clinical disease, when apparent, is generally limited to lesions of the skin and adnexal structures, although ophthalmitis, conjunctivitis, and mastitis have also been reported (475). Lesions are characterized by suppurative inflammation (475). Natural infection of rats with *P. pneumotropica* could compromise research involving the skin.

(ii) *Staphylococcus aureus*. *Staphylococcus aureus* is a gram-positive, coagulase-positive coccus that commonly inhabits the skin, upper respiratory tract, and lower digestive tract of many animals, including laboratory rodents, in which it occasionally causes disease. Transmission is direct, and entry into the body is via breaks in normal barriers. Disease frequently occurs following physiologic changes in the host (e.g., stress and immunosuppression). A variety of clinical presentations have been reported in rats and mice. These include tail lesions, ulcerative dermatitis, and traumatic pododermatitis in rats; and facial abscesses, ulcerative dermatitis, preputial gland abscesses, and penile self-mutilation in mice (475). Lesions are more severe in immunocompromised hosts. In addition, rats inapparently infected during nonsterile surgical procedures are less active in open-field testing. Infected rats have alterations in the fibrinogen level in plasma, the glucose level in serum, total leukocyte counts, and wound histology scores (69). The hallmark of *S. aureus* infection is suppurative inflammation, with abscess formation in virtually any organ. Most commonly, infection occurs in the skin and subcutaneous tissues, but it may also be found in the upper airways, lungs, conjunctiva, and other tissues.

Immunity to *S. aureus* is primarily via complement-mediated killing by neutrophils (475). Cell-mediated immunity may also be important and may secondarily contribute to the pathogenesis of some lesions (475). Nitric oxide, IFN- γ , TNF, and IL-6 are induced during infection (210, 470). *S. aureus* produces several biologically active products, including hemolysins, leukocidins, nuclease, coagulase, lipase, hyaluronidase, exotoxins, fibronectin- and collagen-binding proteins, protein A, and enterotoxins (334, 545, 560). Many of these may be degraded by phagocytic cells into other active products (206). The effects of these products are numerous and include cell lysis (292); increases in pulmonary microvascular permeability (585); contractile dysfunction (50); shock and multiple-organ failure (151); epidermolysis (18); and induction of excess sleep, fever, TNF, cytokine, IL-1, and IL-1 receptor antagonist (206). Staphylococcal enterotoxins have been termed superantigens based on their ability to stimulate polyclonal proliferative responses of murine and human T lymphocytes (230). In addition, infection with *S. aureus* has been shown to alter immune responses (45). Colonization of conventionally housed rodents is unavoidable. Natural infection of immunodeficient rodents can be prevented, but at great expense, by barrier facility housing. However, this may be necessary to prevent infection and to ensure accomplishment of specific research objectives. Natural infection of immunodeficient mice and rats could compromise a variety of studies involving these animals.

(iii) *Corynebacterium* spp. in athymic mice. *Corynebacterium* spp. are gram-positive, diphtheroid bacilli. Reports of hyperkeratosis in nude mice naturally infected with *Corynebacterium* spp. have occasionally appeared in the literature (549). In the report by Richter et al. (549), the pathogen isolated was similar to *Corynebacterium pseudodiphtheriticum*, while in a more recent report, the pathogen was most like *Corynebacterium bovis* based on biochemical profiles (109). The authors of the latter report thoroughly described several aspects of an outbreak of hyperkeratosis in athymic nude (homozygous and heterozy-

gous) mice, with hairlessness being a contributing characteristic. Those authors found that transmission was accomplished via direct contact and via contaminated bedding and gloves (109). Clinical signs included flaking of the skin, primarily along the dorsum, and, in some animals, pruritus. Pathologic changes were characterized as orthokeratotic hyperkeratosis and follicular keratosis; marked acanthosis; and mild neutrophilic, macrophage, and mast cell infiltration (109). While reports of natural infection of mice with this *Corynebacterium* sp. have been rare, this condition may appear with greater frequency in the future. Nude mice naturally infected with this pathogen would be unsuitable for dermatologic and possibly other research projects.

Parasites. (i) Acariasis (mite infestation). While many species of mites infest wild rodents, only three species of nonburrowing mites are commonly found on laboratory mice and rats. *Myobia musculi* and *Myocoptes musculinus* infest mice, while *Radfordia affinis* infests rats (475). Mice are much more commonly infested than are rats. The life cycles of all three mites are direct, with all stages (egg, nymph, and adult) present on the host. Consequently, hairless mice are not susceptible. Life cycles require roughly 3 weeks for completion. Transmission is via direct contact. Once a facility is infested, eradication of the parasites is achievable but labor-intensive. Clinical signs vary in severity depending upon host factors and mite species. C57BL and related strains are most susceptible to severe disease, due to overexuberant type 1 hypersensitivity reactions (475). *M. musculi* is considered the most pathogenic of the three common species because it alone feeds on skin secretions and interstitial fluid (but not on blood) while *M. musculinus* and *R. affinis* feed more superficially (517). Infestation may be asymptomatic or may cause wasting; scruffiness; pruritus; patchy alopecia, which may be extensive; accumulation of fine bran-like material, mostly over affected areas; self-trauma to the point of excoriation or amputation; and secondary pyoderma (20, 340, 475). Lesions are most common on the dorsum, primarily on the back of the neck and interscapular region. Pathologic changes include hyperkeratosis, erythema, mast cell infiltration, ulcerative dermatitis, splenic lymphoid and lymph node hyperplasia, and eventual secondary amyloidosis (339, 340, 475). Mite infestation has reportedly caused secondarily amyloidosis; altered behavior (475); selective increases in immunoglobulin G1 (IgG1), IgE, and IgA levels and depletion of IgM and IgG3 levels in serum; lymphocytopenia; granulocytosis; increased production of IL-4; and decreased production of IL-2 (339, 340). These immunologic changes are consistent with a Th2-type response, with marked systemic consequences (339).

Hematopoietic System

Viruses. (i) Lymphocytic choriomeningitis virus. Lymphocytic choriomeningitis virus (LCMV) is a noncytopathic ssRNA virus of the family *Arenaviridae*. The primary importance of LCMV is as a zoonosis and as a contaminant of transplantable tumors and cultured cell lines (180, 413, 475, 484). Natural infections of mice with LCMV are uncommon, and only mice and hamsters are known to transmit the infection, although rats and many other mammals (and chickens) are also susceptible (475, 511). Along with implantation of infected tumors, transmission is via exposure of mucous membranes and broken skin to infectious urine, saliva, and milk (475) and possibly via ingestion (540). In addition, both transovarian and transuterine transmission occur in mice (475).

Patterns of infection differ depending on host and pathogen factors, including mouse strain and age, inoculum dose, route

of inoculation, and virus strain (465, 475, 652). Typical clinical patterns include the persistent tolerant infection, which follows in utero or neonatal infection. Persistent infection of T-helper lymphocytes, viremia, and lifelong viral shedding occur (475). Clinical signs include initial growth retardation and eventual immune complex glomerulonephritis accompanied by emaciation, ruffled fur, hunched posture, ascites, and, occasionally, death (475). Pathologic features of this pattern, including ICG, stem from unabated B-cell activity, including production of pathologic amounts of anti-LCMV antibodies, lymphoid hyperplasia, and perivascular lymphocyte accumulation (475). In contrast, T-cell activity is diminished. Eventually, immune tolerance breaks down, resulting in chronic illness with widespread lymphocytic infiltration and vasculitis (517). A second clinical pattern is that of the nontolerant infection (475). This pattern occurs with acute infection of postneonatal mice. Viremia occurs without viral shedding. Infected mice either die or eliminate the virus, frequently without showing signs of disease (475). Pathologic features of this pattern include necrotizing hepatitis (246) and generalized lymphoid depletion (517). Lymphocytic choriomeningitis is generally seen only following experimental intracerebral inoculation and is not a feature of natural infection (517).

Eventual clearance of the infection primarily involves cytotoxic (Lyt-2⁺) T cells (341), NK cells (718), IL-2 (125), IL-12 (501), and IFN- γ (671) and involves perforin-dependent mechanisms (342). Intestinal intraepithelial lymphocytes are also activated (632). Virus-specific antibody is also induced (601). Several investigators have reported effects of LCMV on research; however nearly all of this information comes from experimental infections (475). LCMV has been shown to alter synaptic plasticity and cognitive functions (153); abolish experimental hepatitis B infections (261); increase levels and/or expression of ICAM-1 and other endothelial adhesion molecules in serum (107, 422); cause hepatitis (246) and hemolytic anemia (619); alter behavior (242); alter immune system reactivities (65); alter cytokine gene expression (115); inhibit tumor induction by polyomavirus; delay the rejection of skin and tumor allografts; increase susceptibility to other pathogens, bacterial endotoxin, and radiation; and alter the time course of naturally occurring diabetes (475). Natural infection of laboratory mice would jeopardize human health and interfere with a variety of research endeavors, especially those involving the immune system and central nervous system (CNS).

(ii) Lactate dehydrogenase-elevating virus. Lactate dehydrogenase-elevating virus (LDEV) is a ssRNA virus of the family *Togaviridae*. Multiple strains exist (475). Mice and mouse cell cultures are the only hosts (475). Rats are not susceptible. The major importance of LDEV is as a contaminant of transplantable tumors and of inocula of other infectious agents serially passaged in mice (475, 484, 494). Transmission is via transplantation of contaminated tumors, cells, or serum but may also occur via direct contact, bite wounds, and transplacental or transmammary passage; however, given the short period when viral shedding occurs, the latter routes are less important (475, 517). Clinical signs are limited to neurologic disorder in selected mouse strains that have been immunosuppressed (475). Generally, however, there are no clinical signs of infection (475).

Pathologic changes have not been described in natural infections (517) and are mainly in lymphoid organs in experimental infections. Virus replication occurs for one cell cycle only in a small population of macrophages. The virus is therefore concentrated in organs with high macrophage populations (475). Transient thymic necrosis, splenomegaly, and lymphocytopenia occur early in the infection (517). LDEV causes

persistent viremia, which induces antiviral antibodies and, eventually, circulating antigen-antibody complexes (282), which may result in a mild membranous glomerulonephritis (475). The diagnostic hallmark of LDEV infection is elevation of lactate dehydrogenase (LD) levels in serum, which occurs due to reduced clearing of one LD isozyme (475). Levels of other enzymes in serum are also elevated although not to the same extent.

LDEV alters several bodily functions, including those of affected macrophages; it causes transient increases in cytokine and cell receptor activities; transient depression of cellular immunity; increased (or suppressed) tumor growth (both spontaneous and transplanted); prolonged survival of allografts; altered immunity to copathogens; increases in the levels of several enzymes and gamma globulins in serum; altered humoral immunity (475); decreased binding of asparaginase to monocytes (458); suppressed streptozotocin-induced insulinitis (278), neutrophil migration (279), development of antinuclear antibodies, and glomerulonephritis (281); altered superoxide anion production by macrophages (283, 284); inhibited contact sensitivity to 2,4-dinitrofluorobenzene (280); and abrogated increases in ICAM-1 and LFA-1 expression associated with the development of glomerulonephritis seen in (NZB × NZW)_F₁ mice (343). Clearly, infection of laboratory mice with LDEV could seriously alter research results, especially where immune system function is involved, without any outward evidence of infection.

Central Nervous System

Viruses. (i) Theiler's murine encephalomyelitis virus. Theiler's murine encephalomyelitis virus (TMEV) is a ssRNA virus of the family *Picornaviridae*. TMEV has been found infrequently in laboratory mice and even less often in rats (475). Its primary importance is as a model of poliomyelitis, multiple sclerosis, and virus-induced demyelinating disease (475, 660). Multiple strains exist and are classified according to virulence. Because the virus naturally infects the intestinal mucosa, transmission is primarily fecal-oral, although the infection is not highly contagious. Viral shedding occurs for roughly 2 months (475). In addition, transplacental transmission has been documented (2), and mouse and rat cell cultures may be infected.

Generally, no clinical signs of infection are observed. However, viremia may disseminate virus from the intestine to many tissues, including the liver, spleen, and CNS, where spread via direct extension occasionally results in unilateral or bilateral flaccid paralysis of the hind limbs and, rarely, other neurologic signs (267, 475). Following dissemination of the virus, which is rare but occurs most often around 6 to 10 weeks of age (475), pathologic changes may be seen in the spinal cord and brain; they consist of poliomyelitis with necrosis, nonsuppurative meningitis, microgliosis, perivascularitis, neuronophagia of ventral horn cells (517), and demyelination, possibly mediated by CD4⁺ T lymphocytes (356), TNF- α (320), and IL-1 (562). Mouse strains differ in their susceptibility to demyelinating disease (483, 497), which is usually induced via experimental inoculation. In addition, intraperitoneal inoculation results in acute myositis that progresses to a chronic inflammatory muscle disease which may be immune system mediated (243). Clearing of the virus depends on the involvement of virus-specific cytotoxic T lymphocytes and IL-2 (386, 496). Natural infection of mice has reportedly interfered with the study of other viral infections (475). In addition, TMEV slows the conduction of spinal motor and somatosensory evoked potentials (324) and could compromise studies involving the CNS.

Multiple and Miscellaneous Systems

Viruses. (i) Adenoviruses. Mouse adenoviruses are dsDNA viruses of the family *Adenoviridae*. Two strains have been reported, the FL-1 (currently MAd-1) and K87 (MAd-2) strains, which are probably distinct species (269). Infections in the mouse, the principal host, have been reported only rarely. Infection of rats has been suspected based on serologic and morphologic studies (475). Transmission of both strains is by contact. MAd-1 has a systemic distribution pattern and may be shed in the urine for up to 2 years (679). This ability of MAd-1 to persist cannot be explained by the model of reduced class I MHC-associated antigen presentation proposed for human adenoviruses (370). Clinical signs have never been observed during natural infection with either strain. However, clinical signs and/or pathologic changes in mice have been observed in a stock- or strain-dependent manner following experimental infection with MAd-1 (235, 260, 369, 679). MAd-1 infection has a striking tropism for the CNS and causes a fatal illness in adult C57BL/6 mice but not in adult BALB/c mice (260). Susceptible mice show symptoms of acute CNS disease, including tremors, seizures, ataxia, and paralysis. Light microscopic examination of CNS tissue revealed petechial hemorrhages, edema, neovascularization, and mild inflammation in the brain and spinal cord (260). In other studies, pathologic lesions were most prominent in the kidneys, heart, spleen, adrenal glands, pancreas, liver, and intestines (52, 235, 274, 286, 421).

MAd-2 may be shed in the feces for 3 weeks in immunocompetent mice (276) and for at least 6 months in athymic mice (669). In contrast to MAd-1, infection with MAd-2 is localized to the intestine, causes no clinical signs, and results in pathologic changes that are limited to intranuclear inclusions in crypt and villous cells of the small intestine (639). Immunity to adenoviruses is primarily humoral. Einarsson et al. (185) found slightly increased IL-11 elaboration in airway stromal cells. Mouse adenovirus infection, while uncommon, may interfere with a variety of studies, particularly those involving the CNS, renal, and gastrointestinal systems.

(ii) Ectromelia virus. Ectromelia virus is the causative agent of mousepox. It is a dsDNA virus in the family *Poxviridae*. Mice are the natural hosts. Rats may be transiently infected only experimentally (475). Reports of natural infection in laboratory mice have become rare in the United States but continue to be common in Europe. However, clinical mousepox was recently reported in mice at a U.S. government facility. The mice had been injected with contaminated, commercially produced pooled mouse serum (162). Serologic surveys conducted in the United States occasionally reveal seropositive mice, further confirming that the agent is present. Importation of animals and/or tissues from Europe represent additional opportunities for introduction into U.S. animal facilities. Transmission is primarily via direct contact and fomites, with skin abrasions serving as portals of entry. Resistance to mousepox varies among mouse strains and is dependent upon multiple genes (76, 499). The C57BL/6 and C57BL/10 strains are highly resistant and generally do not show signs of infection (475). In contrast, C3H, BALB/c, and DBA/2 are among the strains most commonly showing signs of disease. In these mice, clinical signs are evident in nearly all members of the colony and consist of foot swelling, pocks, lethargy, depression, and sudden death (475). Following entry via broken skin, the virus replicates locally in skin and lymph nodes and then causes mild, primary viremia and spreads to the liver and spleen. Massive replication in the macrophages of these organs results in a greater secondary viremia. The virus then localizes in many tissues but most prominently in the skin, conjunctiva, and

lymph nodes (475). Pathologic changes include massive splenic, lymph node, thymic, and hepatic necrosis; small intestinal mucosal erosions; and cytoplasmic inclusions in the skin and liver. Distal portions of the tail and limbs may necrose and slough, giving rise to the name ectromelia (475). While virus persists for several months in the spleens of infected mice, it is shed in the feces for only about 3 weeks (475). Multiple strains of ectromelia virus exist, with the Moscow strain being most virulent. Virulence appears to be dependent upon the presence of a poxvirus protein with a CHC₄ (RING) zinc finger motif (407, 588). Immune system clearance of the virus is absolutely dependent upon the effector functions of CD8⁺ T cells, while NK cells, CD4⁺ T cells, and macrophages are necessary for the generation of an optimal response (152, 346, 485, 653). Like many other poxviruses, ectromelia virus expresses a soluble IFN- γ receptor homolog capable of inhibiting the antiviral activities of IFN- γ (466). Natural infection of laboratory mice with ectromelia virus would severely compromise most research efforts involving mice.

(iii) H-1 virus. H-1 virus (Toolan's H-1 virus) is an ssDNA virus of the family *Parvoviridae*. Relatively little is known of the natural biology of H-1 virus, and its significance is low in rats, the natural host, since natural infection does not cause clinical disease and effects on research are few (475). The primary importance of H-1 virus is as a model for experimentally produced malformations in the CNS and skeletal system of rats (475). Transmission is via exposure to infectious urine, feces, nasal secretions, and milk (475). Natural infection with H-1 virus does not cause disease. However, pathologic changes observed in experimental H-1 virus infection derive from the need for parvoviruses to infect replicating cells, wherein they are lytic (475). Reports of H-1 virus affecting research are limited to hepatocellular necrosis in rats exposed to pathogens or chemicals causing liver injury (475) and possibly to a reduction of the incidence of *Yersinia*-associated arthritis (257, 258), although in the latter studies other copathogens may also have been present. In spite of the paucity of data incriminating H-1 virus as a confounder of research, natural infection of laboratory rats could alter studies of fetal development.

(iv) Kilham rat virus. Kilham rat virus (KRV) is another ssDNA virus of the family *Parvoviridae*. More is known of the natural biology of KRV than of H-1 virus. As with H-1 virus, rats are the natural host of KRV. Transmission is via direct contact with infectious urine, feces, nasal secretions, and milk or by contact with contaminated fomites. The latter is probably more important than for many other rodent viruses, since parvoviruses are highly resistant to environmental extremes and are highly contagious. In addition, transplantable tumors and cell cultures may be infected (475, 484). Rats may remain persistently infected for variable times depending upon their age at infection. Clinical signs of infection are rarely observed but have been reported in rats at day 13 of gestation (351). Rats in that outbreak had reproductive anomalies, including increased fetal resorptions, as well as runting, ataxia, cerebellar hypoplasia, and jaundice of many offspring. In another report, scrotal cyanosis, abdominal swelling, dehydration, and death occurred in young rats exposed to serologically positive adults (114).

Like other parvoviruses, KRV infects actively replicating cells and results in cell lysis and tissue destruction. Therefore, KRV causes lesions primarily during fetal development and neonatal life. Infection may persist for variable times depending upon the age of the rat at infection, but it generally does not last beyond about 3 to 4 months (475). Lesions may occur in multiple organs, including the CNS and gastrointestinal and reproductive systems (475); they consist of focal necrosis, fre-

quently in the liver; hemorrhage; and hypoplasia (475). Infection of laboratory rats has been reported to result in teratogenesis, suppression of leukemia development due to Moloney murine leukemia virus, alteration of lymphocyte responses, induction of IFN production (475), induction of acute type I diabetes in diabetes-resistant BB/Wor rats (74), and alteration of lipid metabolism following in vitro infection (583). Lastly, KRV may alter leukocyte adhesion to rat aortic endothelium (226) and may reduce the incidence of *Yersinia*-associated arthritis (257, 258), although in those three studies other copathogens may also have been present. KRV could profoundly interfere with research involving a variety of body systems, especially if infection occurred during fetal development.

(v) Minute virus of mice. Minute virus of mice (MVM) is an ssDNA virus of the family *Parvoviridae* and therefore shares many biological features with other murine parvoviruses such as mouse parvovirus-1, H-1 virus, and Kilham rat virus. Like other parvoviruses, MVM is extremely contagious. Transmission is primarily via exposure to infectious feces and urine but may also be via fomites and via exposure to nasal secretions. In addition, MVM is commonly found as a contaminant of transplantable tumors and mouse leukemia virus stocks (475, 484). Multiple strains have been described. Probably the best studied are MVM(p), the prototype strain, and MVM(I), an immunosuppressive strain (475). MVM(I) grows lytically in mouse T lymphocytes, whereas MVM(p) infects fibroblasts (475). Mouse strains differ in their susceptibility to MVM (78, 79, 344); however, there are usually no clinical signs with MVM infection, and natural infections cause no pathologic changes. Experimental infection will, however, cause damage to multiple organs if infection occurs during fetal development or shortly after birth (78, 475, 541). While direct evidence of interference with research is limited to a report of myelosuppression (586), it can be surmised that MVM may interfere with research involving the immune system, since MVM(I) infection results in T-lymphocyte lysis and altered B- and T-lymphocyte activities and MVM(p) suppresses the growth of ascites tumors (475).

(vi) Mouse hepatitis virus. Mouse hepatitis virus (MHV) is probably the most important pathogen of laboratory mice. Rats may also become infected but only as sucklings and only under experimental conditions (635). MHV is an ssRNA virus of the family *Coronaviridae*. It is extremely contagious and is transmitted primarily via aerosol, direct contact, fomites, and, experimentally, via transplantable tumors and transplacental passage (302, 475, 484).

Susceptibility, tissue tropism, clinical signs, and pathologic lesions are dependent on several host, environmental, and pathogen factors (30, 70, 475, 703). Approximately 25 strains or isolates of MHV have been described (475) and have been classified as either respiratory or enterotropic. Recently, an outbreak of a highly hepatotropic strain of MHV was reported from a breeding colony of nude mice in Taiwan (399). The presence or absence of the MHV receptor, a glycoprotein in the carcinoembryonic antigen family of the Ig superfamily, may determine tissue tropism (240). Respiratory (polytropic) strains establish in the nasal mucosa, descend to the lungs, and disseminate hematogenously throughout the body or ascend along neurons to the CNS (35, 378, 475, 521). Intestinal involvement is usually absent. Polytropic strains include MHV-1, MHV-2, MHV-3, A59, S, and JHM (475). Enterotropic strains may also become established in the nasal mucosa or in the intestinal tract and disseminate only locally to the liver, abdominal lymph nodes, and, in some cases, the CNS (475, 523). Pulmonary involvement is uncommon. Enterotropic strains include LIVIM, MHV-D, and MHV-Y (475). While polytropic

strains have historically been considered more common, this situation is thought to have reversed (95, 301). Lesions are present for only 7 to 10 days following infection, are dependent upon strain of virus, and are characterized by multifocal necrosis. Additionally, multinucleate syncytial giant cell formation occurs and may be associated with fragmentation and rearrangement of the Golgi apparatus (389). Lesions due to polytropic strains may be observed in the olfactory mucosa, brain, lungs, and liver, while lesions due to enterotropic strains are generally, though not always, confined to the intestinal tract. Lesions caused by either strain tend to be more severe and widespread in immunocompromised mice (475).

Most infections follow one of three clinical patterns (475). Enzoitic (subclinical) infection, commonly seen in breeding colonies, occurs when infection is endemic in the colony and is maintained only by the continual arrival of susceptible animals (newborns). No carrier state exists, although in a recent study viral RNA was detected in the liver up to 60 days after infection (362). Adults are asymptomatic, and their young become asymptotically infected by the time passively transferred maternal immunity wanes at weaning. Epizootic (clinical) infection occurs less commonly when the pathogen is introduced to a naive colony. Adult infections are again usually asymptomatic. Clinical signs depend upon the virus and mouse strains and are most evident in infant mice; typically, they include diarrhea, poor growth, and death. As the infection becomes established in the colony, the epizootic pattern is replaced with the enzoitic pattern. Immunodeficient mice, such as athymic (*nu/nu*) mice, develop a wasting syndrome characterized by severe generalized disease and eventual death (666). Immunity to MHV is primarily but not entirely cell mediated; is partially protective between closely related virus strains; and is known to involve T lymphocytes, macrophages, IFN, and NK cells (299, 300, 377, 378, 578, 723).

Numerous reports document effects of natural or experimental infection with MHV on host physiology and research. In immunocompromised mice, these effects include necrotic changes in several organs, including the liver, lungs, spleen, intestine, brain, lymph nodes, and bone marrow; differentiation of cells bearing T-lymphocyte markers; altered enzyme activities, bilirubin concentration, and antibody responses to sheep erythrocytes in serum; enhanced phagocytic activity of macrophages; rejection of xenograft tumors; impaired liver regeneration; and hepatosplenic myelopoiesis (311, 475). In immunocompetent mice, reported effects include transient immunostimulation followed by immunodepression; thymic involution; depletion of LDEV-permissive macrophages; microcytic anemia and changes in ferrokinetics; decreases in lymphocyte proliferative responses, antibody secretion, phagocytic activity, liver regeneration, blood cell production, number of hepatic sinusoidal endothelial cell fenestrae, incidence of diabetes mellitus in nonobese diabetic mice, and IFN production during SV infection; apoptotic changes in the thymus; increased tumoricidal activity of peritoneal macrophages, hepatic uptake of injected iron, susceptibility or resistance to copathogens, and IFN and IL-12 production; altered hepatic enzyme activity, behavior of ascites myelomas, and expression of cell surface markers on splenic T lymphocytes; molecular mimicry of the host Fc gamma receptor; nerve demyelination; impaired bone marrow pre-B and B cells; induced production of α -fetoprotein and antiretinal autoantibodies in serum; and induced macrophage procoagulant activity (126, 129, 160, 191, 195, 239, 303, 309, 337, 377, 382, 384, 395, 475, 495, 616, 636, 674, 724). Clearly, natural MHV infection of laboratory mice with MHV may affect a plethora of scientific studies and seri-

ously compromise the value of these animals as research subjects.

(vii) Sialodacryoadenitis virus. Sialodacryoadenitis virus (SDAV) is a common, important, and highly contagious pathogen of laboratory rats. SDAV is an ssRNA virus of the family *Coronaviridae*. Transmission is via direct contact and fomites (385). Infant mice, but not adult immunocompetent or *scid* mice, are susceptible to experimental infection (33, 385, 520). Natural infection of mice has not been reported (475). SDAV infections follow patterns similar to those of MHV, another coronavirus. Enzoitic infection occurs in breeding colonies and is sustained only by the continual introduction of susceptible hosts (newborns). Suckling rats develop transient conjunctivitis. Weanlings and adults are asymptomatic (330). Epizootic infection occurs when the agent is introduced to a fully susceptible population. Clinical signs are again transient, may vary in severity, and include cervical edema, sneezing, photophobia, conjunctivitis, nasal and ocular discharge, porphyrin staining, and corneal ulceration and keratoconus (330, 475).

Multiple strains of SDAV exist (358), and tissue tropisms differ somewhat among strains (475). SDAV has a tissue tropism for tubuloalveolar glands of the serous or mixed serous-mucous types (475). Therefore, inflammatory changes consisting primarily of diffuse necrosis are seen in the lacrimal (including the Harderian) glands and submandibular and orbital salivary glands. Secondary damage may occur to structures of the eye. Cervical lymph nodes and the thymus may also be mildly necrotic. Some strains of SDAV affect the respiratory tract, where pathologic changes may include patchy necrotizing rhinitis, tracheitis, bronchitis, and bronchiolitis, with multifocal pneumonitis (51, 400, 722). SDAV causes more severe respiratory tract lesions in LEW rats than in F344 rats (400). Virus is present in tissues for only about 1 week. There is no carrier state, so clinical signs and pathologic changes are transient. In athymic rats, infection is more severe, is persistent, and may be fatal (266). SDAV has been shown to alter estrous cycles, increase embryonic and postnatal mortality (673), cause depletion of epidermal growth factor in submaxillary salivary glands (518), cause anorexia and weight loss (489, 672), and reduce IL-1 production by alveolar macrophages (66). In addition, SDAV potentiates lesions caused by *M. pulmonis* (580, 582), though not by altering pulmonary clearance or intrapulmonary killing (482). Natural infections of laboratory rats with SDAV would be expected to interfere with studies involving the lacrimal, salivary, respiratory, ocular, olfactory, reproductive, and immune systems and to interfere with growth of infected newborns.

Bacteria. (i) *Corynebacterium kutscheri*. *Corynebacterium kutscheri* is a gram-positive bacillus that infects both mice and rats. Transmission is fecal-oral. The oral cavity and large intestine most commonly serve as reservoir sites for a latent carrier stage (8, 9). Natural infections are usually subclinical (8, 9) and are revealed only by the immunosuppressive effects of certain drugs, experimental manipulations, or other infectious agents (475). Clinical signs in rats, when present, usually include dyspnea with abnormal lung sounds, weight loss, humped posture, and anorexia. Hematogenous spread occurs in both species and accounts for abscess formation in various organs. In rats, abscesses commonly develop in the lungs and extend to the pleura, while in mice, abscesses occur more often in the kidneys and liver (713, 715). Strain differences in colonization sites (9) and susceptibility have been reported. C57BL/6 and B10.BR/SgSn mice are among the more resistant strains, while Swiss, BALB/cCr, and A/J are among the more susceptible strains (10, 295). Strain susceptibility may reflect differences in

the efficiency of mononuclear phagocytes (296) or cytokine responses (352). Experimental procedures that cause immunosuppression of rats or mice may result in the unwanted development of active *C. kutscheri* infection, which could compromise a variety of studies, including those of the respiratory system.

Parasites. (i) *Encephalitozoon cuniculi*. *Encephalitozoon cuniculi* is a microsporidian protozoan parasite infecting a wide range of hosts, including laboratory mice and rats. At least three strains have been identified based on host specificity and other criteria (166). The prevalence remains high in many rabbitries, and rabbits may serve as a source of infection for mice and rats (475). In contrast, the prevalence is low in modern rodent facilities. The primary significance of *E. cuniculi* in laboratory rodents is as a contaminant of transplantable tumors (475). In addition to infected tumors, transmission is via exposure to infectious urine. Following ingestion, sporoplasm from infectious spores gains entrance to host intestinal epithelium, where multiplication occurs. Continued multiplication results in eventual host cell rupture, with dissemination to other organs, including the brain, kidneys, liver, and lungs (475).

Infection is usually asymptomatic in immunocompetent rodents. Lesions are most commonly found in the kidneys and brain. In the kidneys, lesions consist of intracellular parasites in the renal tubular epithelium and inflammatory changes, with eventual focal destruction of tubules and replacement by fibrous connective tissue, resulting in pitting of the renal surface (475). In the brain, lesions consist of meningoencephalitis. In rats, but not in mice, there is also multifocal granulomatous inflammation (475). Mouse strains differ in their susceptibility to infection, with C57BL/6, DBA/1, and 129J being highly susceptible; C57BL/10, DBA/2, and AKR being of intermediate susceptibility; and BALB/c, A/J, and SJL being relatively resistant (475). In contrast to immunocompetent mice, athymic (*nu/nu*) mice experience high mortality with infection (165, 475). Macrophage microbicidal activity may involve nitrite (NO₂) (164). Infection with *E. cuniculi* transiently increases NK cell activity, causes hepatosplenomegaly with ascites, alters brain and kidney architecture, alters host responses to transplanted tumors, and reduces cellular and humoral responses to a variety of immunogens (475). *E. cuniculi* infection of mice is used as a model of human microsporidiosis (164, 365). Natural infection of laboratory mice and rats would compromise studies involving the gastrointestinal, renal, and central nervous system and possibly others.

RABBITS

Respiratory System

Bacteria. (i) *Bordetella bronchiseptica*. *Bordetella bronchiseptica* is a gram-negative rod commonly found inhabiting the respiratory tracts of rabbits. Transmission is via aerosol, fomites, and contact and occurs early in life. There is a high prevalence of seropositivity in laboratory rabbits (519). Most infections are asymptomatic and become problematic only in association with *Pasteurella multocida* infection (148). In those cases, clinical signs include oculonasal discharge ("snuffles"), lethargy, anorexia, dyspnea, and occasionally death. I have also treated cases of rabbit bordetellosis in which no other pathogens could be identified or where a primary infection with *P. multocida* was cleared with antibiotics, only to have clinical signs resume with overgrowth of *B. bronchiseptica*. Rabbits also occasionally develop *B. bronchiseptica* abscesses. Typical pathologic changes of the lower respiratory tract are those of

suppurative bronchopneumonia and interstitial pneumonitis (517). Microscopically, there may be prominent peribronchial lymphocyte cuffing (517). *B. bronchiseptica* causes ciliostasis in canine tracheal outgrowth cultures (44). Similar effects in rabbits could facilitate infection and clinical disease caused by copathogens such as *P. multocida* (517). It has been reported that rabbits with *B. bronchiseptica* infection have defective alveolar macrophage function (746), which supports the hypothesis that infection with *B. bronchiseptica* facilitates infection with other pathologic agents. Clinical bordetellosis would compromise the usefulness of laboratory rabbits used in respiratory studies. However, given the high prevalence of latent *B. bronchiseptica* infection, it is unlikely that a laboratory rabbit colony can become or remain free of infection without resorting to expensive barrier housing. Clinically affected rabbits should be treated immediately or, preferably, culled.

(ii) **CAR bacillus.** As described above, CAR bacillus is a gram-negative, filamentous, rod-shaped, gliding bacterium. Analyses of 16S rRNA gene sequences from rabbit-origin CAR bacillus suggest close relationship to members of the genus *Helicobacter* (137). Infection of laboratory rabbits has been reported in the United States (136) and Japan (375). Clinical disease in rabbits has not been demonstrated or induced. Kurisu et al. (375) reported that organisms were primarily found colonizing the apices of cells lining the larynx, trachea, and bronchi. Lesions consisted of slight hypertrophy and hyperplasia of ciliated upper respiratory epithelium, with occasional loss of cilia and mild inflammation of the lamina propria. Others have reported seroconversion without the development of either lesions or clinical disease following experimental infection of rabbits with CAR bacillus of rat (426) or mouse (598) origin. Natural infection of rabbits may confound studies in which upper airway architecture is evaluated histologically.

(iii) *Pasteurella multocida*. *P. multocida*, a gram-negative, bipolarly staining rod, is the most common pathogen of laboratory rabbits. Infection is nearly ubiquitous among rabbit colonies; within a colony, infection is also common, frequently occurs at birth, and increases with age. Transmission is by direct contact and, to a lesser extent, fomite, aerosol, and sexual exposure. Disease susceptibility depends upon host, environmental, and bacterial factors. Differences in susceptibility have been reported among rabbit strains (172). Environmental factors such as shipping, experimentation, wide temperature fluctuations, and high ammonia levels increase susceptibility (154). Lastly, bacterial strains differ in many aspects including growth characteristics (169) and colonization site. The colonization site may indirectly affect virulence, probably due to production of specific adhesion molecules (59, 155, 237). Bacterial strains also differ in endotoxin and exotoxin production and in their ability to resist phagocytosis and killing by neutrophils. However, these factors have not been absolutely correlated with virulence (154, 170, 627). Bacterial strains have been grouped based on an indirect hemagglutination assay or gel diffusion precipitin test.

The majority of rabbits infected with *P. multocida* are asymptomatic carriers. Transition from asymptomatic to symptomatic infection is related to factors discussed above. When present, clinical signs can occur in nearly any organ, probably due to hematogenous spread of the organism. The most common presentations, in descending order of occurrence, are rhinitis (snuffles), conjunctivitis, pneumonia, otitis media, otitis interna, abscesses, genital tract infections, and septicemia (154). Physiologic alterations may also occur (656). Colonization often occurs initially in the pharynx. The infection quickly spreads to the nasal cavity, from which it disseminates via

direct or hematogenous spread to the lungs, middle ear, conjunctival sac, subcutaneous tissues, and visceral organs (154). Regardless of the organ system affected, the hallmark of *P. multocida* infection is suppurative inflammation. The accompanying exudate is most often purulent. Microscopically, affected tissues may be edematous, hyperemic, congested, and necrotic (517). As alluded to above, the factors responsible for tissue damage are incompletely known but may include the production of toxins, antiphagocytic substances, or adhesions (154). Large amounts of thick pus may also place direct pressure on adjacent tissues, such as in the lungs, and may further compromise organ function. *P. multocida* infection has been shown to increase the expression of vascular cell adhesion molecule 1 by aortic endothelium (548) and to alter host physiology (656). Eventual natural infection of laboratory rabbits with *P. multocida* is nearly unavoidable without the use of expensive barrier housing. While latent nasal colonization will probably have no effect on experimental studies, clinical pasteurellosis could invalidate several types of studies, particularly those involving the respiratory tract.

Digestive System

Viruses. (i) Adenovirus. Adenoviruses are dsDNA viruses that have been recovered from many animal species. However, adenovirus infections are uncommon in rabbits and have been reported only in Europe. Bodon and coworkers (54, 55) reported isolating an adenovirus from the spleen, kidney, lungs, and intestines of 6- to 8-week-old rabbits with diarrhea. The virus agglutinated rabbit erythrocytes. Little information is available on the mechanisms and consequences of adenovirus infection in rabbits. Therefore, much of what is known about adenovirus infection of rabbit tissues comes from studies with rabbit models and adenoviruses from other species. Reddick and Lefkowitz (543) observed persistent viral infection of lymphoid tissues following experimental infection of rabbits with human adenovirus type 5. Lippe et al. (403) demonstrated binding of the E3/19K protein component of adenovirus type 2 to newly synthesized human cell line MHC class I molecules, with inhibition of MHC molecule phosphorylation and trafficking to the cell surface.

Recombinant adenoviruses have successfully infected rabbit hepatocytes (367), autologous rabbit vascular interposition grafts (374), and cultured rabbit corneal epithelial cells (12). Others have used an in vivo rabbit model system to test the efficacy of novel antiviral drugs against human adenovirus type 5 infections (244). These studies illustrate the utility of rabbit-adenovirus model systems. It is likely that endogenous infections with rabbit adenovirus would interfere with such studies as well as with research on rabbit intestinal physiology or with adenovirus vaccine studies conducted in rabbits (742).

(ii) Rabbit enteric coronavirus. Two distinct forms of coronavirus infection have been reported in rabbits. These include rabbit enteric coronavirus and pleural effusion disease/myopathy virus, which is discussed in the section on multiple systems, below. The inability to culture these viruses in vitro has limited experimental study of them.

Rabbit enteric coronavirus, an ssRNA virus, has been detected in the feces of young rabbits with diarrhea in Canada and Europe (181, 383, 503, 514). Serologic surveys have extended knowledge of the range of infected rabbitries to the United States (149). However, only one natural outbreak of disease has been reported, in Germany (181). In that outbreak, clinical signs in 3- to 8-week old rabbits included lethargy, diarrhea, abdominal distension, and 100% mortality. The cecum was distended with watery fluid, and diffuse inflammation

and mucosal edema were found throughout the intestinal tract. In experimental infections, clinical signs are limited to variable fecal water content without mortality (158, 503). In one study, the small intestines were congested, with transient evidence of villus tip and M cell necrosis, atrophy, and crypt hyperplasia. The cecal contents were watery (158). The virus hemagglutinates rabbit erythrocytes but has not been shown to be cytopathic for a variety of cell lines (159, 383).

There is a high level of serologic cross-reactivity between rabbit enteric coronavirus and other mammalian group 1 viruses (604). Therefore, natural infection of laboratory rabbits would not only interfere with research involving the intestinal tract but would also confound research with polyclonal anti-mammalian coronavirus serum produced in infected antibody-producing rabbits.

(iii) Lapine parvovirus. Lapine parvovirus is an ssDNA virus. Infection has been identified serologically in commercial rabbitries in the United States, Europe, and Japan (442). Like other parvoviruses, transmission is fecal-oral. Clinical signs in neonatal rabbits consist of anorexia and listlessness. Pathologic changes consist of catarrhal enteritis with hyperemia of the small intestine, hypersecretion of intestinal mucus, and exfoliation of small intestinal epithelial cells. Virus can be detected in most visceral organs (424). Natural infection of laboratory rabbits could interfere with research in which rabbit cell cultures or in vitro immunologic assays are used and in research in which architectural changes in visceral organs would be confounding.

(iv) Rabbit oral papillomavirus. Rabbit oral papillomavirus is a dsDNA virus of the family *Papovaviridae*. The prevalence of infection is low in laboratory rabbit colonies. Transmission is via direct contact. Development of lesions may be facilitated by damage to the oral mucosa (716). When present, lesions are usually found on the ventral surface of the tongue but may also be found on the mucosal surface of the buccal cavity (517); they consist of small whitish growths which may eventually ulcerate (171) before disappearing (509). Histologically, the lesions appear as papillomas (716). Natural infection of laboratory rabbits with rabbit oral papillomavirus could interfere with feeding and studies in which feed intake and/or weight gain is measured.

(v) Rotavirus. Rotaviruses are dsRNA viruses of the family *Reoviridae*. Rotaviruses are classified into groups and subgroups (171). The isolate infecting rabbits, group A serotype 3, also infects humans and other animals. Infection is common in both wild and laboratory rabbits. The virus is extremely contagious, and transmission is fecal-oral. Clinical signs vary depending on host age, exposure history, and the presence of other synergistic organisms (171). In endemically infected colonies, outbreaks are most common in recently weaned rabbits, probably due to waning of passively transferred maternal antibodies. Disease is most severe in preweanlings from naive colonies. Clinical signs include severe diarrhea, anorexia, dehydration, and high mortality (171). Pathologic changes include marked congestion, distension, and petechiation of the colon (572); small intestinal distension with mucosal hemorrhages; and a fluid-filled cecum (98). It should be borne in mind, however, that in most reports of outbreaks, attempts to demonstrate the presence of other pathogens have not been made. It is generally thought that pure rotavirus infections are mild and that lesions are limited to a fluid-filled cecum, swollen mesenteric lymph nodes, small intestinal villous atrophy most pronounced in the ileum, increased crypt depth, and lymphocytic infiltrates in the lamina propria, without involvement of the large intestine (171, 396, 514, 648). In this regard, Thouless et al. (647) reported a synergistic effect between rotavirus and

Escherichia coli, whereby weanling rabbits developed more severe diarrheal disease than that resulting from either pathogen alone. Infection is self-limiting, and immunity is long-lasting (118, 171, 268). Therefore, natural infection of laboratory rabbits with rotavirus would have at least temporary adverse effects on research involving intestinal physiology.

Bacteria (i) *Clostridium piliforme*. As discussed in the section on pathogens of mice and rats, *C. piliforme* is a gram-negative, filamentous bacteria infecting a wide range of animals, including rabbits, and is the causative agent of Tyzzer's disease. The prevalence of infection remains high in domestic rabbits supplied for research (247). Transmission is via ingestion of infectious endospores. Young rabbits are most susceptible, although rabbits of all ages may develop clinical signs. Both epizootic and enzootic infections occur (154). Clinical signs include profuse, watery diarrhea; lethargy; anorexia; dehydration; and death. Surviving rabbits may become chronically affected and serve as a source of infection for other rabbits. Enzootic infections may be revealed following immunosuppression or other stressors (6). Lesions of Tyzzer's disease consist primarily of necrotic foci in the cecum and adjacent intestinal segments, the liver, and, rarely, the myocardium. There are petechial and ecchymotic hemorrhages on the serosal surface of the cecum and adjacent intestine. Intestinal stenosis may follow fibrotic healing of necrotic foci (6, 154). Natural infection of rabbits used in research would compromise studies involving the gastrointestinal and cardiac system even if no deaths occurred.

(ii) *Clostridium spiroforme*. Enteric diseases in general and specifically enterotoxemic conditions are common in laboratory rabbits. *Clostridium spiroforme*, a gram-positive, endospore-forming anaerobe, is the predominant causative agent of rabbit enterotoxemia. Occasionally, other clostridial species such as *C. perfringens* and *C. difficile* are involved (154). Rabbits do not normally harbor *C. spiroforme*, and transmission is fecal-oral. Recently weaned rabbits are most susceptible to enterotoxemia, probably due to opportunistic overgrowth of their immature gastrointestinal flora by *C. spiroforme*. Overgrowth is facilitated by, but does not require, some local or systemic stress such as weaning, antibiotic administration, or change of feed to a high-energy, low-fiber diet (154). Disease also occurs in adults following disruption of the normal flora by antibiotics; copathogens; or other stressors, including lactation or dietary changes (154). The hallmark of enterotoxemia is acute onset of watery diarrhea accompanied by anorexia and lethargy, which may end in death. Peracute cases with no premonitory signs, and chronic cases presenting as anorexia and weight loss, also occur. Pathologic findings include petechial and ecchymotic hemorrhaging on the serosal surface of the cecum and, occasionally, other segments of the large intestine. The cecum is usually filled with fluid and gas (154). Mucosal lesions consist of inflammation, focal necrosis, and formation of erosions and ulcers. All rabbit isolates of *C. spiroforme* produce a cytotoxin similar to *C. perfringens* type E iota toxin. Natural infection of laboratory rabbits would interfere with many types of studies, most notably those involving the gastrointestinal system.

Parasites. (i) *Cryptosporidium parvum*. Rabbits, like other mammals, may become infected with *Cryptosporidium parvum*, an intracellular, extracytoplasmic parasitic protozoan inhabiting the epithelial lining of the ileum and jejunum. The prevalence of infection is assumed to be low in laboratory rabbits. The life cycle is direct, and sporulated infectious oocysts are released in the feces. Unlike in other mammals, in which infection often results in severe disease and clinicopathologic changes (140), both natural and experimental infections of rabbits are usually asymptomatic (319, 544). Despite the lack

of clinical signs, histologic examination of the intestines of infected rabbits reveals alterations in villus architecture, including a decrease in the villus-to-crypt ratio, disruption of microvilli, mild edema of the lamina propria, and dilation of intestinal lacteals (319, 544).

Rabbits are used in a variety of ways in cryptosporidiosis research. Near-term fetal rabbit small intestinal xenografts are suitable for studies of early events of cryptosporidial infection (649). Laboratory rabbits are used to produce polyclonal anti-cryptosporidial antiserum (487, 546). Natural infection of antibody-producing rabbits with *C. parvum* might skew the seroreactivity profiles of such rabbits. Also, natural infection may complicate the interpretation of histologic changes in the intestines of rabbits in studies in which the intestinal mucosal architecture is evaluated.

(ii) *Eimeria stiedae*. *Eimeria stiedae*, an Apicomplexan parasite, is the causative agent of hepatic coccidiosis in rabbits. While infection may be common in some commercial rabbitries (533, 700), modern laboratory animal husbandry methods and effective chemotherapeutics have considerably reduced the prevalence of infection in laboratory rabbits. The life cycle is direct, with unsporulated oocysts released in the bile and exiting the rabbit with the feces. Sporulation to the infective stage occurs in less than 3 days under optimal conditions (609). Sanitation of cages removes infectious oocysts. Sporozoites penetrate the small intestinal mucosa and arrive in the liver. The exact means of transport from the intestine to the liver is uncertain, although evidence exists for both hematogenous and lymphatic migration (506). Once in the liver, sporozoites invade the bile duct epithelium and undergo asexual replication (schizogony) followed by the production of sexual stages (gametogony), which unite to form oocysts. Revets et al. (547) reported finding virus-like RNA particles in sporozoites of all isolates of *E. stiedae* examined. The significance of such particles is unknown.

Mild infections are frequently asymptomatic. When present, severe infections usually occur in young rabbits (27, 700) and proceed through four pathophysiologic events: (i) hepatic damage during schizogony, (ii) cholestasis, (iii) metabolic dysfunction, and (iv) "immunodepression" (28). When present, clinical signs are referable to hepatic dysfunction and biliary blockage and include anorexia, icterus, diarrhea or constipation, and, rarely, death. Gross necropsy findings include hepatomegaly with dilated bile ducts appearing as yellowish lesions throughout the liver. The gallbladder may also be enlarged and contain exudate. Microscopically, there is destruction and regeneration of the bile duct epithelium resulting in bile duct hyperplasia, reduplication, fibrosis, distension, and lymphoplasmacytic infiltration. Rupture of enlarged bile ducts results in a severe granulomatous response, while compression of adjacent liver tissue results in ischemic hepatic necrosis (506). Clinicopathologic changes in natural and/or experimental infections include increases in β - and γ -globulin, β -lipoprotein, succinate dehydrogenase (which later declines), bilirubin, alanine transaminase, and aspartate transaminase levels in serum. Decreases in α -lipoprotein, glucose, and protein levels in serum and in alkaline phosphatase activity in the liver have also been noted (1, 27, 28, 506). In addition, pharmacokinetics, hepatic biotransformation, and biliary and urinary excretion of conjugated bromosulfophthalein are markedly altered following experimental infection (190).

Mildly infected rabbits mount both cellular and humoral immune responses (355, 506). In contrast, Barriga and Arnoni (28) reported that the final pathophysiologic event of overwhelming hepatic coccidiosis is "immunodepression," so called because young rabbits were unable to control the production of

sexual stages of the parasite. However, caution is warranted in using the term "immunodepression," since no immune function tests were conducted to evaluate immune system status. Rabbits may have been unable to control the infection due to immunosuppression, clonal exhaustion, anergy, clinicopathologic changes, etc. Further studies are needed to explain the apparent unresponsiveness in terminal hepatic coccidiosis.

E. stiedae has been used to establish a model of liver disease mimicking biliary cirrhosis (190). Natural infection of laboratory rabbits with *E. stiedae* would interfere with such studies and may confound other studies involving the hepatobiliary system and/or evaluation of enzyme profiles in serum.

(iii) Intestinal coccidiosis. Coccidia of several species of the genus *Eimeria* are known to infect laboratory rabbits. The most pathogenic species are *E. intestinalis* and *E. flavescens*, followed by *E. magna*, *E. irresidua*, *E. piriformis*, *E. perforans*, *E. neoleporis* (*E. coecicola*), and *E. media* (682, 690). Both mixed- and single-species infections are common, although the prevalence has declined with improvements in facility management. The life cycles of intestinal coccidia are similar to that of *E. stiedae*, except that all stages occur in the intestine (401), with the exact location depending upon the species of *Eimeria*. Drouet-Viard et al. (175) have suggested that sporozoites invade the duodenal epithelium and migrate to the ileum by an as yet unknown nonluminal tissue route. Asexual stages have also been reported to develop in intestinal lymphoid tissue (505). Clinical signs are variable and are usually present only in young animals; they include weight loss, diarrhea with or without blood, intussusception, and death (506). The cecum and colon contain dark, watery, foul-smelling fluid. Histopathologic changes in infected intestinal segments include epithelial necrosis; mucosal ulceration, congestion, edema, and, occasionally, hemorrhages; villous atrophy; and leukocytic exudate. Clinicopathologic changes reported in cases of experimental coccidiosis included hemodilution and hypokalemia (517). Unlike for avian coccidia, where considerable information is available on physiologic effects of *Eimeria* spp., such as on TNF production (747), little similar information is available on intestinal coccidiosis of rabbits. As with *E. stiedae*, mild infections result in the development of protective immunity (124, 486). However, immunity is not cross-protective among intestinal coccidia. Natural infection of laboratory rabbits with intestinal coccidia may confound studies of intestinal physiology and/or architecture.

(iv) *Passalurus ambiguus*. *Passalurus ambiguus*, the rabbit pinworm, is common in lagomorphs in many parts of the world. The life cycle is direct, with adult worms found principally in the anterior cecum and large intestine and larval stages found in the mucosa of the small intestine and cecum. Infection is established following ingestion of infective eggs (297). Many consider rabbit pinworms harmless, while others have reported declines in the general condition and breeding performance of rabbits coinfecting with *P. ambiguus* and *Obeliscoides cuniculi*, a helminth parasite uncommonly found in the stomachs of rabbits (179). As is the case with rodent pinworm infections, more sophisticated studies may reveal subtle effects of these parasites on rabbit health and suitability as research subjects.

Dermal System

Viruses. (i) Cottontail rabbit (Shope) papillomavirus. Cottontail rabbit papillomavirus is a dsDNA virus of the family *Papovaviridae*. Infection is common in wild rabbits of the mid-western and western United States but uncommon in laboratory rabbits. Transmission to domestic rabbits most probably occurs only from infected wild rabbits, since virus is rarely

detected in lesions of domestic rabbits but is common in lesions of wild rabbits. Transmission is via arthropod vectors such as mosquitoes and, historically, ticks (171). In domestic rabbits, wartlike growths (papillomas) occur most commonly on the eyelids and ears (264) and frequently progress to squamous cell carcinomas that commonly metastasize to regional lymph nodes and lungs (368). Amyloid deposition in the kidneys, liver, and spleen is also common (171). Cottontail rabbit papillomavirus was the first oncogenic mammalian virus recognized. It has been extensively studied as a model of oncogenesis (402, 558). Natural infection of laboratory rabbits would compromise several types of studies, most obviously long-term carcinogenicity studies.

Bacteria. (i) *Staphylococcus aureus*. The reader is referred to the section on mice and rats for a discussion of the biology of *S. aureus*. Multiple strains of *S. aureus* have been isolated from rabbits (161). In addition to entry via breaks in normal barriers, transmission may occur following ingestion of mastitic milk. Infection occurs most commonly in the skin and subcutaneous tissues but may also be found in the upper airways, lungs, conjunctiva, middle ear, feet, and mammary glands. Occasionally, staphylococcal septicemia occurs, initiating disseminated abscess formation (154). Suppurative inflammation consists primarily of neutrophils and necrotic cellular debris and may be accompanied by edema, hemorrhage, and fibrin deposition (154). As discussed in the section on *S. aureus* infection of mice and rats, biologically active products of *S. aureus* (86, 105, 130, 154, 206, 334, 498, 545, 560) have profound effects on the host (50, 206, 292, 585). In addition, specific effects in rabbits include vasoconstriction (699), inhibition of myocardial function (498), changes in the activity of hepatic enzymes (363), and decreased neutrophil function (24).

Rabbits are highly susceptible to staphylococcal infections and are therefore used extensively in *S. aureus* research (11, 25, 39, 88, 90, 105, 121, 187, 431). While asymptomatic colonization is of no concern and, indeed, is unavoidable outside of strict barrier containment, active infection would interfere with many studies involving rabbits.

(ii) *Treponema cuniculi*. *Treponema cuniculi* is a gram-negative spirochete and is the causative agent of rabbit syphilis. Infection is common in wild hares from many parts of the world and occasionally occurs in rabbits produced for research facilities. Transmission is primarily sexual via penetration of mucous membranes but may also occur by other routes (154). Susceptibility is rabbit age and strain dependent (139). The course of the disease is relatively lengthy. Lesions develop 3 to 6 weeks following exposure and are most apparent on and around mucocutaneous junctions of the face and genitalia. Lesions begin as areas of erythema and edema, with or without vesicles, and progress to ulcers and crusts. The lesions generally resolve after several weeks (138). Histologically, advanced lesions consist of epidermal ulceration, hyperkeratosis, hyperplasia, and acanthosis overlain by crusts (154). Dermal inflammation consists primarily of macrophages and plasma cells. Serologic responses are also slow to develop, requiring 2 to 3 months from the time of infection (139). In unmedicated rabbits, in contrast to rabbits treated with antibiotics, antibodies may remain positive (168), suggesting a carrier state, possibly in regional lymph nodes (154).

Because most treponemes cannot be grown *in vitro* and because *T. pallidum*, the causative agent of human syphilis, is known to infect rabbits, the laboratory rabbit has been extensively used as a model of human syphilis (22, 83, 474, 530, 587). Consequently, a considerable body of information has been gathered on *T. pallidum* infections of rabbits, and cautious extrapolation to *T. cuniculi* is possible. By using the rabbit-*T.*

pallidum model, it has been demonstrated that the development of immunity is extremely complex and involves a composite of both stimulation and down-regulation (207). Mononuclear cells from rabbits chronically infected with *T. pallidum* may lose the ability to produce or bind IL-2 (530). Spleen cells of rabbits infected with *T. pallidum* produce antitreponemal lymphotoxins. This ability was disturbed when circulating immune complexes and autolymphocytotoxins were present, suggesting that the impairment of the ability of the cells to produce antitreponemal lymphotoxins may facilitate the survival of treponemes in the host despite the presence of immunologically competent cells (529). Defensins produced by rabbit alveolar macrophages and neutrophils may contribute to the control of local *T. pallidum* infection, suggesting a role for acute inflammatory processes in the resolution of early experimental syphilis (64). Natural infection of laboratory rabbits would interfere with several types of studies, such as those involving the dermal and immune systems.

Parasites. (i) *Cheyletiella parasitivorax*. *Cheyletiella parasitivorax* is a nonburrowing mite with widespread distribution (297). The entire life cycle is completed on the rabbit host. Mites attach to the host, primarily in the interscapular region, and obtain tissue fluids. When present, histopathologic changes include subacute dermatitis with mild hyperkeratosis, accompanied by an inflammatory exudate. Affected areas may be partially alopecic, with a finely granular material (dried exudate) covering the skin. The lesions are nonpruritic (216, 675). While infested rabbits appear largely unaffected by the parasite, histopathologic changes in the skin could compromise dermal studies conducted in affected rabbits.

(ii) *Psoroptes cuniculi*. *Psoroptes cuniculi* is an obligate, nonburrowing parasite causing otoacariasis in domestic rabbits. The prevalence of infestation is high, and infestation has been found worldwide. Mites are found almost exclusively on the inner surface of the pinnae. The entire life cycle is completed on the rabbit. Clinical signs include intense pruritus (itching), scratching, and head shaking with subsequent serum exudation and crusting on the pinnae, which are painful. Self-excoriation may lead to secondary bacterial infections. The mites initially feed on skin detritus and later feed on serum exudates. Gross observations include inflammation and serum crusting of the inner surfaces of the pinnae. Histologically, the pinnae become chronically inflamed with hypertrophy of the malpighian layer, parakeratosis of the horny layer, and epithelial sloughing (297). As in other animal species with psoroptic mange, the clinical signs and histopathology of infested rabbits are suggestive of an IgE-mediated type 1 hypersensitivity response. Lymphocyte responsiveness and antibody production are suppressed in heavily infested rabbits (667), and immunogenic parasite glycoprotein antigens have been identified (668). While very mild infestations may not alter immune responsiveness (667), heavy infestations could alter the immune function of laboratory rabbits. Additionally, behavioral changes in pruritic rabbits could alter a variety of studies, including those dependent upon adequate feed intake. Laboratory rabbits are routinely treated prophylactically with ivermectin to prevent clinical infestations.

(iii) *Sarcoptes scabiei*. *Sarcoptes scabiei* is an obligate, burrowing parasite that rarely infests domestic rabbits. Infestations usually begin on the muzzle and extend to the remainder of the head. The entire life cycle is completed on the rabbit. Female mites tunnel burrows into the epidermis and are found within these burrows, along with eggs and young larvae, while older larvae, nymphs, and adult males are found on the surface (297). Mites feed on epithelial cells and serum exudates. Pruritus associated with scabies is considered among the most

intense known in veterinary or human medicine. Animals will forego feeding in favor of scratching in an attempt to obtain some relief. Self-excoriation often leads to secondary bacterial infections. In addition to pruritus, clinical signs may include general debility, emaciation, and death (297). Pathologic findings include dermatitis with serum exudation. Heavy infestations may result in anemia, leukopenia, and changes in biochemical levels in serum (14). It is possible that rabbits proceed through stages of cutaneous hypersensitivity and show immune response patterns similar to those described for swine with sarcoptic mange (21); however, this has not been explored. Serum antibody profiles of infested rabbits have been reported (456). Natural infestation would probably render laboratory rabbits unusable for nearly any purposes, pending treatment with ivermectin or other acaricides.

Fungi. (i) Dermatophytes. Dermatophytes, most commonly *Trichophyton mentagrophytes* but also *Microsporum gypsum* and *M. canis*, are common in rabbitries in many parts of the world (119, 457, 599, 655). Similar species of dermatophytes infect laboratory rabbits (48, 694), although the incidences of infection and clinical disease (dermatophytosis, ringworm, favus) are low in well-managed animal facilities. Young or immunocompromised rabbits are thought to be most susceptible (48). Dermatophytes infect the epidermis and adnexal structures, including hair follicles and shafts, usually on or around the head, and cause pruritus, patchy alopecia, erythema, and crusting. Histopathologic changes in the underlying skin include neutrophilic and lymphoplasmacytic dermatitis, hyperkeratosis, folliculitis, and acanthosis. Abscess formation in hair follicles may occur secondarily (48, 517). Natural infection of laboratory rabbits may result in histopathologic changes which could confound studies involving the skin.

Genitourinary System

Viruses. (i) Rabbit hemorrhagic disease virus. Rabbit hemorrhagic disease virus is an ssRNA virus, most probably of the family *Caliciviridae* (493); it is closely related to European brown hare syndrome virus (729) and the newly named rabbit calicivirus (89). On the basis of both outbreaks and serologic studies, distribution appears to be worldwide (171). Transmission is horizontal. Sudden death may preclude the observation of additional clinical signs. When observed, the clinical signs may be referable to nearly any body system, since the underlying pathology is one of viremia followed by disseminated intravascular coagulation and multiple organ system failure. Pathologic changes are most prominent in the lungs and consist of congestion, hemorrhage, and thrombosis. Acute hepatic necrosis is also usually evident. Virtually any other organ may have pathologic changes due to microinfarction (419). Hematologic alterations include lymphopenia, thrombocytopenia, and prolongation of clotting times (171). The effects of natural rabbit hemorrhagic disease virus infection on research could vary from mild to catastrophic, depending on the virulence of the infecting strain. Strains exist for which clinical signs have not been readily observed (554) and for which mortality is high (687).

Parasites. (i) *Encephalitozoon cuniculi*. *E. cuniculi* is a microsporidian protozoan parasite capable of infecting a range of hosts, including rabbits and humans (157). The prevalence remains high in some rabbitries (253, 719), ensuring that at least some laboratory rabbits are infected. The life cycle is incompletely known. Transmission is thought to be horizontal, primarily via the urine. Following ingestion, sporoplasm from infectious spores gains entrance to the host intestinal epithelium, where multiplication occurs. Continued multiplication

results in eventual host cell rupture, with dissemination to other organs, including the liver, lungs, brain, and kidneys (128).

Infection is usually asymptomatic. When clinical signs do appear, they are generally referable to the nervous system and include torticollis, convulsions, tremors, paresis, and coma (510). Infection of dwarf rabbits has also been implicated in phacoclastic uveitis (731). Lesions are most commonly found in the kidneys and brain. Multiple, pinpoint lesions may be observed on the surface of the kidneys. Microscopically, these represent areas of granulomatous nephritis or lymphoplasmacytic infiltration, with fibrosis, tubular degeneration, and eventual focal and segmental hyalinosis and sclerosis (209, 504). Organisms may be observed, following special staining, within renal tubule cells. In the brain, the lesions consist of randomly distributed, multifocal granulomas (granulomatous encephalitis), characterized by areas of necrosis, often containing organisms, and usually surrounded by mixed leukocytes. Lesions are often perivascular and periventricular. Lymphoplasmacytic perivascular cuffing and nonsuppurative meningitis may also be present (506). Though less common, cardiac, pulmonary, and/or hepatic lesions have also been reported (222, 359, 721).

E. cuniculi infection of mice is used as a model of human microsporidiosis, and it may be possible to cautiously extrapolate pathophysiologic and/or immune mechanisms observed in the mouse model to the rabbit. For example, Didier (164) demonstrated that reactive nitrogen intermediates contribute to the killing of *E. cuniculi* by LPS plus IFN- γ -activated murine peritoneal macrophages in vitro.

Natural infection of laboratory rabbits used directly in microsporidial (721), renal, or brain research would probably compromise such efforts. In addition, infection of rabbits used in the production of antimicrosporidial antibodies may compromise the usefulness of these antisera, since antibodies to *E. cuniculi* cross-react with antigens of several microsporidia, including *E. bienersi* (717).

Multiple Systems

Viruses. (i) Coronavirus (pleural effusion disease/infectious cardiomyopathy virus). During the 1960s in Scandinavia, and subsequently elsewhere in the world, a coronavirus was found contaminating stocks of *T. pallidum* used experimentally in rabbits (201, 259, 338). It remains uncertain whether the agent is a natural pathogen of rabbits. A lack of any reports of natural infections suggests that the virus may be from another species (171). Clinical signs of infection depend on the strain and passage of the agent (171) but may include fever, anorexia, weight loss, atony, muscular weakness, tachypnea, iridocyclitis, circulatory insufficiency, and death. Likewise, pathologic findings depend on the phase of the disease and may include pulmonary edema, pleural effusion, and right ventricular dilation in the acute phase. Rabbits dying after the first week may have ascites and subepicardial and subendocardial hemorrhages. Other pathologic findings include myocarditis with myocardial degeneration and necrosis; hepatosplenomegaly with reduction of splenic white pulp; focal hepatic necrosis; congestion and focal degeneration of lymph nodes followed by proliferation; focal degenerative changes of the thymus; mild proliferative changes of renal glomeruli; and mild nonsuppurative, nongranulomatous anterior uveitis (171). The major target organ is the heart (182, 203, 338). In one report, infectious sera produced cytopathic effects in primary rabbit kidney and newborn human intestine cells (603). Clinical pathologic changes include transient lymphopenia, heterophilia, transient hypoalbuminemia, increased potassium and lactate dehydro-

genase levels in serum and elevated serum γ -globulin levels (200, 202, 203). Manifestations of pleural effusion disease/infectious cardiomyopathy (PED/IC) virus infection are multisystemic, and are similar to those observed in cats with feline infectious peritonitis, another systemic coronavirus infection (193). In addition, antisera to the PED/IC virus cross-react with other members of the mammalian group I viruses, including feline infectious peritonitis virus, canine coronavirus, porcine transmissible gastroenteritis virus, and human coronavirus (604).

PED/IC virus infection of rabbits is currently used as a model of cardiomyopathy (4). Infection of laboratory rabbits with PED/IC virus would result in undesirable changes in multiple body systems, including the lymphoid, hematologic, pulmonary, cardiovascular, ophthalmic, and renal systems, and would result in profound alterations of research results.

(ii) Myxoma virus. Myxoma virus is a dsDNA virus of the family *Poxviridae* with nearly worldwide distribution in wild rabbit populations. Infection is uncommon in laboratory rabbits but can occur via arthropod vectors, primarily mosquitoes and fleas. Clinical signs of infection (myxomatosis) vary greatly depending on the strains of both virus and host. Virulent strains, such as that found in California, frequently cause sudden death, often with conjunctivitis and edema and inflammation of the eyelids and around the nasal, anal, genital, and oral orifices. Skin nodules, while characteristic of the disease caused by strains elsewhere in the world, are not observed. Due to the generalized nature of the infection, pathologic changes, which are again virus strain dependent, may be observed in many organs. When present, localized skin tumors consist of masses of stellate mesenchymal cells ("myxoma cells") and occasional inflammatory cells, interspersed within a matrix of mucin-like material. Other pathologic changes include cutaneous edema and hemorrhaging of the skin, heart, and gastrointestinal subserosa. In addition, proliferative and/or hemorrhagic lesions, followed by degeneration and necrosis, may be observed in the lungs, liver, spleen, vasculature, kidneys, lymph nodes, and testes (171).

Recent studies have shown that myxoma virus, like other leporipoxviruses (285), may be immunosuppressive through down regulation of class I-mediated presentation of viral antigen (67) and through inhibition of TNF activity (581). Also, myxoma virus produces a serine proteinase inhibitor which ameliorates chronic inflammation in an antigen-induced arthritis model of chronic inflammation (416). Experimental rabbit-myxoma virus models are therefore used to study the biology of poxviruses and are used in arthritis research. Given the generalized nature of infection, natural infection of laboratory rabbits would compromise these and many other fields of research involving rabbits.

Bacteria. (i) *Listeria monocytogenes*. *Listeria monocytogenes* is a gram-positive, rod-shaped, intracellular bacterium which uncommonly causes disease in rabbits. Infection is acquired with contaminated feed. Clinical signs are generally absent or may be nonspecific, including anorexia, ascites, depression, weight loss, and sudden death. Pregnant does may abort and are more susceptible to infection, either because of physiological stress or because of a uterine microenvironment more conducive to survival of the organism (154). Pathologic findings are most prominent in the liver and consist of multifocal hepatic necrosis. Similar microabscesses may be seen in the spleen and adrenal glands. Septicemic spread is facilitated by phagocytosis and transport by macrophages. Pregnant does may develop acute necrotizing suppurative metritis. Pathogenesis is dependent on hemolysin production (40, 710). Abortion may also be related to the ability of pathogenic strains of *L. monocytogenes*

to cause myometrial contraction (393). Hematologic changes include a marked monocytic reaction (429). While protection is primarily cell mediated (469), serologic responses also develop and are greater in rabbits infected orally rather than intragastrically (42). Laboratory rabbits are frequently used to produce anti-*Listeria* antiserum, and a rabbit-*L. monocytogenes* model has been used to study human keratitis (745). Natural infection of laboratory rabbits could interfere with these studies or with other studies in which the cellular architecture of a variety of visceral organs is studied.

(ii) *Francisella tularensis*. *Francisella tularensis* is a gram-negative coccobacillus that causes acute septicemic disease (tularemia) in a wide range of mammalian hosts, including humans. Infection is common in wild rabbits but rare in laboratory rabbits. Two biovars infect rabbits, with *F. tularensis* bv. *tularensis* (found only in North America) being the more pathogenic (462). Virulence appears to be associated with catalase activity, cytochrome *b*₁ levels (184), and the presence of a newly recognized "envelope antigen C" (628). Transmission is via multiple routes, most commonly arthropod vectors and direct contact. Clinical signs, when present, may consist of anorexia, depression, and ataxia, or sudden death without premonitory signs. Pathologic changes include focal coagulative necrosis and congestion of the liver, spleen, and bone marrow (154). Natural infection of laboratory rabbits not only could be fatal, but also could alter the results of research involving the liver, spleen, and bone marrow.

ANIMAL HOUSING FOR PATHOGEN EXCLUSION OR CONTAINMENT

Several excellent publications describe animal housing for pathogen exclusion or containment (475). Animal housing ranges from "conventional" housing in open cages with little pathogen protection to rigid "barrier" housing designed to exclude all pathogens. The laboratory animal professional can advise the investigator on the level of protection that is appropriate to meet the research needs.

HEALTH-MONITORING PROGRAMS

Most modern animal facilities incorporate some form of health monitoring into their animal care program. While health monitoring is costly, it is sure to result in significant long-term savings in time, effort, and money. Through these programs, the animal facility director and/or manager can monitor the health status of the colony, inform the investigator of the pathogen status of the colony, prevent the entry of most pathogens into the facility, and promptly detect and deal with pathogens that do manage to enter the colony. It is far more cost effective to prevent the entry of pathogens into a facility or to detect and eliminate them early than to throw out months of research data because undetected infection rendered laboratory animals unfit for research and hence rendered the data unreliable. The interested reader is referred to other publications for more detailed information on health-monitoring programs (100, 379, 475, 602).

FUTURE TRENDS

What does the future hold regarding the natural pathogens of laboratory mice, rats, and rabbits? Several events can be anticipated. First, the decline in the prevalence of natural pathogens will continue as housing and husbandry methods improve even more. This continued "cleansing" of animal colonies will be driven by the efforts of animal facility personnel to

facilitate meaningful research, by accrediting and funding bodies, by the public, intent on seeing only valid animal-based research conducted, and by investigators increasingly aware of the impact of pathogens on research results. It is unreasonable to expect that all infectious agents will be eradicated from all animal colonies. After all, they are natural pathogens and therefore exist in feral animal populations. Breaks in the physical integrity of an animal facility or failure to adhere to standard operating procedures for pathogen exclusion will continue to allow pathogens occasional access. Second, additional effects of currently known pathogens will be reported as new research uses are found for traditional laboratory animals, new questions are asked, and new technologies are applied to those questions. Third, new pathogens will continue to be discovered and reported. Most of these previously unknown agents will not result in clinical disease, but many may affect experimental results. According to Weisbroth (714), many of these "emerging" pathogens may even be acquired from humans. While the range and magnitude of infections has decreased in laboratory mice, rats, and rabbits, continued diligence and additional study are required to ensure the wellbeing of animals used in biomedical research.

REFERENCES

1. Abdel-Ghaffar, F., M. Marzouk, M. B. Ashour, and M. N. Mosaad. 1990. Effects of *Eimeria labbeana* and *E. stiedai* infection on the activity of some enzymes in the serum and liver of their hosts. *Parasitol. Res.* **76**:440-443.
2. Abzug, M. J. 1993. Identification of trophoblastic giant cells as the initial principal target of early gestational murine enterovirus infection. *Placenta* **14**:137-148.
3. Acha-Orbea, H., and H. R. MacDonald. 1995. Superantigens of mouse mammary tumor virus. *Annu. Rev. Immunol.* **13**:459-486.
4. Alexander, L. K., B. W. Keene, and R. S. Baric. 1995. Echocardiographic changes following rabbit coronavirus infection. *Adv. Exp. Med. Biol.* **380P**: 113-115.
5. Aliouat, E. M., E. Dei-Cas, A. Ouaisi, F. Palluault, B. Soulez, and D. Camus. 1993. In vitro attachment of *Pneumocystis carinii* from mouse and rat origin. *Biol. Cell.* **77**:209-217.
6. Allen, A. M., J. R. Ganaway, T. D. Moore, and R. F. Kinard. 1965. Tyzzer's disease syndrome in laboratory rabbits. *Am. J. Pathol.* **46**:859-882.
7. al-Sheboul, S., D. Crosley, and T. A. Steele. 1996. Inhibition of reovirus-stimulated murine natural killer cell cytotoxicity by cyclosporine. *Life Sci.* **59**:1675-1682.
8. Amao, H., Y. Komukai, T. Akimoto, M. Sugiyama, K. W. Takahashi, T. Sawada, and M. Saito. 1995. Natural and subclinical *Corynebacterium kutscheri* infection in rats. *Lab. Anim. Sci.* **45**:11-14.
9. Amao, H., Y. Komukai, M. Sugiyama, K. W. Takahashi, T. Sawada, and M. Saito. 1995. Natural habitats of *Corynebacterium kutscheri* in subclinically infected ICGN and DBA/2 strains of mice. *Lab. Anim. Sci.* **45**:6-10.
10. Amao, H., Y. Komukai, M. Sugiyama, T. R. Saito, K. W. Takahashi, and M. Saito. 1993. Differences in susceptibility of mice among various strains to oral infection with *Corynebacterium kutscheri*. *Jikken Dobutsu* **42**:539-545. (In Japanese).
11. Amorena, B., J. A. Garcia de Jalon, R. Baselga, J. Duchá, M. V. Latre, L. M. Ferrer, F. Sancho, I. Mansson, K. Krovacek, and A. Faris. 1991. Infection of rabbit mammary glands with ovine mastitis bacterial strains. *J. Comp. Pathol.* **104**:289-302.
12. Araki, K., Y. Ohashi, T. Sasabe, S. Kinoshita, K. Hayashi, X. Z. Yang, Y. Hosaka, S. Aizawa, and H. Handa. 1993. Immortalization of rabbit corneal epithelial cells by a recombinant SV40-adenovirus vector. *Investig. Ophthalmol. Visual Sci.* **34**:2665-2671.
13. Araki, S., M. Suzuki, M. Fujimoto, and M. Kimura. 1995. Enhancement of resistance to bacterial infection in mice by vitamin B2. *J. Vet. Med. Sci.* **57**:599-602.
14. Arlian, L. G., M. Ahmed, and D. L. Vyszenski-Moher. 1988. Effects of *S. scabiei* var. *canis* (Acari: Sarcoptidae) on blood indexes of parasitized rabbits. *J. Med. Entomol.* **25**:360-369.
15. Armstrong, M. Y., A. L. Smith, and F. F. Richards. 1991. *Pneumocystis carinii* pneumonia in the rat model. *J. Protozool.* **38**:136S-138S.
16. Arva, E., U. Dahlgren, R. Lock, and B. Andersson. 1996. Antibody response in bronchoalveolar lavage and serum of rats after aerosol immunization of the airways with a well-adhering and a poorly adhering strain of *Streptococcus pneumoniae*. *Int. Arch. Allergy Immunol.* **109**:35-43.
17. Athanassiou, R., and G. Lussier. 1992. Mouse thymic virus infection: ultrastructural and immunocytochemical studies of infected thymus cells. *J. Exp. Anim. Sci.* **35**:63-70.
18. Bailey, C. J., B. P. Lockhart, M. B. Redpath, and T. P. Smith. 1995. The

- epidermolytic (exfoliative) toxins of *Staphylococcus aureus*. Med. Microbiol. Immunol. (Berlin) **184**:53–61.
19. **Baillie, M. B., T. J. Standiford, L. L. Laichalk, M. J. Coffey, R. Strieter, and M. Peters-Golden.** 1996. Leukotriene-deficient mice manifest enhanced lethality from *Klebsiella pneumoniae* in association with decreased alveolar macrophage phagocytic and bactericidal activities. J. Immunol. **157**:5221–5224.
 20. **Baker, D. G.** 1994. Unpublished data.
 21. **Baker, D. G., J. D. Bryant, J. F. Urban, Jr., and J. K. Lunney.** 1994. Swine immunity to selected parasites. Vet. Immunol. Immunopathol. **43**:127–133.
 22. **Baker-Zander, S. A., and S. A. Lukehart.** 1992. Macrophage-mediated killing of opsonized *Treponema pallidum*. J. Infect. Dis. **165**:69–74.
 23. **Ball-Goodrich, L. J., and E. Johnson.** 1994. Molecular characterization of a newly recognized mouse parvovirus. J. Virol. **68**:6476–6486.
 24. **Bamberger, D. M., B. L. Herndon, K. M. Bettin, and D. N. Gerding.** 1989. Neutrophil chemotaxis and adherence in vitro and localization in vivo in rabbits with *Staphylococcus aureus* abscesses. J. Lab. Clin. Med. **114**:135–141.
 25. **Bamberger, D. M., and B. L. Herndon.** 1990. Bactericidal capacity of neutrophils in rabbits with experimental acute and chronic abscesses. J. Infect. Dis. **162**:186–192.
 26. **Barkon, M. L., B. L. Haller, and H. W. Virgin IV.** 1996. Circulating immunoglobulin G can play a critical role in clearance of intestinal reovirus infection. J. Virol. **70**:1109–1116.
 27. **Barriga, O. O., and J. V. Arnoni.** 1979. *Eimeria stiedae*: oocyst output and hepatic function of rabbits with graded infections. Exp. Parasitol. **48**:407–414.
 28. **Barriga, O. O., and J. V. Arnoni.** 1981. Pathophysiology of hepatic coccidiosis in rabbits. Vet. Parasitol. **8**:201–210.
 29. **Barthold, S. W.** 1991. A review of common infectious disease agents of laboratory mice and rats: potential influence on *Pneumocystis carinii*. J. Protozool. **38**:131S–133S.
 30. **Barthold, S. W., D. S. Beck, and A. L. Smith.** 1993. Enterotropic coronavirus (mouse hepatitis virus) in mice: influence of host age and strain on infection and disease. Lab. Anim. Sci. **43**:276–284.
 31. **Barthold, S. W., G. L. Coleman, P. N. Bhatt, G. W. Osbaldiston, and A. M. Jonas.** 1976. The etiology of transmissible murine colonic hyperplasia. Lab. Anim. Sci. **26**:889–894.
 32. **Barthold, S. W., G. L. Coleman, R. O. Jacoby, E. M. Livstone, and A. M. Jonas.** 1978. Transmissible murine colonic hyperplasia. Vet. Pathol. **15**:223–236.
 33. **Barthold, S. W., M. S. de Souza, and A. L. Smith.** 1990. Susceptibility of laboratory mice to intranasal and contact infection with coronaviruses of other species. Lab. Anim. Sci. **40**:481–485.
 34. **Barthold, S. W., and A. M. Jonas.** 1977. Morphogenesis of early 1,2-dimethylhydrazine-induced lesions and latent period reduction of colon carcinogenesis in mice by a variant of *Citrobacter freundii*. Cancer Res. **37**:4352–4360.
 35. **Barthold, S. W., and A. L. Smith.** 1992. Viremic dissemination of mouse hepatitis virus-JHM following intranasal inoculation of mice. Arch. Virol. **122**:35–44.
 36. **Barthold, S. W., A. L. Smith, and P. N. Bhatt.** 1993. Infectivity, disease patterns, and serologic profiles of reovirus serotypes 1, 2, and 3 in infant and weanling mice. Lab. Anim. Sci. **43**:425–430.
 37. **Barthold, S. W., G. W. Osbaldiston, and A. M. Jonas.** 1977. Dietary, bacterial and host genetic interactions in the pathogenesis of transmissible murine colonic hyperplasia. Lab. Anim. Sci. **27**:938–945.
 38. **Bauer, N. L., J. R. Paulsrud, M. S. Bartlett, J. W. Smith, and C. E. Wilde III.** 1993. *Pneumocystis carinii* organisms obtained from rats, ferrets, and mice are antigenically different. Infect. Immun. **61**:1315–1319.
 39. **Bawdon, R. E., A. M. Fiskin, B. B. Little, L. L. Davis, and G. Vergarra.** 1989. Fibronectin and postpartum infection in rabbits: an animal model. Gynecol. Obstet. Invest. **28**:185–190.
 40. **Beattie, I. A., B. Swaminathan, and H. K. Ziegler.** 1990. Cloning and characterization of T-cell-reactive protein antigens from *Listeria monocytogenes*. Infect. Immun. **58**:2792–2803.
 41. **Beck, J. M., R. L. Newbury, B. E. Palmer, M. L. Warnock, P. K. Byrd, and H. B. Kaltreider.** 1996. Role of CD8+ lymphocytes in host defense against *Pneumocystis carinii* in mice. J. Lab. Clin. Med. **128**:477–487.
 42. **Belen-Lopez, M., V. Briones, J. F. Fernandez-Garayzabal, J. A. Vazquez-Boland, J. A. Garcia, M. M. Blanco, G. Suarez, and L. Dominguez.** 1993. Serological response in rabbits to *Listeria monocytogenes* after oral or intragastric inoculation. FEMS Immunol. Med. Microbiol. **7**:131–134.
 43. **Belosevic, M., G. M. Faubert, and J. D. MacLean.** 1985. Suppression of primary antibody response to sheep erythrocytes in susceptible and resistant mice infected with *Giardia muris*. Infect. Immun. **47**:21–25.
 44. **Bemis, D. A., and S. A. Wilson.** 1985. Influence of potential virulence determinants on *Bordetella bronchiseptica*-induced ciliostasis. Infect. Immunol. **50**:35–42.
 45. **Benedettini, G., G. DeLibero, L. Mori, and M. Campa.** 1984. *Staphylococcus aureus* inhibits contact sensitivity to oxazolone by activating suppressor B cells in mice. Int. Arch. Allergy Appl. Immunol. **73**:269–273.
 46. **Bennette, J. G.** 1960. Isolation of a non-pathogenic tumour-destroying virus from mouse ascites. Nature **187**:72–73.
 47. **Bentvelzen, P., and J. Briinkhof.** 1980. Ubiquity of natural antibodies to the mammary tumour virus in mice. Arch. Geschwulstforsch. **50**:193–203.
 48. **Bergdall, V. K., and R. C. Dysko.** 1994. Metabolic, traumatic, mycotic, and miscellaneous diseases, p. 345–353. In P. J. Manning, D. H. Ringler, and C. E. Newcomer (ed.), The biology of the laboratory rabbit. Academic Press, Inc., San Diego, Calif.
 49. **Besselsen, D. G., D. J. Pintel, G. A. Purdy, C. L. Besch-Williford, C. L. Franklin, R. R. Hook, Jr., and L. K. Riley.** 1996. Molecular characterization of newly recognized rodent parvoviruses. J. Gen. Virol. **77**:899–911.
 50. **Bhakdi, S., and J. Trantum-Jensen.** 1991. Alpha-toxin of *Staphylococcus aureus*. Microbiol. Rev. **55**:733–751.
 51. **Bihun, C. G., and D. H. Percy.** 1995. Morphologic changes in the nasal cavity associated with sialodacryoadenitis virus infection in the Wistar rat. Vet. Pathol. **32**:1–10.
 52. **Blailock, Z. R., E. R. Rabin, and J. L. Melnick.** 1967. Adenovirus endocarditis in mice. Science **157**:69–70.
 53. **Blakley, B. R., and C. G. Rousseaux.** 1991. Effect of ivermectin on the immune response in mice. Am. J. Vet. Res. **52**:593–595.
 54. **Bodon, L., and L. Prohaszka.** 1980. Isolation of adenovirus from rabbits with diarrhea. Acta. Vet. Acad. Sci. Hung. **28**:247–255.
 55. **Bodon, L., L. Prohaszka, E. Adam, and I. Nasz.** 1979. Isolation of an adenovirus from rabbits. Acta. Vet. Acad. Sci. Hung. **27**:73–75.
 56. **Bolander, F. F., Jr.** 1994. The effect of mouse mammary tumor virus receptor activation on mammary epithelial cell sensitivity toward prolactin. Biochem. Biophys. Res. Commun. **205**:524–528.
 57. **Bolander, F. F., Jr., and M. E. Blackstone.** 1990. Thyroid hormone requirement for retinoic acid induction of mouse mammary tumor virus expression. J. Virol. **64**:5192–5193.
 58. **Bolister, N. J., H. E. Johnson, and C. M. Wathes.** 1992. The ability of airborne *Klebsiella pneumoniae* to colonize mouse lungs. Epidemiol. Infect. **109**:121–131.
 59. **Bonilla-Ruz, L. F., and G. A. Garcia-Delgado.** 1993. Adherence of *Pasteurella multocida* to rabbit respiratory epithelial cells in vitro. Rev. Latinoam. Microbiol. **35**:361–369.
 60. **Boorman, G. A., P. H. C. Lina, C. Zurcher, and H. T. M. Nieuwerkerk.** 1973. *Hexamita* and *Giardia* as a cause of mortality in congenitally thymus-less (nude) mice. Clin. Exp. Immunol. **15**:623–627.
 61. **Boot, R., H. van Herck, and J. van der Logt.** 1996. Mutual viral and bacterial infections after housing rats of various breeders within an experimental unit. Lab. Anim. **30**:42–45.
 62. **Boot, R., and M. Bisgaard.** 1995. Reclassification of 30 Pasteurellaceae strains isolated from rodents. Lab. Anim. **29**:314–319.
 63. **Booth, T. W., A. A. Scalzo, C. Carrello, P. A. Lyons, H. E. Farrell, G. R. Singleton, and G. R. Shellam.** 1993. Molecular and biological characterization of new strains of murine cytomegalovirus isolated from wild mice. Arch. Virol. **132**:209–220.
 64. **Borenstein, L. A., T. Ganz, S. Sell, R. I. Lehrer, and J. N. Miller.** 1991. Contribution of rabbit leukocyte defensins to the host response in experimental syphilis. Infect. Immun. **59**:1368–1377.
 65. **Borrow, P., C. F. Evans, and M. B. Oldstone.** 1995. Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J. Virol. **69**:1059–1070.
 66. **Boschert, K. R., T. R. Schoeb, D. B. Chandler, and D. L. Dillehay.** 1988. Inhibition of phagocytosis and interleukin-1 production in pulmonary macrophages from rats with sialodacryoadenitis virus infection. J. Leukocyte Biol. **44**:87–92.
 67. **Boshkov, L. K., J. L. Macen, and G. McFadden.** 1992. Virus-induced loss of class I MHC antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus. J. Immunol. **148**:881–887.
 68. **Bowden, J. J., P. Baluk, P. M. Lefevre, T. R. Schoeb, J. R. Lindsey, and D. M. McDonald.** 1996. Sensory denervation by neonatal capsaicin treatment exacerbates *Mycoplasma pulmonis* infection in rat airways. Am. J. Physiol. **270**:L393–403.
 69. **Bradfield, J. F., T. R. Schachtman, R. M. McLaughlin, and E. K. Steffen.** 1992. Behavioral and physiologic effects of inapparent wound infection in rats. Lab. Anim. Sci. **42**:572–578.
 70. **Braunwald, J., H. Nonnenmacher, C. A. Pereira, and A. Kirn.** 1991. Increased susceptibility to mouse hepatitis virus type 3 (MHV3) infection induced by a hypercholesterolaemic diet with increased adsorption of MHV3 to primary hepatocyte cultures. Res. Virol. **142**:5–15.
 71. **Brennan, P. C., T. E. Fritz, R. J. Flynn, and C. M. Poole.** 1965. *Citrobacter freundii* associated with diarrhea in laboratory mice. Lab. Anim. Care **15**:266–275.
 72. **Brijlal, S., A. V. Lakshmi, M. S. Bamji, and P. Suresh.** 1996. Flavin metabolism during respiratory infection in mice. Br. J. Nutr. **76**:453–462.
 73. **Broegden, K. A., R. C. Cutlip, and H. D. Lehmkuhl.** 1993. Cilia-associated respiratory bacillus in wild rats in central Iowa. J. Wildl. Dis. **29**:123–126.
 74. **Brown, D. W., R. M. Welsh, and A. A. Like.** 1993. Infection of peripancreatic lymph nodes but not islets precedes Kilham rat virus-induced diabetes

- in BB/Wor rats. *J. Virol.* **67**:5873–5878.
75. **Brown, M. B., and D. A. Steiner.** 1996. Experimental genital mycoplasmosis: time of infection influences pregnancy outcome. *Infect. Immun.* **64**:2315–2321.
 76. **Brownstein, D. G., and L. Gras.** 1997. Differential pathogenesis of lethal mousepox in congenic DBA/2 mice implicates natural killer cell receptor NKR-P1 in necrotizing hepatitis and the fifth component of complement in recruitment of circulating leukocytes to spleen. *Am. J. Pathol.* **150**:1407–1420.
 77. **Brownstein, D. G., and E. C. Weir.** 1987. Immunostimulation in mice infected with Sendai virus. *Am. J. Vet. Res.* **12**:1692–1696.
 78. **Brownstein, D. G., A. L. Smith, R. O. Jacoby, E. A. Johnson, G. Hansen, and P. Tattersall.** 1991. Pathogenesis of infection with a virulent allotropic variant of minute virus of mice and regulation by host genotype. *Lab. Invest.* **65**:357–364.
 79. **Brownstein, D. G., A. L. Smith, E. A. Johnson, D. J. Pintel, L. K. Naeger, and P. Tattersall.** 1992. The pathogenesis of infection with minute virus of mice depends on expression of the small nonstructural protein NS2 and on the genotype of the allotropic determinants VP1 and VP2. *J. Virol.* **66**:3118–3124.
 80. **Bruce, M. G., I. Campbell, Y. Xiong, M. Redmond, and D. R. Snodgrass.** 1994. Recognition of rotavirus antigens by mouse L3T4-positive T helper cells. *J. Gen. Virol.* **75**:1859–1866.
 81. **Bruggeman, C. A., H. Meijer, P. H. J. Dormans, W. M. H. Debie, G. E. L. M. Grauls, and C. P. A. van Boven.** 1982. Isolation of a cytomegalovirus-like agent from wild rats. *Arch. Virol.* **73**:231–241.
 82. **Brunner, C. J., and C. C. Muscoplat.** 1980. Immunomodulatory effects of levamisole. *J. Am. Vet. Med. Assoc.* **176**:1159–1162.
 83. **Burgess, A. W., L. J. Paradise, D. Hilbelink, and H. Friedman.** 1994. Adherence of *Treponema pallidum* subsp. *pallidum* in the rabbit placenta. *Proc. Soc. Exp. Biol. Med.* **207**:180–185.
 84. **Burns, J. W., A. A. Krishnaney, P. T. Vo, R. V. Rouse, L. J. Anderson, and H. B. Greenberg.** 1995. Analyses of homologous rotavirus infection in the mouse model. *Virology* **207**:143–153.
 85. **Busch, K., and T. Naglic.** 1995. Natural uterine *Mycoplasma pulmonis* infection in female rats. *Vet. Med. (Prague)* **40**:253–255.
 86. **Callegan M. C., L. S. Engel, J. M. Hill, and R. J. O'Callaghan.** 1994. Corneal virulence of *Staphylococcus aureus*: roles of alpha-toxin and protein A in pathogenesis. *Infect. Immun.* **62**:2478–2482.
 87. **Camprubi, S., S. Merino, V. J. Benedi, and J. M. Tomas.** 1993. The role of the O-antigen lipopolysaccharide and capsule on an experimental *Klebsiella pneumoniae* infection of the rat urinary tract. *FEMS Microbiol. Lett.* **111**:9–13.
 88. **Canella, K. A., B. A. Diwan, P. L. Gorelick, P. J. Donovan, M. A. Sipowicz, K. S. Kasprzak, C. M. Weghorst, E. G. Synderwine, C. D. Davis, L. K. Keefer, S. A. Kyrtopoulos, S. S. Hecht, M. Wang, L. M. Anderson, and J. M. Rice.** 1996. Liver tumorigenesis by *Helicobacter hepaticus*: considerations of mechanism. *In Vivo* **10**:285–292.
 89. **Capucci, L., P. Fusi, A. Lavazza, M. L. Pacciarini, and C. Rossi.** 1996. Detection and preliminary characterization of a new rabbit calicivirus related to rabbit hemorrhagic disease virus but nonpathogenic. *J. Virol.* **70**:8614–8623.
 90. **Carruth, W. A., M. P. Byron, D. D. Solomon, W. L. White, G. J. Stoddard, R. D. Marosok, and R. J. Sherertz.** 1994. Subcutaneous, catheter-related inflammation in a rabbit model correlates with peripheral vein phlebitis in human volunteers. *J. Biomed. Mater. Res.* **28**:259–267.
 91. **Carthew, P., and S. Sparrow.** 1980. A comparison in germ-free mice of the pathogenesis of Sendai virus and mouse pneumonia virus infection. *J. Pathol.* **130**:153–158.
 92. **Carthew, P., and S. Sparrow.** 1980. Persistence of pneumonia virus of mice and Sendai virus in germ-free (*nu/nu*) mice. *Br. J. Exp. Pathol.* **61**:172–175.
 93. **Cartner, S. C., J. W. Simecka, D. E. Briles, G. H. Cassell, and J. R. Lindsey.** 1996. Resistance to mycoplasma lung disease in mice is a complex genetic trait. *Infect. Immun.* **64**:5326–5331.
 94. **Cartner, S. C., J. W. Simecka, J. R. Lindsey, G. H. Cassell, and J. K. Davis.** 1995. Chronic respiratory mycoplasmosis in C3H/HeN and C57BL/6N mice: lesion severity and antibody response. *Infect. Immun.* **63**:4138–4142.
 95. **Casebolt, D. B., B. Qian, and C. B. Stephenson.** 1997. Detection of enterotropic mouse hepatitis virus fecal excretion by polymerase chain reaction. *Lab. Anim. Sci.* **47**:6–10.
 96. **Cassell, G. H.** 1982. The pathogenic potential of mycoplasmas: *Mycoplasma pulmonis* as a model. *Rev. Infect. Dis.* **4**:S18–S34.
 97. **Castro, M., T. I. Morgenthaler, O. A. Hoffman, J. E. Standing, M. S. Rohrbach, and A. H. Limper.** 1993. *Pneumocystis carinii* induces the release of arachidonic acid and its metabolites from alveolar macrophages. *Am. J. Respir. Cell. Mol. Biol.* **9**:73–81.
 98. **Castrucci, G., M. Ferrari, F. Frigeri, V. Cilli, L. Perucca, and G. Donelli.** 1985. Isolation and characterization of cytopathic strains of rotavirus from rabbits. *Arch. Virol.* **83**:99–104.
 99. **Champagne, E., L. Scarpellino, P. Lane, and H. Acha-Orbea.** 1996. CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. *Eur. J. Immunol.* **26**:1595–1602.
 100. **Charles River Laboratories.** 1990. A laboratory animal health monitoring program: rationale and development. Charles River Laboratories Technical Bulletin. Charles River Laboratories, Wilmington, Mass.
 101. **Chen, C. C., M. Baylor, and D. M. Bass.** 1993. Murine intestinal mucins inhibit rotavirus infection. *Gastroenterology* **105**:84–92.
 102. **Chen, W., E. A. Havell, F. Gigliotti, and A. G. Harmsen.** 1993. Interleukin-6 production in a murine model of *Pneumocystis carinii* pneumonia: relation to resistance and inflammatory response. *Infect. Immun.* **61**:97–102.
 103. **Chen, W., E. A. Havell, L. L. Moldawer, K. W. McIntyre, R. A. Chizzonite, and A. G. Harmsen.** 1992. Interleukin 1: an important mediator of host resistance against *Pneumocystis carinii*. *J. Exp. Med.* **176**:713–718.
 104. **Chen, W., J. W. Mills, and A. G. Harmsen.** 1992. Development and resolution of *Pneumocystis carinii* pneumonia in severe combined immunodeficient mice: a morphological study of host inflammatory responses. *Int. J. Exp. Pathol.* **73**:709–720.
 105. **Cheung, A. L., K. J. Eberhardt, E. Chung, M. R. Yeaman, P. M. Sullam, M. Ramos, and A. S. Bayer.** 1994. Diminished virulence of a *sar- Δ agr-* mutant of *Staphylococcus aureus* in the rabbit model of endocarditis. *J. Clin. Invest.* **94**:1815–1822.
 106. **Chhibber, S., and J. Bajaj.** 1995. Polysaccharide-iron-regulated cell surface protein conjugate vaccine: its role in protection against *Klebsiella pneumoniae*-induced lobar pneumonia. *Vaccine* **13**:179–184.
 107. **Christensen, J. P., J. Johansen, O. Marker, and A. R. Thomsen.** 1995. Circulating intercellular adhesion molecule-1 (ICAM-1) as an early and sensitive marker for virus-induced T cell activation. *Clin. Exp. Immunol.* **102**:268–273.
 108. **Clark, E. A., P. H. Russell, M. Egghart, and M. A. Horton.** 1979. Characteristics and genetic control of NK-cell-mediated cytotoxicity activated by naturally acquired infection in the mouse. *Int. J. Cancer* **24**:688–699.
 109. **Clifford, C. B., B. J. Walton, T. H. Reed, M. B. Coyle, W. J. White, and H. L. Amyx.** 1995. Hyperkeratosis in athymic nude mice caused by a coryneform bacterium: microbiology, transmission, clinical signs, and pathology. *Lab. Anim. Sci.* **45**:131–139.
 110. **Cochran, J. B., H. Chen, M. La Via, V. Cusumano, G. Teti, and J. A. Cook.** 1995. Age-related mortality and adherent splenic cell mediator production to endotoxin in the rat. *Shock* **4**:450–454.
 111. **Cohen, L., B. David, and J. M. Cavaillon.** 1991. Interleukin-3 enhances cytokine production by LPS-stimulated macrophages. *Immunol. Lett.* **28**:121–126.
 112. **Cohen, P. L., S. S. Cross, and D. E. Mosier.** 1975. Immunologic effects of neonatal infection with mouse thymic virus. *J. Immunol.* **115**:706–710.
 113. **Cole, G. A., J. M. Katz, T. L. Hogg, K. W. Ryan, A. Portner, and D. L. Woodland.** 1994. Analysis of the primary T-cell response to Sendai virus infection in C57BL/6 mice: CD4⁺ T-cell recognition is directed predominantly to the hemagglutinin-neuraminidase glycoprotein. *J. Virol.* **68**:6863–6870.
 114. **Coleman, G. L., R. O. Jacoby, P. N. Bhatt, A. L. Smith, and A. M. Jonas.** 1983. Naturally occurring lethal parvovirus infection in juvenile and young adult rats. *Vet. Pathol.* **20**:44–45.
 115. **Colle, J. H., M. F. Saron, and P. Truffa-Bachi.** 1993. Altered cytokine genes expression by conA-activated spleen cells from mice infected by lymphocytic choriomeningitis virus. *Immunol. Lett.* **35**:247–253.
 116. **Collins, J., W. G. Starkey, T. S. Walls, G. J. Clarke, K. K. Worton, A. J. Spencer, S. J. Haddon, M. P. Osborne, D. C. A. Candy, and J. Stephen.** 1988. Intestinal enzyme profiles in normal and rotavirus-infected mice. *J. Pediatr. Gastroenterol. Nutr.* **7**:264–272.
 117. **Collins, T., C. Pomeroy, and M. C. Jordan.** 1993. Detection of latent cytomegalovirus DNA in diverse organs of mice. *J. Infect. Dis.* **168**:725–729.
 118. **Conner, M. E., M. A. Gilger, M. K. Estes, and D. Y. Graham.** 1991. Serologic and mucosal immune response to rotavirus infection in the rabbit model. *J. Virol.* **65**:2562–2571.
 119. **Connole, M. D.** 1990. Review of animal mycoses in Australia. *Mycopathologia* **111**:133–164.
 120. **Cook, I.** 1963. Reovirus type 3 infection in laboratory mice. *Aust. J. Exp. Biol. Med. Sci.* **41**:651–660.
 121. **Cordero, J., L. Munuera, and M. D. Folgueira.** 1996. Influence of bacterial strains on bone infection. *J. Orthop. Res.* **14**:663–667.
 122. **Cormier, Y., E. Israel-Assayag, M. Fournier, and G. M. Tremblay.** 1993. Modulation of experimental hypersensitivity pneumonitis by Sendai virus. *J. Lab. Clin. Med.* **121**:683–688.
 123. **Costas, M. A., D. Mella, M. Criscuolo, A. Diaz, S. Finkielman, V. E. Nahmod, and E. Arzt.** 1993. Superinduction of mitogen-stimulated interferon-gamma production and other lymphokines by Sendai virus. *J. Interferon Res.* **13**:407–412.
 124. **Coudert, P., D. Licois, F. Provot, and F. Drouet-Viard.** 1993. *Eimeria* sp. from the rabbit (*Oryctolagus cuniculus*): pathogenicity and immunogenicity of *Eimeria intestinalis*. *Parasitol. Res.* **79**:186–190.
 125. **Cousens, L. P., J. S. Orange, and C. A. Biron.** 1995. Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection. *J. Immunol.* **155**:5690–5699.
 126. **Coutelier, J. P., J. Van Broeck, and S. F. Wolf.** 1995. Interleukin-12 gene

- expression after viral infection in the mouse. *J. Virol.* **69**:1955–1958.
127. Cover, T. L., and M. J. Blaser. 1995. *Helicobacter pylori*: a bacterial cause of gastritis, peptic ulcer disease, and gastric cancer. *ASM News* **61**:21–26.
 128. Cox, J. C., R. C. Hamilton, and H. D. Attwood. 1979. An investigation of the route and progression of *Encephalitozoon cuniculi* infection in adult rabbits. *J. Protozool.* **26**:260–265.
 129. Cray, C., M. O. Mateo, and N. H. Altman. 1993. In vitro and long-term in vivo immune dysfunction after infection of BALB/c mice with mouse hepatitis virus strain A59. *Lab. Anim. Sci.* **43**:169–174.
 130. Cribier, B., G. Prevost, P. Couppie, V. Finck-Barbancon, E. Grosshans, and Y. Piemont. 1992. *Staphylococcus aureus* leukocidin: a new virulence factor in cutaneous infections? An epidemiological and experimental study. *Dermatology* **185**:175–180.
 131. Cripps, A. W., M. L. Dunkley, R. L. Clancy, F. Wallace, A. Buret, and D. C. Taylor. 1995. An animal model to study the mechanisms of immunity induced in the respiratory tract by intestinal immunization. *Adv. Exp. Med. Biol.* **371P**:749–753.
 132. Cross, S. S., H. C. Morse, III, and R. Asofsky. 1976. Neonatal infection with mouse thymic virus. Differential effects on T cells mediating the graft-versus-host reaction. *J. Immunol.* **117**:635–638.
 133. Cuff, C. F., C. K. Cebra, E. Lavi, E. H. Molowitz, D. H. Rubin, and J. J. Cebra. 1991. Protection of neonatal mice from fatal reovirus infection by immune serum and gut derived lymphocytes. *Adv. Exp. Med. Biol.* **310P**:307–315.
 134. Cuff, C. F., C. K. Cebra, D. H. Rubin, and J. J. Cebra. 1993. Developmental relationship between cytotoxic alpha/beta T cell receptor-positive intraepithelial lymphocytes and Peyer's patch lymphocytes. *Eur. J. Immunol.* **23**:1333–1339.
 135. Cundiff, D. D., and C. Besch-Williford. 1992. Respiratory disease in a colony of rats. *Lab. Anim.* **21**:16–19.
 136. Cundiff, D. D., C. L. Besch-Williford, R. R. Hook, Jr., C. L. Franklin, and L. K. Riley. 1994. Characterization of cilia-associated respiratory bacillus isolates from rats and rabbits. *Lab. Anim. Sci.* **44**:305–312.
 137. Cundiff, D. D., C. L. Besch-Williford, R. R. Hook, Jr., C. L. Franklin, and L. K. Riley. 1995. Characterization of cilia-associated respiratory bacillus in rabbits and analysis of the 16S rRNA gene sequence. *Lab. Anim. Sci.* **45**:22–26.
 138. Cunliffe-Beamer, T. L., and R. R. Fox. 1981. Venereal spirochetosis of rabbits: description and diagnosis. *Lab. Anim. Sci.* **31**:366–371.
 139. Cunliffe-Beamer, T. L., and R. R. Fox. 1981. Venereal spirochetosis of rabbits: epidemiology. *Lab. Anim. Sci.* **31**:372–378.
 140. Current, W. L., and L. S. Garcia. 1991. Cryptosporidiosis. *Clin. Microbiol. Rev.* **4**:325–358.
 141. Dangler, C. A., S. E. Baker, M. Kariuki Njenga, and S. H. Chia. 1995. Murine cytomegalovirus-associated arteritis. *Vet. Pathol.* **32**:127–133.
 142. Daniels, C. W., and M. Belosevic. 1992. Disaccharidase activity in the small intestine of susceptible and resistant mice after primary and challenge infections with *Giardia muris*. *Am. J. Trop. Med. Hyg.* **46**:382–390.
 143. Daniels, C. W., and M. Belosevic. 1995a. Comparison of the course of infection with *Giardia muris* in male and female mice. *Int. J. Parasitol.* **25**:131–135.
 144. Daniels, C. W., and M. Belosevic. 1995b. Disaccharidase activity in male and female C57BL/6 mice infected with *Giardia muris*. *Parasitol. Res.* **81**:143–147.
 145. Davidson, M. K., J. R. Lindsey, M. B. Brown, T. R. Schoeb, and G. H. Cassell. 1981. Comparison of methods for detection of *Mycoplasma pulmonis* in experimentally and naturally infected rats. *J. Clin. Microbiol.* **14**:644–646.
 146. Davis, J. K., M. Davidson, and T. R. Schoeb. 1991. Murine respiratory mycoplasmosis: a model to study effects of oxidants. *Res. Rep. Health Eff. Inst.* **47**:1–43.
 147. Davis, J. K., M. K. Davidson, T. R. Schoeb, and J. R. Lindsey. 1992. Decreased intrapulmonary killing of *Mycoplasma pulmonis* after short-term exposure to NO₂ is associated with damaged alveolar macrophages. *Am. Rev. Respir. Dis.* **145**:406–411.
 148. Deeb, B. J., R. F. DiGiacomo, B. L. Bernard, and S. M. Silbernagel. 1990. *Pasteurella multocida* and *Bordetella bronchiseptica* infection in rabbits. *J. Clin. Microbiol.* **28**:70–75.
 149. Deeb, B. J., R. F. DiGiacomo, J. F. Evermann, and M. E. Thouless. 1993. Prevalence of coronavirus antibodies in rabbits. *Lab. Anim. Sci.* **43**:431–433.
 150. Deerberg, F., G. Pohlmeier, M. Wullenweber, and H. J. Hedrich. 1993. History and pathology of an enzootic *Pneumocystis carinii* pneumonia in athymic Han:RNU and Han:NZNU rats. *J. Exp. Anim. Sci.* **36**:1–11.
 151. De Kimpe, S. J., M. Kengatharan, C. Thiemermann, and J. R. Vane. 1995. The cell wall components peptidoglycan and lipoteichoic acid from *Staphylococcus aureus* act in synergy to cause shock and multiple organ failure. *Proc. Natl. Acad. Sci. USA* **92**:10359–10363.
 152. Delano, M. L., and D. G. Brownstein. 1995. Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. *J. Virol.* **69**:5875–5877.
 153. de la Torre, J. C., M. Mallory, M. Brot, L. Gold, G. Koob, M. B. Oldstone, and E. Masliah. 1996. Viral persistence in neurons alters synaptic plasticity and cognitive functions without destruction of brain cells. *Virology* **220**:508–515.
 154. DeLong, D., and P. J. Manning. 1994. Bacterial diseases, p. 131–170. *In* P. J. Manning, D. H. Ringler, and C. E. Newcomer (ed.), *The biology of the laboratory rabbit*, 2nd ed. Academic Press, Inc., San Diego, Calif.
 155. DeLong, D., P. J. Manning, R. Gunther, and D. L. Swanson. 1992. Colonization of rabbits by *Pasteurella multocida*: serum IgG responses following intranasal challenge with serologically distinct isolates. *Lab. Anim. Sci.* **42**:13–18.
 156. de los Toyos, J. R., F. J. Mendez, J. F. Aparicio, F. Vazquez, M. Del Mar Garcia Suarez, A. Fleites, C. Hardisson, P. J. Morgan, P. W. Andrew, and T. J. Mitchell. 1996. Functional analysis of pneumolysin by use of monoclonal antibodies. *Infect. Immun.* **64**:480–484.
 157. Deplazes, P., A. Mathis, R. Baumgartner, I. Tanner, and R. Weber. 1996. Immunologic and molecular characteristics of Encephalitozoon-like microsporidia isolated from humans and rabbits indicate that *Encephalitozoon cuniculi* is a zoonotic parasite. *Clin. Infect. Dis.* **22**:557–559.
 158. Descoteaux, J. P., and G. Lussier. 1990. Experimental infection of young rabbits with a rabbit enteric coronavirus. *Can. J. Vet. Res.* **54**:473–476.
 159. Descoteaux, J. P., G. Lussier, L. Berthiaume, R. Alain, C. Seguin, and M. Trudel. 1985. An enteric coronavirus of the rabbit: detection by immunoelectron microscopy and identification of the structural polypeptides. *Arch. Virol.* **84**:241–250.
 160. de Souza, M. S., A. L. Smith, and K. Bottomly. 1991. Infection of BALB/cByJ mice with the JHM strain of mouse hepatitis virus alters in vitro splenic T cell proliferation and cytokine production. *Lab. Anim. Sci.* **41**:99–105.
 161. Devriese, L. A., W. Hendrickx, C. Godard, L. Okerman, and F. Haesebrouck. 1996. A new pathogenic *Staphylococcus aureus* type in commercial rabbits. *Zentralbl. Veterinärmed.* **43**:313–315.
 162. Dick, E. J., Jr., C. L. Kittell, H. Meyer, P. L. Farrar, S. L. Ropp, J. J. Esposito, R. M. L. Buller, H. Neubauer, Y. H. Kang, and A. E. McKee. 1996. Mousepox outbreak in a laboratory mouse colony. *Lab. Anim. Sci.* **46**:602–611.
 163. Dickneite, G., and J. Czech. 1994. Combination of antibiotic treatment with the thrombin inhibitor recombinant hirudin for the therapy of experimental *Klebsiella pneumoniae* sepsis. *Thromb. Haemostasis* **71**:768–772.
 164. Didier, E. S. 1995. Reactive nitrogen intermediates implicated in the inhibition of *Encephalitozoon cuniculi* (phylum Microspora) replication in murine peritoneal macrophages. *Parasite Immunol.* **17**:405–412.
 165. Didier, E. S., P. W. Varner, P. J. Didier, A. M. Aldras, N. J. Millichamp, M. Murphey-Corb, R. Bohm, and J. A. Shaddock. 1994. Experimental microsporidiosis in immunocompetent and immunodeficient mice and monkeys. *Folia Parasitol. (Prague)* **41**:1–11.
 166. Didier, E. S., C. R. Vossbrinck, M. D. Baker, L. B. Rogers, D. C. Bertucci, and J. A. Shaddock. 1995. Identification and characterization of three *Encephalitozoon cuniculi* strains. *Parasitology* **111**:411–421.
 167. Dietrich, H. M., D. Khaschabi, and B. Albini. 1996. Isolation of *Enterococcus durans* and *Pseudomonas aeruginosa* in a scid mouse colony. *Lab. Anim.* **30**:102–107.
 168. DiGiacomo, R. F., S. A. Lukehart, C. D. Talburt, S. A. Baker-Zander, J. Condon, and C. W. Brown. 1984. Clinical course and treatment of venereal spirochaetosis in New Zealand White rabbits. *Br. J. Vener. Dis.* **60**:214–218.
 169. DiGiacomo, R. F., V. Allen, and M. H. Hinton. 1991. Naturally acquired *Pasteurella multocida* subsp. *multocida* infection in a closed colony of rabbits: characteristics of isolates. *Lab. Anim.* **25**:236–241.
 170. DiGiacomo, R. F., B. J. Deeb, S. J. Brodie, T. E. Zimmerman, E. R. Veltkamp, and C. E. Chrisp. 1993. Toxin production by *Pasteurella multocida* isolated from rabbits with atrophic rhinitis. *Am. J. Vet. Res.* **54**:1280–1286.
 171. DiGiacomo, R. F., and C. J. Maré. 1994. Viral diseases, p. 171–204. *In* P. J. Manning, D. H. Ringler, and C. E. Newcomer (ed.), *The biology of the laboratory rabbit*, 2nd ed. Academic Press, Inc., San Diego, Calif.
 172. Dillehay, D. L., K. S. Paul, R. F. DiGiacomo, and M. M. Chengappa. 1991. Pathogenicity of *Pasteurella multocida* A:3 in Flemish giant and New Zealand white rabbits. *Lab. Anim.* **25**:337–341.
 173. Dixon, D. M., and M. L. Misfeldt. 1994. Proliferation of immature T cells within the splenocytes of athymic mice by *Pseudomonas* exotoxin A. *Cell. Immunol.* **158**:71–82.
 174. Domenico, P., D. C. Straus, D. E. Woods, and B. A. Cunha. 1993. Salicylate potentiates amikacin therapy in rodent models of *Klebsiella pneumoniae* infection. *J. Infect. Dis.* **168**:766–769.
 175. Drouet-Viard, F., D. Licois, F. Provôt, and P. Coudert. 1994. The invasion of the rabbit intestinal tract by *Eimeria intestinalis* sporozoites. *Parasitol. Res.* **80**:706–707.
 176. Duan, Y., and S. S. Atherton. 1996. Immunosuppression induces transcription of murine cytomegalovirus glycoprotein H in the eye and at non-ocular sites. *Arch. Virol.* **141**:411–423.
 177. Duncan, A. J., R. J. Carman, G. J. Olsen, and K. H. Wilson. 1993. Assignment of the agent of Tyzzer's disease to *Clostridium piliforme* comb. nov. on

- the basis of 16S rRNA sequence analysis. *Int. J. Syst. Bacteriol.* **43**:314–318.
178. Dunkley, M. L., R. L. Clancy, and A. W. Cripps. 1994. A role for CD4+ T cells from orally immunized rats in enhanced clearance of *Pseudomonas aeruginosa* from the lung. *Immunology* **83**:362–369.
 179. Duwel, D., and K. Brech. 1981. Control of oxyuriasis in rabbits by fenbendazole. *Lab. Anim.* **15**:101–105.
 180. Dykewicz, C. A., V. M. Dato, S. P. Fisher-Hoch, M. V. Howarth, G. I. Perez-Orozco, S. M. Ostroff, H. Gary, Jr., L. B. Schonberger, and J. B. McCormick. 1992. Lymphocytic choriomeningitis outbreak associated with nude mice in a research institute. *JAMA* **267**:1349–1353.
 181. Eaton, P. 1984. Preliminary observations on enteritis associated with a coronavirus-like agent in rabbits. *Lab. Anim.* **18**:71–74.
 182. Edwards, S., J. D. Small, J. D. Geratz, L. K. Alexander, and R. S. Baric. 1992. An experimental model for myocarditis and congestive heart failure after rabbit coronavirus infection. *J. Infect. Dis.* **165**:134–140.
 183. Eiden, J., H. M. Lederman, S. Vonderfecht, and R. Yolken. 1986. T-cell-deficient mice display normal recovery from experimental rotavirus infection. *J. Virol.* **57**:706–708.
 184. Eigelsbach, H. T., and V. G. McGann. 1984. Genus *Francisella*, p. 394–399. In J. G. Holt and N. R. Krieg (ed.), *Bergey's manual of systematic bacteriology*, vol. 1. The Williams & Wilkins Co., Baltimore, Md.
 185. Einarsson, O., G. P. Geba, Z. Zhu, M. Landry, and J. A. Elias. 1996. Interleukin-11: stimulation in vivo and in vitro by respiratory viruses and induction of airways hyperresponsiveness. *J. Clin. Invest.* **97**:915–924.
 186. el-Nassery, S. M., A. E. Rahmy, W. M. el Gebaly, and H. A. Sadaka. 1994. *Pneumocystis carinii*: recognition of the infection in albino rats using different strains. *J. Egypt. Soc. Parasitol.* **24**:285–294.
 187. Engstrom, R. E., Jr., B. J. Mondino, B. J. Glasgow, H. Pitcheikian-Halabi, and S. A. Adamu. 1991. Immune response to *Staphylococcus aureus* endophthalmitis in a rabbit model. *Investig. Ophthalmol. Visual Sci.* **32**:1523–1533.
 188. Erny, K. M., J. Peli, J. F. Lambert, V. Muller, and H. Diggelmann. 1996. Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis. *Oncogene*. **13**:2015–2020.
 189. Essani, N. A., G. M. McGuire, A. M. Manning, and H. Jaeschke. 1996. Endotoxin-induced activation of the nuclear transcription factor kappa B and expression of E-selectin messenger RNA in hepatocytes, Kupffer cells, and endothelial cells in vivo. *J. Immunol.* **156**:2956–2963.
 190. Esteller, A., M. D. Torres, M. Gomez-Bautista, E. L. Marino, C. Fernandez-Lastra, and R. Jimenez. 1990. Pharmacokinetics, hepatic biotransformation and biliary and urinary excretion of bromosulfophthalein (BSP) in an experimental liver disease mimicking biliary cirrhosis. *Eur. J. Drug Metab. Pharmacokinet.* **15**:7–14.
 191. Even, C., R. R. Rowland, and P. G. Plagemann. 1995. Mouse hepatitis virus infection of mice causes long-term depletion of lactate dehydrogenase-elevating virus-permissive macrophages and T lymphocyte alterations. *Virus Res.* **39**:355–364.
 192. Evengard, B., K. Sandstedt, G. Bolske, R. Feinstein, I. Riesenfelt-Orn, and C. I. Smith. 1994. Intranasal inoculation of *Mycoplasma pulmonis* in mice with severe combined immunodeficiency (SCID) causes a wasting disease with grave arthritis. *Clin. Exp. Immunol.* **98**:388–394.
 193. Evermann, J. F., C. J. Henry, and S. L. Marks. Feline infectious peritonitis. 1995. *J. Am. Vet. Med. Assoc.* **206**:1130–1134.
 194. Ewing, C., D. J. Topham, and P. C. Doherty. 1995. Prevalence and activation phenotype of Sendai virus-specific CD4+ T cells. *Virology* **210**:179–185.
 195. Fallon, M. T., W. H. Benjamin, Jr., T. R. Schoeb, and D. E. Briles. 1991. Mouse hepatitis virus strain UAB infection enhances resistance to *Salmonella typhimurium* in mice by inducing suppression of bacterial growth. *Infect. Immun.* **59**:852–856.
 196. Farone, A. L., C. W. Frevert, M. B. Farone, M. J. Morin, B. N. Fields, J. D. Paulauskis, and L. Kobzik. 1996. Serotype-dependent induction of pulmonary neutrophilia and inflammatory cytokine gene expression by reovirus. *J. Virol.* **70**:7079–7084.
 197. Farone, A. L., P. C. O'Brien, and D. C. Cox. 1993. Tumor necrosis factor-alpha induction by reovirus serotype 3. *J. Leukocyte Biol.* **53**:133–137.
 198. Faulkner, C. B., M. K. Davidson, J. K. Davis, T. R. Schoeb, J. W. Simecka, and J. R. Lindsey. 1995. Acute *Mycoplasma pulmonis* infection associated with coagulopathy in C3H/HeN mice. *Lab. Anim. Sci.* **45**:368–372.
 199. Faulkner, C. B., J. W. Simecka, M. K. Davidson, J. K. Davis, T. R. Schoeb, J. R. Lindsey, and M. P. Everson. 1995. Gene expression and production of tumor necrosis factor alpha, interleukin 1, interleukin 6, and gamma interferon in C3H/HeN and C57BL/6N mice in acute *Mycoplasma pulmonis* disease. *Infect. Immun.* **63**:4084–4090.
 200. Fennestad, K. L. 1985. Pathogenetic observations on pleural effusion disease in rabbits. *Arch. Virol.* **84**:163–174.
 201. Fennestad, K. L., L. Bruun, and E. Wedo. 1980. Pleural effusion disease agent as passenger of *Treponema pallidum* suspensions from rabbits. Survey of laboratories. *Br. J. Vener. Dis.* **56**:198–203.
 202. Fennestad, K. L., B. Mansa, N. Christensen, S. Larsen, and S. V. E. Svehag. 1986. Pathogenicity and persistence of pleural effusion disease virus isolates in rabbits. *J. Gen. Virol.* **67**:993–1000.
 203. Fennestad, K. L., H. J. Skovgaard Jensen, S. Moller, and M. W. Bentzon. 1975. Pleural effusion disease in rabbits. Clinical and post mortem observations. *Acta Pathol. Microbiol. Scand. Sect. B* **83**:541–548.
 204. Fernandes, G., B. Chandrasekar, D. A. Troyer, J. T. Venkatraman, and R. A. Good. 1995. Dietary lipids and calorie restriction affect mammary tumor incidence and gene expression in mouse mammary tumor virus/v-Ha-ras transgenic mice. *Proc. Natl. Acad. Sci. USA* **92**:6494–6498.
 205. Finberg, R., H. Cantor, B. Benacerraf, and S. Burakoff. 1980. The origins of alloreactivity: differentiation of prekiller cells to virus infection results in alloreactive cytolytic T lymphocytes. *J. Immunol.* **124**:1858–1860.
 206. Fincher, E. F., IV, L. Johannsen, L. Kapas, S. Takahashi, and J. M. Krueger. 1996. Microglia digest *Staphylococcus aureus* into low molecular weight biologically active compounds. *Am. J. Physiol.* **271**:149–156.
 207. Fitzgerald, T. J., and M. A. Tomai. 1991. Splenic T-lymphocyte functions during early syphilitic infection are complex. *Infect. Immun.* **59**:4180–4186.
 208. Flamm, H. 1957. *Klebsiella*-Enzootic in einer Mausezucht. *Schweiz. Z. Pathol. Bakteriologie*. **20**:23–27.
 209. Flatt, R. E., and S. J. Jackson. 1970. Renal nose matosis in young rabbits. *Pathol. Vet.* **7**:492–497.
 210. Florquin, S., Z. Amraoui, C. Dubois, J. Decuyper, and M. Goldman. 1994. The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. *J. Exp. Med.* **180**:1153–1158.
 211. Fox, J. G., F. E. Dewhirst, J. G. Tully, B. J. Paster, L. Yan, N. S. Taylor, M. J. Collins, Jr., P. L. Gorelick, and J. M. Ward. 1994. *Helicobacter hepaticus* sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. *J. Clin. Microbiol.* **32**:1238–1245.
 212. Fox, J. G., and A. Lee. 1997. The role of *Helicobacter* species in newly recognized gastrointestinal tract diseases of animals. *Lab. Anim. Sci.* **47**:222–255.
 213. Fox, J. G., X. Li, L. Yan, R. J. Cahill, R. Hurley, R. Lewis, and J. C. Murphy. 1996. Chronic proliferative hepatitis in A/JCr mice associated with persistent *Helicobacter hepaticus* infection: a model of *Helicobacter*-induced carcinogenesis. *Infect. Immun.* **64**:1548–1558.
 214. Fox, J. G., L. L. Yan, F. E. Dewhirst, B. J. Paster, B. Shames, J. C. Murphy, A. Hayward, J. C. Belcher, and E. N. Mendes. 1995. *Helicobacter bilis* sp. nov., a novel *Helicobacter* species isolated from bile, livers, and intestines of aged, inbred mice. *J. Clin. Microbiol.* **33**:445–454.
 215. Fox, J. G., L. Yan, B. Shames, J. Campbell, J. C. Murphy, and X. Li. 1996. Persistent hepatitis and enterocolitis in germfree mice infected with *Helicobacter hepaticus*. *Infect. Immun.* **64**:3673–3681.
 216. Foxx, T. S., and S. A. Ewing. 1969. Morphologic features, behavior and life history of *Cheyletiella yasguri*. *Am. J. Vet. Res.* **30**:269–285.
 217. Franco, M. A., N. Feng, and H. B. Greenberg. 1996. Molecular determinants of immunity and pathogenicity of rotavirus infection in the mouse model. *J. Infect. Dis.* **174**:S47–50.
 218. Frankel, G., A. D. Phillips, M. Novakova, H. Field, D. C. Candy, D. B. Schauer, G. Douce, and G. Dougan. 1996. Intimin from enteropathogenic *Escherichia coli* restores murine virulence to a *Citrobacter rodentium eaeA* mutant: induction of an immunoglobulin A response to intimin and EspB. *Infect. Immun.* **64**:5315–5325.
 219. Franklin, C. L., S. L. Motzel, C. L. Besch-Williford, R. R. Hook, Jr., and L. K. Riley. 1994. Tyzzer's infection: host specificity of *Clostridium piliforme* isolates. *Lab. Anim. Sci.* **44**:568–572.
 220. Frimodt-Moller, N. 1993. The mouse peritonitis model: present and future use. *J. Antimicrob. Chemother.* **31**(Suppl. D):55–60.
 221. Fruh, R., B. Blum, H. Mossmann, H. Domdey, and B. U. von Specht. 1995. TH1 cells trigger tumor necrosis factor alpha-mediated hypersensitivity to *Pseudomonas aeruginosa* after adoptive transfer into SCID mice. *Infect. Immun.* **63**:1107–1112.
 222. Fuentealba, I. C., N. T. Mahoney, J. A. Shaddock, J. Harvill, V. Wicher, and K. Wicher. 1992. Hepatic lesions in rabbits infected with *Encephalitozoon cuniculi* administered per rectum. *Vet. Pathol.* **29**:536–540.
 223. Fukushima, T., K. Sekizawa, M. Yamaya, S. Okinaga, M. Satoh, and H. Sasaki. 1995. Viral respiratory infection increases alveolar macrophage cytoplasmic motility in rats: role of NO. *Am. J. Physiol.* **268**:L399–406.
 224. Furrarrah, A. M., and C. Sweet. 1994. Studies of the pathogenesis of wild-type virus and six temperature-sensitive mutants of mouse cytomegalovirus. *J. Med. Virol.* **43**:317–330.
 225. Furuya, N., Y. Hirakata, K. Tomono, T. Matsumoto, K. Tateda, M. Kaku, and K. Yamaguchi. 1993. Mortality rates amongst mice with endogenous septicaemia caused by *Pseudomonas aeruginosa* isolates from various clinical sources. *J. Med. Microbiol.* **39**:141–146.
 226. Gabaldon, M., C. Capdevila, and A. Zuniga. 1992. Effect of spontaneous pathology and thrombin on leukocyte adhesion to rat aortic endothelium. *Atherosclerosis* **93**:217–228.
 227. Garlinghouse, L. E., and G. L. Van Hoosier. 1978. Studies on adjuvant-induced arthritis, tumor transplantability and serologic response to bovine serum albumin in Sendai virus infected rats. *Am. J. Vet. Res.* **39**:297–300.
 228. Garssen, J., H. Van der Vliet, A. De Klerk, W. Goettsch, J. A. Dormans, C. A. Bruggeman, A. D. Osterhaus, and H. Van Loveren. 1995. A rat cytomegalovirus infection model as a tool for immunotoxicity testing. *Eur. J. Pharmacol.* **292**:223–231.

229. Garvy, B. A., and A. G. Harmsen. 1996. Susceptibility to *Pneumocystis carinii* infection: host responses of neonatal mice from immune or naive mothers and of immune or naive adults. *Infect. Immun.* **64**:3987–3992.
230. Gelfand, E. W., J. Saloga, and G. Lack. 1995. Modification of immediate hypersensitivity responses by staphylococcal enterotoxin B. *J. Clin. Immunol.* **15**:37S–41S.
231. Genovese, F., G. Mancuso, M. Cuzzola, V. Cusumano, F. Nicoletti, K. Bendtzen, and G. Teti. 1996. Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock. *Antimicrob. Agents Chemother.* **40**:1733–1735.
232. Gigliotti, F., and T. McCool. 1996. Glycoprotein A is the immunodominant antigen of *Pneumocystis carinii* in mice following immunization. *Parasitol. Res.* **82**:90–91.
233. Gill, R., H. Wang, H. Bluethmann, A. Iglesias, and W. Z. Wei. 1994. Activation of natural killer cells by mouse mammary tumor virus C4 in BALB/c and T-cell receptor V beta 2-transgenic mice. *Cancer Res.* **54**:1529–1535.
234. Gillioli, R., J. K. Sakurada, L. A. G. Andrade, V. Kraft, B. Meyer, and H. A. Rangel. 1996. Virus infection in rat and mouse colonies reared in Brazilian animal facilities. *Lab. Anim. Sci.* **46**:582–584.
235. Ginder, D. R. 1964. Increased susceptibility of mice infected with mouse adenoviruses to *Escherichia coli*-induced pyelonephritis. *J. Exp. Med.* **120**:1117–1128.
236. Glembot, T. M., L. D. Britt, and M. A. Hill. 1996. Endotoxin interacts with tumor necrosis factor-alpha to induce vasodilation of isolated rat skeletal muscle arterioles. *Shock* **5**:251–257.
237. Glorioso, J. C., G. W. Jones, H. G. Rush, L. J. Pentler, C. A. DaRif, and J. E. Coward. 1982. Adhesion of type A *Pasteurella multocida* to rabbit pharyngeal cells and its possible role in rabbit respiratory tract infections. *Infect. Immun.* **35**:1103–1109.
238. Gobl, A. E., and G. V. Alm. 1994. Interleukin-4 down-regulates Sendai virus-induced production of interferon-alpha and -beta in human peripheral blood monocytes in vitro. *Scand. J. Immunol.* **35**:167–175.
239. Godfraind, C., K. V. Holmes, and J. P. Coutelier. 1995. Thymus involution induced by mouse hepatitis virus A59 in BALB/c mice. *J. Virol.* **69**:6541–6547.
240. Godfraind, C., S. G. Langreth, C. B. Cardellicchio, R. Knobler, J. P. Coutelier, M. Dubois-Dalcq, and K. V. Holmes. 1995. Tissue and cellular distribution of an adhesion molecule in the carcinoembryonic antigen family that serves as a receptor for mouse hepatitis virus. *Lab. Invest.* **73**:615–627.
241. Goetz, L., and C. Pomeroy. 1996. Impact of prophylactic ganciclovir on bronchoalveolar lavage lymphocyte numbers and phenotypes in murine cytomegalovirus-induced reactivation of *Toxoplasma pneumoniae*. *J. Lab. Clin. Med.* **128**:384–391.
242. Gold, L. H., M. D. Brot, I. Polis, R. Schroeder, A. Tishon, J. C. de la Torre, M. B. Oldstone, and G. F. Koob. 1994. Behavioral effects of persistent lymphocytic choriomeningitis virus infection in mice. *Behav. Neural Biol.* **62**:100–109.
243. Gomez, R. M., J. E. Rinehart, R. Wollmann, and R. P. Roos. 1996. Theiler's murine encephalomyelitis virus-induced cardiac and skeletal muscle disease. *J. Virol.* **70**:8926–8933.
244. Gordon, Y. J., E. G. Romanowski, and T. Araullo-Cruz. 1994. Topical HPMPc inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. *Investig. Ophthalmol. Visual Sci.* **35**:4135–4134.
245. Gosselin, D., J. DeSanctis, M. Boule, E. Skamene, C. Matouk, and D. Radzioch. 1995. Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with *Pseudomonas aeruginosa*. *Infect. Immun.* **63**:3272–3278.
246. Gossmann, J., J. Lohler, O. Utermohlen, and F. Lehmann-Grube. 1995. Murine hepatitis caused by lymphocytic choriomeningitis virus. II. Cells involved in pathogenesis. *Lab. Invest.* **72**:559–570.
247. Goto, K., T. Itoh, A. Takakura, S. Kunita, E. Terada, and N. Kagiya. 1991. A serological survey on *Bacillus piliformis* infection in laboratory rabbits in Japan. *Jikken Dobutsu* **40**:231–233.
248. Goto, M., W. P. Zeller, and R. C. Lichtenberg. 1994. Decreased gluconeogenesis and increased glucose disposal without hyperinsulinemia in 10-day-old rats with endotoxin shock. *Metabolism* **43**:1248–1254.
249. Graves, D. C., X. H. Li, and W. D. Paiva. 1991. Delayed-type hypersensitivity response in mice to *Pneumocystis carinii*. *J. Protozool.* **38**:49S–52S.
250. Greenberger, M. J., S. L. Kunkel, R. M. Strieter, N. W. Lukacs, J. Bramson, J. Gaudie, F. L. Graham, M. Hitt, J. M. Danforth, and T. J. Standiford. 1996. IL-12 gene therapy protects mice in lethal *Klebsiella pneumoniae*. *J. Immunol.* **157**:3006–3012.
251. Greenberger, M. J., R. M. Strieter, S. L. Kunkel, J. M. Danforth, R. E. Goodman, and T. J. Standiford. 1995. Neutralization of IL-10 increases survival in a murine model of *Klebsiella pneumoniae*. *J. Immunol.* **155**:722–729.
252. Greenberger, M. J., R. M. Strieter, S. L. Kunkel, J. M. Danforth, L. L. Laichalk, D. C. McGillicuddy, and T. J. Standiford. 1996. Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine *Klebsiella pneumoniae*. *J. Infect. Dis.* **173**:59–165.
253. Greenstein, G., C. K. Drozdowicz, F. G. Garcia, and L. L. Lewis. 1991. The incidence of *Encephalitozoon cuniculi* in a commercial barrier-maintained rabbit breeding colony. *Lab. Anim.* **25**:287–290.
254. Griffith, J. W., W. J. White, P. J. Danneman, and C. M. Lang. 1988. Cilia-associated respiratory (CAR) bacillus infection in obese mice. *Vet. Pathol.* **25**:72–76.
255. Griffiths, M. M., A. D. Sawitzke, D. S. Harper, S. McCall, V. R. Reese, and G. W. Cannon. 1994. Exacerbation of collagen-induced arthritis in rats by rat cytomegalovirus is antigen-specific. *Autoimmunity* **18**:177–187.
256. Griffiths, M. M., C. B. Smith, L. S. Wei, and S. C. Ting-Yu. 1991. Effects of rat cytomegalovirus infection on immune functions in rats with collagen induced arthritis. *J. Rheumatol.* **18**:497–504.
257. Gripenberg-Lerche, C., and P. Toivanen. 1993. *Yersinia* associated arthritis in SHR rats: effect of the microbial status of the host. *Ann. Rheum. Dis.* **52**:223–228.
258. Gripenberg-Lerche, C., and P. Toivanen. 1994. Variability in the induction of experimental arthritis: *Yersinia* associated arthritis in Lewis rats. *Scand. J. Rheumatol.* **23**:124–127.
259. Gudjonsson, H., B. Newman, and T. B. Turner. 1970. Demonstration of a virus-like agent contaminating material containing the Stockholm substrain of the Nichols pathogenic *Treponema pallidum*. *Br. J. Vener. Dis.* **46**:435–440.
260. Guida, J. D., G. Fejer, L. A. Pirofski, C. F. Brosnan, and M. S. Horwitz. 1995. Mouse adenovirus type 1 causes a fatal hemorrhagic encephalomyelitis in adult C57BL/6 but not BALB/c mice. *J. Virol.* **69**:7674–7681.
261. Guidotti, L. G., P. Borrow, M. V. Hobbs, B. Matzke, I. Gresser, M. B. Oldstone, and F. V. Chisari. 1996. Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. *Proc. Natl. Acad. Sci. USA* **93**:4589–4594.
262. Gupta, S., L. Feng, T. Yoshimura, J. Redick, S. M. Fu, and C. E. Rose, Jr. 1996. Intra-alveolar macrophage-inflammatory peptide 2 induces rapid neutrophil localization in the lung. *Am. J. Respir. Cell. Mol. Biol.* **15**:656–663.
263. Gupta, S. K., S. A. Masinick, J. A. Hobden, R. S. Berk, and L. D. Hazlett. 1996. Bacterial proteases and adherence of *Pseudomonas aeruginosa* to mouse cornea. *Exp. Eye Res.* **62**:641–650.
264. Hagen, K. W. 1966. Spontaneous papillomatosis in domestic rabbits. *Bull. Wildl. Dis. Assoc.* **2**:108–110.
265. Haghgo, S., T. Hasegawa, M. Nadai, L. Wang, T. Nabeshima, and N. Kato. 1995. Effect of a bacterial lipopolysaccharide on biliary excretion of a beta-lactam antibiotic, cefoperazone, in rats. *Antimicrob. Agents Chemother.* **39**:2258–2261.
266. Hajjar, A. M., R. F. DiGiacomo, J. K. Carpenter, S. A. Bingel, and T. C. Moazed. 1991. Chronic sialodacryoadenitis virus (SDAV) infection in athymic rats. *Lab. Anim. Sci.* **41**:22–25.
267. Ha-Lee, Y. M., K. Dillon, B. Kosaras, R. Sidman, P. Revell, R. Fujinamik, and M. Chow. 1995. Mode of spread to and within the central nervous system after oral infection of neonatal mice with the DA strain of Theiler's murine encephalomyelitis virus. *J. Virol.* **69**:7354–7361.
268. Hambraeus, B. A., L. E. Hambraeus, and G. Wadell. 1989. Animal model of rotavirus infection in rabbits—protection obtained without shedding of viral antigen. *Arch. Virol.* **107**:237–251.
269. Hamelin, C., and G. Lussier. 1988. Genotypic differences between the mouse adenovirus strains FL and K87. *Experientia* **44**:65–66.
270. Hanano, R., K. Reifenberg, and S. H. Kaufmann. 1996. T- and B-lymphocyte-independent formation of alveolar macrophage-derived multinucleated giant cells in murine *Pneumocystis carinii* pneumonia. *Infect. Immun.* **64**:2821–2823.
271. Hangai, M., Y. Kaneda, H. Tanihara, and Y. Honda. 1996. In vivo gene transfer into the retina mediated by a novel liposome system. *Investig. Ophthalmol. Visual Sci.* **37**:2678–2685.
272. Hansen, A. K. 1995. Antibiotic treatment of nude rats and its impact on the aerobic bacterial flora. *Lab. Anim.* **29**:37–44.
273. Hansen, A. K., H. V. Andersen, and O. Svendsen. 1994. Studies on the diagnosis of Tyzzer's disease in laboratory rat colonies with antibodies against *Bacillus piliformis* (*Clostridium piliforme*). *Lab. Anim. Sci.* **44**:424–429.
274. Hartley, J. W., and W. P. Rowe. 1960. A new mouse virus apparently related to the adenovirus group. *Virology* **11**:645–647.
275. Hartwich, J., and M. T. Shouman. 1965. Untersuchungen über gehäuft auftretende *Klebsiella*-Infektionen bei Versuchsratten. *Z. Versuchstierkd.* **6**:141–146.
276. Hashimoto, K., T. Sugiyama, M. Yoshikawa, and S. Sasaki. 1970. Intestinal resistance in the experimental enteric infection of mice with a mouse adenovirus. I. Growth of the virus and appearance of a neutralizing substance in the intestinal tract. *Jpn. J. Microbiol.* **14**:381–395.
277. Haslov, K., A. Fomsgaard, K. Takayama, J. S. Fomsgaard, P. Ibsen, M. B. Fauntleroy, P. W. Stashak, C. E. Taylor, and P. J. Baker. 1992. Immunosuppressive effects induced by the polysaccharide moiety of some bacterial lipopolysaccharides. *Immunobiology* **186**:378–393.
278. Hayashi, T., S. Hashimoto, and A. Kawashima. 1994. Effect of infection by lactic dehydrogenase virus on expression of intercellular adhesion mole-

- cule-1 on vascular endothelial cells of pancreatic islets in streptozotocin-induced insulinitis of CD-1 mice. *Int. J. Exp. Pathol.* **75**:211-217.
279. Hayashi, T., H. Iwata, T. Hasegawa, M. Ozaki, H. Yamamoto, and T. Onodera. 1991. Decrease in neutrophil migration induced by endotoxin and suppression of interleukin-1 production by macrophages in lactic dehydrogenase virus-infected mice. *J. Comp. Pathol.* **104**:161-170.
 280. Hayashi, T., Y. Koike, T. Hasegawa, M. Tsurudome, M. Ozaki, H. Yamamoto, and T. Onodera. 1991. Inhibition of contact sensitivity by interferon in mice infected with lactic dehydrogenase virus. *J. Comp. Pathol.* **104**:357-366.
 281. Hayashi, T., Y. Noguchi, and Y. Kameyama. 1993. Suppression of development of anti-nuclear antibody and glomerulonephritis in NZB × NZWF1 mice by persistent infection with lactic dehydrogenase virus: possible involvement of superoxide anion as a progressive effector. *Int. J. Exp. Pathol.* **74**:553-560.
 282. Hayashi, T., T. Onodera, and H. Yamamoto. 1992. Detection of the binding of IgG2a and IgG2b on the surface of macrophages from mice chronically infected with lactic dehydrogenase virus. *J. Comp. Pathol.* **107**:35-40.
 283. Hayashi, T., M. Ozaki, Y. Ami, T. Onodera, and H. Yamamoto. 1992. Increased superoxide anion release by peritoneal macrophages in mice with a chronic infection of lactic dehydrogenase virus. *J. Comp. Pathol.* **106**:93-98.
 284. Hayashi, T., M. Ozaki, T. Onodera, Y. Ami, and H. Yamamoto. 1992. Macrophage function in the acute phase of lactic dehydrogenase virus-infection of mice: suppression of superoxide anion production in normal mouse peritoneal macrophages by interferon-alpha in vitro. *J. Comp. Pathol.* **106**:183-193.
 285. Heard, H. K., K. O'Connor, and D. S. Strayer. 1990. Molecular analysis of immunosuppression induced by virus replication in lymphocytes. *J. Immunol.* **144**:3992-3999.
 286. Heck, F. C., Jr., W. G. Sheldon, and C. A. Gleiser. 1972. Pathogenesis of experimentally produced mouse adenovirus infection in mice. *Am. J. Vet. Res.* **33**:841-846.
 287. Heggors, J. P., S. Haydon, F. Ko, P. G. Hayward, S. Carp, and M. C. Robson. 1992. *Pseudomonas aeruginosa* exotoxin A: its role in retardation of wound healing: the 1992 Lindberg Award. *J. Burn Care Rehabil.* **13**:512-518.
 288. Heinzel, F. P. 1990. The role of IFN-gamma in the pathology of experimental endotoxemia. *J. Immunol.* **145**:2920-2924.
 289. Held, T. K., M. Trautmann, M. E. Mielke, H. Neudeck, S. J. Cryz, Jr., and A. S. Cross. 1992. Monoclonal antibody against *Klebsiella* capsular polysaccharide reduces severity and hematogenic spread of experimental *Klebsiella pneumoniae* pneumonia. *Infect. Immun.* **60**:1771-1778.
 290. Held, W., H. Acha-Orbea, H. R. MacDonald, and G. A. Waanders. 1994. Superantigens and retroviral infection: insights from mouse mammary tumor virus. *Immunol. Today* **15**:184-190.
 291. Heyworth, M. F. 1992. Relative susceptibility of *Giardia muris* trophozoites to killing by mouse antibodies of different isotypes. *J. Parasitol.* **78**:73-76.
 292. Hildebrand, A., M. Pohl, and S. Bhakdi. 1991. *Staphylococcus aureus* alpha-toxin. Dual mechanism of binding to target cells. *J. Biol. Chem.* **266**:17195-17200.
 293. Hirakata, Y., N. Furuya, T. Matsumoto, K. Tateda, and K. Yamaguchi. 1996. Experimental endogenous septicaemia caused by *Klebsiella pneumoniae* and *Escherichia coli* in mice. *J. Med. Microbiol.* **44**:211-214.
 294. Hirakata, Y., N. Furuya, K. Tateda, T. Matsumoto, and K. Yamaguchi. 1995. The influence of exo-enzyme S and proteases on endogenous *Pseudomonas aeruginosa* bacteraemia in mice. *J. Med. Microbiol.* **43**:258-261.
 295. Hirst, R. G., and R. Campbell. 1977. Mechanisms of resistance to *Corynebacterium kutscheri* in mice. *Infect. Immun.* **17**:319-324.
 296. Hoffman, L. M., K. T. Hogan, and L. W. Cashdollar. 1996. The reovirus nonstructural protein sigma 1NS is recognized by murine cytotoxic T lymphocytes. *J. Virol.* **70**:8160-8164.
 297. Hofing, G. L., and A. L. Kraus. 1994. Arthropod and helminth parasites, p. 231-257. *In* P. J. Manning, D. H. Ringler, and C. E. Newcomer (ed.), *The biology of the laboratory rabbit*, 2nd ed. Academic Press, Inc., San Diego, Calif.
 298. Holecek, M., F. Skopec, L. Sprongl, and M. Pecka. 1995. Protein metabolism in specific tissues of endotoxin-treated rats: effect of nutritional status. *Physiol. Res.* **44**:399-406.
 299. Homberger, F. R., and S. W. Barthold. 1992. Passively acquired challenge immunity to enterotropic coronavirus in mice. *Arch. Virol.* **126**:35-43.
 300. Homberger, F. R., S. W. Barthold, and A. L. Smith. 1992. Duration and strain-specificity of immunity to enterotropic mouse hepatitis virus. *Lab. Anim. Sci.* **42**:347-351.
 301. Homberger, F. R., and L. Zhang. 1997. Characterization of mRNAs 4 and 5 of enterotropic mouse hepatitis virus. *Lab. Anim. Sci.* **47**:86-90.
 302. Homberger, F. R., and P. E. Thomann. 1994. Transmission of murine viruses and mycoplasma in laboratory mouse colonies with respect to housing conditions. *Lab. Anim.* **28**:113-120.
 303. Hooks, J. J., C. Percopo, Y. Wang, and B. Detrick. 1993. Retina and retinal pigment epithelial cell autoantibodies are produced during murine coronavirus retinopathy. *J. Immunol.* **151**:3381-3389.
 304. Hou, S., and P. C. Doherty. 1993. Partitioning of responder CD8+ T cells in lymph node and lung of mice with Sendai virus pneumonia by LECAM-1 and CD45RB phenotype. *J. Immunol.* **150**:5494-5500.
 305. Hou, S., and P. C. Doherty. 1995. Clearance of Sendai virus by CD8+ T cells requires direct targeting to virus-infected epithelium. *Eur. J. Immunol.* **25**:111-116.
 306. Hou, S., P. C. Doherty, M. Zijlstra, R. Jaenisch, and J. M. Katz. 1992. Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells. *J. Immunol.* **149**:1319-1325.
 307. Hou, S., M. Fishman, K. G. Murti, and P. C. Doherty. 1993. Divergence between cytotoxic effector function and tumor necrosis factor alpha production for inflammatory CD4+ T cells from mice with Sendai virus pneumonia. *J. Virol.* **67**:6299-6302.
 308. Hou, S., X. Y. Mo, L. Hyland, and P. C. Doherty. 1995. Host response to Sendai virus in mice lacking class II major histocompatibility complex glycoproteins. *J. Virol.* **69**:1429-1434.
 309. Houtman, J. J., H. C. Hinze, and J. O. Fleming. 1995. Demyelination induced by murine coronavirus JHM infection of congenitally immunodeficient mice. *Adv. Exp. Med. Biol.* **380P**:159-163.
 310. Hua, J., M. J. Liao, and A. Rashidbaigi. 1996. Cytokines induced by Sendai virus in human peripheral blood leukocytes. *J. Leukocyte Biol.* **60**:125-128.
 311. Huang, D. S., S. N. Emancipator, D. R. Fletcher, M. E. Lamm, and M. B. Mazanec. 1996. Hepatic pathology resulting from mouse hepatitis virus S infection in severe combined immunodeficiency mice. *Lab. Anim. Sci.* **46**:167-173.
 312. Huber, B. T., P. N. Hsu, and N. Sutkowski. 1996. Virus-encoded superantigens. *Microbiol. Rev.* **60**:473-482.
 313. Hyland, L., S. Hou, C. Coleclough, T. Takimoto, and P. C. Doherty. 1994. Mice lacking CD8+ T cells develop greater numbers of IgA-producing cells in response to a respiratory virus infection. *Virology* **204**:234-241.
 314. Iglauer, F., W. Deutsch, K. Gartner, and G. O. Schwarz. 1992. The influence of genotypes and social ranks in the clinical course of an experimental infection with *Mycoplasma pulmonis* (MRM) in inbred rats. *Zentralbl. Vet. Erinarmed. Reihe B* **39**:672-682.
 315. Iizawa, Y., T. Nishi, M. Kondo, and A. Imada. 1991. Examination of host defense factors responsible for experimental chronic respiratory tract infection caused by *Klebsiella pneumoniae* in mice. *Microbiol. Immunol.* **35**:615-622.
 316. Ijaz, M. K., M. I. Sabara, T. Alkarmi, P. J. Frenchick, K. F. Ready, M. Longson, F. K. Dar, and L. A. Babiuk. 1993. Characterization of two rotaviruses differing in their in vitro and in vivo virulence. *J. Vet. Med. Sci.* **55**:963-971.
 317. Ijaz, M. K., M. I. Sabara, P. J. Frenchick, and L. A. Babiuk. 1987. Assessment of intestinal damage in rotavirus infected neonatal mice by a D-xylose absorption test. *J. Virol. Methods* **18**:153-157.
 318. Ilback, N. G., G. Friman, D. J. Crawford, and H. A. Neufeld. 1991. Effects of training on metabolic responses and performance capacity in *Streptococcus pneumoniae* infected rats. *Med. Sci. Sports Exercise* **23**:422-427.
 319. Inman, L. R., and A. Takeuchi. 1979. Spontaneous cryptosporidiosis in an adult female rabbit. *Vet. Pathol.* **16**:89-95.
 320. Inoue, A., C. S. Koh, H. Yahikozawa, N. Yanagisawa, H. Yagita, Y. Ishihara, and B. S. Kim. 1996. The level of tumor necrosis factor-alpha producing cells in the spinal cord correlates with the degree of Theiler's murine encephalomyelitis virus-induced demyelinating disease. *Int. Immunol.* **8**:1001-1008.
 321. Ito, M., T. Sugane, T. K. Kobayashi, T. Kuramochi, K. Hioki, T. Furuta, and T. Nomura. 1991. Study on placental transmission of *Pneumocystis carinii* in mice using immunodeficient SCID mice as a new animal model. *J. Protozool.* **38**:218S-219S.
 322. Itoh, T., H. Iwai, and K. Ueda. 1991. Comparative lung pathology of inbred strains of mice resistant and susceptible to Sendai virus infection. *J. Vet. Med. Sci.* **53**:275-279.
 323. Itoh, T., K. Kohyama, A. Takakura, T. Takenouchi, and N. Kagiya. 1987. Naturally occurring CAR bacillus infection in a laboratory rat colony and epizootiological observations. *Exp. Anim.* **36**:387-393.
 324. Iuliano, B. A., J. D. Schmelzer, R. L. Thiemann, P. A. Low, and M. Rodriguez. 1994. Motor and somatosensory evoked potentials in mice infected with Theiler's murine encephalomyelitis virus. *J. Neurol. Sci.* **123**:186-194.
 325. Jackson, N. N., H. G. Wall, C. A. Miller, and M. Rogul. 1980. Naturally acquired infections of *Klebsiella pneumoniae* in Wistar rats. *Lab. Anim.* **14**:357-361.
 326. Jacobson, R. H., and N. D. Reed. 1974. The thymus dependency of resistance to pinworm infection in mice. *J. Parasitol.* **60**:976-979.
 327. Jacoby, R. O., and L. J. Ball-Goodrich. 1995. Parvovirus infections of mice and rats. *Semin. Virol.* **6**:329-333.
 328. Jacoby, R. O., L. Ball-Goodrich, D. G. Besselsen, M. D. McKisic, L. K. Riley, and A. L. Smith. 1996. Rodent parvovirus infections. *Lab. Anim. Sci.* **46**:370-380.
 329. Jacoby, R. O., P. N. Bhatt, S. W. Barthold, and D. G. Brownstein. 1994. Sendai viral pneumonia in aged BALB/c mice. *Exp. Gerontol.* **29**:89-100.
 330. Jacoby, R. O., P. N. Bhatt, and A. M. Jonas. 1979. Viral diseases, p. 271-306. *In* H. J. Baker, J. R. Lindsey, and S. H. Weisbroth (ed.), *The*

- laboratory rat, vol. I. Biology and diseases. Academic Press, Inc., New York, N.Y.
331. **Jacoby, R. O., E. A. Johnson, L. Ball-Goodrich, A. L. Smith, and M. D. McKisic.** 1995. Characterization of mouse parvovirus infection by in situ hybridization. *J. Virol.* **69**:3915-3919.
 332. **Jakab, G. J.** 1981. Interactions between Sendai virus and bacterial pathogens in the murine lung: a review. *Lab. Anim. Sci.* **31**:170-177.
 333. **Jakab, G. J., and G. A. Warr.** 1981. Immune enhanced phagocytic dysfunction in pulmonary macrophages infected with parainfluenza I (Sendai) virus. *Am. Rev. Respir. Dis.* **124**:575-581.
 334. **Jett, M., R. Neill, C. Welch, T. Boyle, E. Bernton, D. Hoover, G. Lowell, R. E. Hunt, S. Chatterjee, and P. Gemski.** 1994. Identification of staphylococcal enterotoxin B sequences important for induction of lymphocyte proliferation by using synthetic peptide fragments of the toxin. *Infect. Immun.* **62**:3408-3415.
 335. **Johansen, H. K., F. Espersen, S. S. Pedersen, H. P. Hougen, J. Rygaard, and N. Hoiby.** 1993. Chronic *Pseudomonas aeruginosa* lung infection in normal and athymic rats. *APMIS* **101**:207-225.
 336. **Johansen, H. K., H. P. Hougen, J. Rygaard, and N. Hoiby.** 1996. Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic *Pseudomonas aeruginosa* pneumonia in rats. *Clin. Exp. Immunol.* **103**:212-218.
 337. **Jolicoeur, P., and L. Lamontagne.** 1995. Impairment of bone marrow pre-B and B cells in MHV3 chronically-infected mice. *Adv. Exp. Med. Biol.* **380P**:193-195.
 338. **Jorgensen, B. B.** 1968. Spontaneous deaths among rabbits inoculated with *Treponema pallidum* less than 2 weeks before abnormal susceptibility in apparently normal laboratory rabbits indicated by serological tests for human syphilis. *Z. Versterkd.* **10**:46-54.
 339. **Jungmann, P., A. Freitas, A. Bandeira, A. Nobrega, A. Coutinho, M. A. Marcos, and P. Minoprio.** 1996. Murine acariasis. II. Immunological dysfunction and evidence for chronic activation of Th-2 lymphocytes. *Scand. J. Immunol.* **43**:604-612.
 340. **Jungmann, P., J. L. Guenet, P. A. Cazenave, A. Coutinho, and M. Huerre.** 1996. Murine acariasis. I. Pathological and clinical evidence suggesting cutaneous allergy and wasting syndrome in BALB/c mouse. *Res. Immunol.* **147**:27-38.
 341. **Kagi, D., and H. Hengartner.** 1996. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. *Curr. Opin. Immunol.* **8**:472-477.
 342. **Kagi, D., P. Seiler, J. Pavlovic, B. Ledermann, K. Burki, R. M. Zinkernagel, and H. Hengartner.** 1995. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. *Eur. J. Immunol.* **25**:3256-3262.
 343. **Kameyama, Y., and T. Hayashi.** 1994. Suppression of development of glomerulonephritis in NZB × NZWF1 mice by persistent infection with lactic dehydrogenase virus: relations between intercellular adhesion molecule-1 expression on endothelial cells and leucocyte accumulation in glomeruli. *Int. J. Exp. Pathol.* **18**:245-304.
 344. **Kapil, S.** 1995. Minute virus of mice (MVM) nucleic acid production in susceptible and resistant strains of mice and F1 hybrids. *Comp. Immunol. Microbiol. Infect. Dis.* **18**:245-252.
 345. **Karapetian, O., A. N. Shakhov, J. P. Kraehenbuhl, and H. Acha-Orbea.** 1994. Retroviral infection of neonatal Peyer's patch lymphocytes: the mouse mammary tumor virus model. *J. Exp. Med.* **180**:1511-1516.
 346. **Karupiah, G., R. M. Buller, N. Van Rooijen, C. J. Duarte, and J. Chen.** 1996. Different roles for CD4⁺ and CD8⁺ T lymphocytes and macrophage subsets in the control of a generalized virus infection. *J. Virol.* **70**:8301-8309.
 347. **Kay, M. M. B.** 1978. Long term subclinical effects of parainfluenza (Sendai) infection on immune cells of aging mice. *Proc. Soc. Exp. Biol. Med.* **158**:326-331.
 348. **Kenyon, A. J.** 1983. Delayed wound healing in mice associated with viral alteration of macrophages. *Am. J. Vet. Res.* **44**:652-656.
 349. **Kern, E. R.** 1996. Role of animal models in selecting antiviral combinations for clinical studies. *Antiviral Res.* **29**:57-59.
 350. **Ketyi, I.** 1995. A model for testing drug susceptibility of *Pseudomonas aeruginosa* and *Staphylococcus aureus* grown in biofilms on medical devices. *Acta Microbiol. Immunol. Hung.* **42**:215-219.
 351. **Kilham, L., and G. Margolis.** 1966. Spontaneous hepatitis and cerebellar hypoplasia in suckling rats due to congenital infection with rat virus. *Am. J. Pathol.* **49**:457-475.
 352. **Kita, E., N. Kamikaidou, D. Oku, A. Nakano, N. Katsui, and S. Kashiba.** 1992. Nonspecific stimulation of host defense by *Corynebacterium kutscheri*. III. Enhanced cytokine induction by the active moiety of *C. kutscheri*. *Nat. Immun.* **11**:46-55.
 353. **Kitahara, Y., T. Ishibashi, Y. Harada, M. Takamoto, and K. Tanaka.** 1981. Reduced resistance to *Pseudomonas* septicemia in diabetic mice. *Clin. Exp. Immunol.* **43**:590-598.
 354. **Klein, J. O., G. M. Green, J. G. Tilles, E. H. Kass, and M. Finland.** 1969. Effect of intranasal reovirus infection in antibacterial activity of mouse lung. *J. Infect. Dis.* **119**:43-50.
 355. **Klesius, P. H., T. T. Kramer, and J. C. Frandsen.** 1976. *Eimeria stiedae*: delayed hypersensitivity response in rabbit coccidiosis. *Exp. Parasitol.* **39**:59-68.
 356. **Kohanawa, M., M. Asano, Y. Min, T. Minagawa, and A. Nakane.** 1995. Paralysis caused by acute myelitis in Theiler's murine encephalomyelitis virus strain GD VII infection is induced by CD4⁺ lymphocytes infiltrating the spinal cord. *J. Gen. Virol.* **76**:2251-2256.
 357. **Kohashi, O., T. Ono, K. Ohki, T. Soejima, T. Moriya, A. Umeda, Y. Meno, K. Amako, S. Funakosi, M. Masuda, and N. Fujii.** 1992. Bactericidal activities of rat defensins and synthetic rabbit defensins on staphylococci, *Klebsiella pneumoniae* (Chedid, 277, and 8N3), *Pseudomonas aeruginosa* (mucoid and nonmucoid strains), *Salmonella typhimurium* (Ra, Rc, Rd, and Re of LPS mutants) and *Escherichia coli*. *Microbiol. Immunol.* **36**:369-380.
 358. **Kojima, A., and A. Okaniwa.** 1991. Antigenic heterogeneity of sialo-dacryoadenitis virus isolates. *J. Vet. Med. Sci.* **53**:1059-1063.
 359. **Koller, L. D.** 1969. Spontaneous *Nosema cuniculi* infection in laboratory rabbits. *J. Am. Vet. Med. Assoc.* **155**:1108-1114.
 360. **Kollmorgen, G. M., D. C. Cox, J. J. Killion, J. L. Cantrell, and W. A. Sansing.** 1976. Immunotherapy of EL4 lymphoma with reovirus. *Cancer Immunol. Immunother.* **1**:239-244.
 361. **Kolls, J. K., J. M. Beck, S. Nelson, W. R. Summer, and J. Shellito.** 1993. Alveolar macrophage release of tumor necrosis factor during murine *Pneumocystis carinii* pneumonia. *Am. J. Respir. Cell. Mol. Biol.* **8**:370-376.
 362. **Komurasaki, Y., C. N. Nagineni, Y. Wang, and J. J. Hooks.** 1996. Virus RNA persists within the retina in coronavirus-induced retinopathy. *Virology* **222**:446-450.
 363. **Korinteli, V. I., V. A. Akhobadze, L. S. H. Dzhidzhishvili, D. V. Gamreli, and D. D. Giorgelidze.** 1989. A study of the subcellular structure of the rabbit liver during the development of a bacterial infection. *Zh. Mikrobiol. Epidemiol. Immunobiol.* **4**:77-80. (In Russian.)
 364. **Koskinen, P., K. Lemstrom, H. Bruning, M. Daemen, C. Bruggeman, and P. Hayry.** 1995. Cytomegalovirus infection induces vascular wall inflammation and doubles arteriosclerotic changes in rat cardiac allografts. *Transplant. Proc.* **27**:574-575.
 365. **Koudela, B., J. Vitovec, Z. Kucerova, O. Ditrich, and J. Travnicek.** 1993. The severe combined immunodeficient mouse as a model for *Encephalitozoon cuniculi* microsporidiosis. *Folia Parasitol. (Prague)* **40**:279-286.
 366. **Kovacevic, S., and M. Knezevic.** 1995. Pulmonary pathohistological changes in mice in experimental infection with *Pneumocystis carinii*. *Vojnosanit. Pregl.* **52**:3-8.
 367. **Kozarsky, K. F., D. K. Bonen, F. Giannoni, T. Funahashi, J. M. Wilson, and N. O. Davidson.** 1996. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits. *Hum. Gene Ther.* **7**:943-957.
 368. **Kreider, J., and G. Bartlett.** 1981. The Shope papilloma-carcinoma complex of rabbits: a model system of neoplastic progression and spontaneous regression. *Adv. Cancer Res.* **35**:81-109.
 369. **Kring, S. C., C. S. King, and K. R. Spindler.** 1995. Susceptibility and signs associated with mouse adenovirus type 1 infection of adult outbred Swiss mice. *J. Virol.* **69**:8084-8088.
 370. **Kring, S. C., and K. R. Spindler.** 1996. Lack of effect of mouse adenovirus type 1 infection on cell surface expression of major histocompatibility complex class I antigens. *J. Virol.* **70**:5495-5502.
 371. **Kunstýř, I., B. Meyer, and E. Ammerpohl.** 1977. Spirochaetosis in nude mice: An animal model for immuno-parasitologic studies, p. 17-27. *In Proceedings of the Second International Workshop on Nude Mice.* Gustav Fischer Verlag, Stuttgart, Germany.
 372. **Kunstýř, I., U. Schoeneberg, and K. T. Friedhoff.** 1992. Host specificity of *Giardia muris* isolates from mouse and golden hamster. *Parasitol. Res.* **78**:621-622.
 373. **Kunz, S., U. Junker, J. Blaser, B. Joos, B. Meyer, O. Zak, and T. O'Reilly.** 1995. The scid mouse as an experimental model for the evaluation of anti-*Pneumocystis carinii* therapy. *J. Antimicrob. Chemother.* **36**:137-155.
 374. **Kupfer, J. M., X. M. Ruan, G. Liu, J. Matloff, J. Forrester, and A. Chau.** 1994. High-efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. *Hum. Gene Ther.* **5**:1437-1443.
 375. **Kurisu, K., S. Kyo, Y. Shimoto, and S. Matsushita.** 1990. Cilia-associated respiratory bacillus infection in rabbits. *Lab. Anim. Sci.* **40**:413-415.
 376. **Kwiatkowska-Patzer, B., J. A. Patzer, and L. J. Heller.** 1993. *Pseudomonas aeruginosa* exotoxin A enhances automaticity and potentiates hypoxic depression of isolated rat hearts. *Proc. Soc. Exp. Biol. Med.* **202**:377-383.
 377. **Kyuwa, S., K. Machii, A. Okumura, and Y. Toyoda.** 1996. Characterization of T cells expanded in vivo during primary mouse hepatitis virus infection in mice. *J. Vet. Med. Sci.* **58**:431-437.
 378. **Kyuwa, S., K. Machii, and S. Shibata.** 1996. Role of CD4⁺ and CD8⁺ T cells in mouse hepatitis virus infection in mice. *AADE Ed. J.* **45**:81-83.
 379. **Laber-Laird, K., and M. Proctor.** 1993. An example of a rodent health monitoring program. *Lab. Anim.* **22**:24-32.
 380. **Lai, W. C., G. Linton, M. Bennett, and S. P. Pakes.** 1993. Genetic control

- of resistance to *Mycoplasma pulmonis* infection in mice. *Infect. Immun.* **61**:4615-4621.
381. Laichalk, L. L., S. L. Kunkel, R. M. Strieter, J. M. Danforth, M. B. Bailie, and T. J. Standiford. 1996. Tumor necrosis factor mediates lung antibacterial host defense in murine *Klebsiella pneumoniae*. *Infect. Immun.* **64**:5211-5218.
382. Lamontagne, L., P. Jolicœur, D. Decarie, and J. Menezes. 1996. Effect of adoptive transfer of CD4, CD8 and B cells on recovery from MHV3-induced immunodeficiencies. *Immunology* **88**:220-229.
383. La Pierre, J., G. Marsolais, P. Pilon, and J. P. Descoteaux. 1980. Preliminary report on the observation of a coronavirus in the intestine of the laboratory rabbit. *Can. J. Microbiol.* **26**:1204-1208.
384. Lardans, V., C. Godfraind, J. T. van der Logt, W. A. Heessen, M. D. Gonzalez, and J. P. Coutelier. 1996. Polyclonal B lymphocyte activation induced by mouse hepatitis virus A59 infection. *J. Gen. Virol.* **77**:1005-1009.
385. La Regina, M., L. Woods, P. Klender, D. J. Gaertner, and F. X. Paturzo. 1992. Transmission of sialodacryoadenitis virus (SDAV) from infected rats to rats and mice through handling, close contact, and soiled bedding. *Lab. Anim. Sci.* **42**:344-346.
386. Larsson-Sciard, E. L., S. Dethlefs, and M. Brahic. 1997. In vivo administration of interleukin-2 protects susceptible mice from Theiler's virus persistence. *J. Virol.* **71**:797-799.
387. Lathbury, L. J., J. E. Allan, G. R. Shellam, and A. A. Scalzo. 1996. Effect of host genotype in determining the relative roles of natural killer cells and T cells in mediating protection against murine cytomegalovirus infection. *J. Gen. Virol.* **77**:2605-2613.
388. Laursen, A. L., N. Obel, J. Rungby, and P. L. Andersen. 1993. Phagocytosis and stimulation of the respiratory burst in neutrophils by *Pneumocystis carinii*. *J. Infect. Dis.* **168**:1466-1471.
389. Lavi, E., Q. Wang, S. R. Weiss, and N. K. Gonatas. 1996. Syncytia formation induced by coronavirus infection is associated with fragmentation and rearrangement of the Golgi apparatus. *Virology* **221**:325-334.
390. Lavilla-Apelo, C., H. Kida, and H. Kanagawa. 1992. The effect of experimental infection of mouse preimplantation embryos with paramyxovirus Sendai. *J. Vet. Med. Sci.* **54**:335-340.
391. Lawson, C. M., H. L. O'Donoghue, H. E. Farrell, G. R. Shellam, and W. D. Reed. 1991. Murine anti-cytomegalovirus monoclonal antibodies with autoreactivity. *Immunology* **72**:426-433.
392. Le Bon, A., B. Lucas, F. Vasseur, C. Penit, and M. Papiernik. 1996. In vivo T cell response to viral superantigen. Selective migration rather than proliferation. *J. Immunol.* **156**:4602-4608.
393. Lechner, W., F. Allerberger, A. Bergant, E. Solder, and M. P. Dierich. 1993. Einfluss von Listerien auf die Kontraktibilität humaner Uterusmuskulatur. *Z. Geburtshilfe Perinatol.* **197**:179-183.
394. Lee, A., M. W. Phillips, J. L. O'Rourke, B. J. Paster, F. E. Dewhirst, G. J. Fraser, J. G. Fox, L. I. Sly, P. J. Romaniuk, T. J. Trust, et al. 1992. *Helicobacter muridarum* sp. nov., a microaerophilic helical bacterium with a novel ultrastructure isolated from the intestinal mucosa of rodents. *Int. J. Syst. Bacteriol.* **42**:27-36.
395. Lee, S. K., H. Y. Youn, A. Hasegawa, H. Nakayama, and N. Goto. 1994. Apoptotic changes in the thymus of mice infected with mouse hepatitis virus, MHV-2. *J. Vet. Med. Sci.* **56**:879-882.
396. Leichus, L. S., J. M. Goldhill, J. D. Long, W. H. Percy, R. D. Shaw, V. Donovan, and R. Burakoff. 1994. Effects of rotavirus on epithelial transport in rabbit small intestine. *Dig. Dis. Sci.* **39**:2202-2208.
397. Lemstrom, K. B., J. H. Bruning, C. A. Bruggeman, I. T. Lautenschlager, and P. J. Hayry. 1993. Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts. *J. Clin. Invest.* **92**:549-558.
398. Lentsch, R. H., B. K. Kirchner, L. W. Dixon, and J. E. Wagner. 1983. A report of an outbreak of *Salmonella oranienburg* in a hybrid mouse colony. *Vet. Microbiol.* **8**:105-109.
399. Liang, S.-C., W.-C. Lian, F.-J. Leu, P.-J. Lee, A.-J. Chao, C.-C. Hong, and W.-F. Chen. 1995. Epizootic of low-virulence hepatotropic murine hepatitis virus in a nude mice breeding colony in Taiwan. *Lab. Anim. Sci.* **45**:519-522.
400. Liang, S. C., T. R. Schoeb, J. K. Davis, J. W. Simecka, G. H. Cassell, and J. R. Lindsey. 1995. Comparative severity of respiratory lesions of sialodacryoadenitis virus and Sendai virus infections in LEW and F344 rats. *Vet. Pathol.* **32**:661-667.
401. Licois, D., P. Coudert, S. Bahagia, and G. L. Rossi. 1992. Endogenous development of *Eimeria intestinalis* in rabbits (*Oryctolagus cuniculus*). *J. Parasitol.* **78**:1041-1048.
402. Lin, Y. L., L. A. Borenstein, R. Selvakumar, R. Ahmed, and F. O. Wettstein. 1993. Progression from papilloma to carcinoma is accompanied by changes in antibody response to papillomavirus proteins. *J. Virol.* **67**:382-389.
403. Lippe, R., E. Luke, Y. T. Kuah, C. Lomas, and W. A. Jefferies. 1991. Adenovirus infection inhibits the phosphorylation of major histocompatibility complex class I proteins. *J. Exp. Med.* **174**:1159-1166.
404. Little, L. M., and J. A. Shaddock. 1982. Pathogenesis of rotavirus infection in mice. *Infect. Immun.* **38**:755-763.
405. Livingston, R. S., C. L. Franklin, C. L. Besch-Williford, R. R. Hook, Jr., and L. K. Riley. 1996. A novel presentation of *Clostridium piliforme* infection (Tyzzer's disease) in nude mice. *Lab. Anim. Sci.* **46**:21-25.
406. Ljungstrom, I., J. Holmgren, A.-M. Svennerholm, and A. Ferrante. 1985. Changes in intestinal fluid and mucosal immune responses to cholera toxin in *Giardia muris* infection and binding of cholera toxin to *Giardia muris* trophozoites. *Infect. Immun.* **50**:243-249.
407. Loving, R., I. M. Hanson, K. L. B. Borden, S. Martin, N. J. O'Reilly, G. I. Evan, D. R. Rahman, D. J. C. Pappin, J. Trowsdale, and P. S. Freemont. 1993. Identification and preliminary characterization of a protein motif related to the zinc finger. *Proc. Natl. Acad. Sci.* **90**:2112-2116.
408. Lubcke, R., F. A. Hutcheson, and G. O. Barbezat. 1992. Impaired intestinal electrolyte transport in rats infested with the common parasite *Syphacia muris*. *Dig. Dis. Sci.* **37**:60-64.
409. Lussier, G. 1988. Potential detrimental effects of rodent viral infections on long-term experiments. *Vet. Res. Commun.* **12**:199-217.
410. Magnuson, K., A. Hermansson, and S. Hellstrom. 1996. Healing of tympanic membrane after myringotomy during *Streptococcus pneumoniae* otitis media. An otomicroscopic and histologic study in the rat. *Ann. Otol. Rhinol. Laryngol.* **105**:397-404.
411. Mahenthalingam, E., M. E. Campbell, and D. P. Speert. 1994. Nonmotility and phagocytic resistance of *Pseudomonas aeruginosa* isolates from chronically colonized patients with cystic fibrosis. *Infect. Immun.* **62**:596-605.
412. Mahenthalingam, E., and D. P. Speert. 1995. Nonopsonic phagocytosis of *Pseudomonas aeruginosa* by macrophages and polymorphonuclear leukocytes requires the presence of the bacterial flagellum. *Infect. Immun.* **63**:4519-4523.
413. Mahy, B. W., C. Dykewicz, S. Fisher-Hoch, S. Ostroff, M. Tipple, and A. Sanchez. 1991. Virus zoonoses and their potential for contamination of cell cultures. *Dev. Biol. Stand.* **75P**:183-189.
414. Makhlof, M., S. H. Ashton, J. Hildebrandt, N. Mehta, T. W. Gettys, P. V. Halushka, and J. A. Cook. 1996. Alterations in macrophage G proteins are associated with endotoxin tolerance. *Biochim. Biophys. Acta* **1312**:163-168.
415. Makino, S., S. Seko, H. Nakao, and K. Mikazuki. 1972. An epizootic of Sendai virus infection in a rat colony. *Exp. Anim.* **22**:275-280.
416. Maksymowych, W. P., N. Nation, P. Nash, J. Macen, A. Lucas, G. McFadden, and A. S. Russell. 1996. Amelioration of antigen induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor. *J. Rheumatol.* **23**:878-882.
417. Malaviya, R., T. Ikeda, E. Ross, and S. N. Abraham. 1996. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. *Nature* **381**:77-80.
418. Malina, J., J. Hofmann, and J. Franek. 1991. Informative value of a mouse model of *Klebsiella pneumoniae* infection used as a host-resistance assay. *Folia Microbiol. (Prague)* **36**:183-191.
419. Marcato, P. S., C. Benazzi, G. Vecchi, M. Galeotti, L. Della Salda, G. Sarli, and P. Lucidi. 1991. Clinical and pathological features of viral haemorrhagic disease of rabbits and the European brown hare syndrome. *Rev. Sci. Tech. Off. Int. Epizoot.* **10**:371-392.
420. Marcotte, H., D. Levesque, K. Delanay, A. Bourgeault, R. de la Durantaye, S. Brochu, and M. C. Lavoie. 1996. *Pneumocystis carinii* infection in transgenic B cell-deficient mice. *J. Infect. Dis.* **173**:1034-1037.
421. Margolis, G., L. Kilham, and E. M. Hoening. 1974. Experimental adenovirus infection of the mouse adrenal gland. I. Light microscopic observations. *Am. J. Pathol.* **75**:363-372.
422. Marker, O., A. Scheynius, J. P. Christensen, and A. R. Thomsen. 1995. Virus-activated T cells regulate expression of adhesion molecules on endothelial cells in sites of infection. *J. Neuroimmunol.* **62**:35-42.
423. Marshall, J. C., M. B. Ribeiro, P. T. Chu, O. D. Rotstein, and P. A. Sheiner. 1993. Portal endotoxemia stimulates the release of an immunosuppressive factor from alveolar and splenic macrophages. *J. Surg. Res.* **55**:14-20.
424. Matsunaga, Y., and F. Chino. 1981. Experimental infection of young rabbits with rabbit parvovirus. *Arch. Virol.* **68**:257-264.
425. Matsushita, S., and H. Joshima. 1989. Pathology of rats intranasally inoculated with the cilia-associated respiratory bacillus. *Lab. Anim.* **23**:89-95.
426. Matsushita, S., J. Joshima, T. Matsumoto, and K. Fukutsu. 1989. Transmission experiments of cilia-associated respiratory bacillus in mice, rabbits, and guinea pigs. *Lab. Anim.* **23**:96-102.
427. Matsuya, Y., T. Kusano, S. Endo, N. Takahashi, and I. Yamane. 1978. Reduced tumorigenicity by addition in vitro of Sendai virus. *Eur. J. Cancer* **14**:837-850.
428. Matsuzawa, A., H. Nakano, T. Yoshimoto, and K. Sayama. 1995. Biology of mouse mammary tumor virus (MMTV). *Cancer Lett.* **90**:3-11.
429. Mazing, Y. A., M. A. Danilova, V. N. Kokryakov, V. G. Seliverstova, V. E. Pigarevskii, S. Voros, M. Kerenyi, and B. Ralovich. 1990. Haematological reactions of rabbits infected intravenously with *Listeria* strains of different virulence. *Acta Microbiol. Hung.* **37**:135-144.
430. McClure, C. D., and N. L. Schiller. 1996. Inhibition of macrophage phagocytosis by *Pseudomonas aeruginosa* rhamnolipids in vitro and in vivo. *Curr. Microbiol.* **33**:109-117.
431. McCollister, B. D., B. N. Kreiswirth, R. P. Novick, and P. M. Schlievert. 1990. Production of toxic shock syndrome-like illness in rabbits by *Staphy-*

- lococcus aureus* D4508: association with enterotoxin A. Infect. Immun. 58:2067-2070.
432. McGinn, M. D., D. Bean-Knudsen, and R. W. Ermel. 1992. Incidence of otitis media in CBA/J and CBA/CaJ mice. Hear. Res. 59:1-6.
433. McIntosh, J. C., J. W. Simecka, S. E. Ross, J. K. Davis, E. J. Miller, and G. H. Cassell. 1992. Infection-induced airway fibrosis in two rat strains with differential susceptibility. Infect. Immun. 60:2936-2942.
434. McKisic, M. D., D. W. Lancki, G. Otto, P. Padrid, S. Snook, D. C. Cronin II, P. D. Lohmar, T. Wong, and F. W. Fitch. 1993. Identification and propagation of a putative immunosuppressive orphan parvovirus in cloned T cells. J. Immunol. 150:419-428.
435. McKisic, M. D., F. X. Paturzo, and A. L. Smith. 1996. Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions. Transplantation 61:292-299.
436. McNeal, M. M., K. S. Barone, M. N. Rae, and R. L. Ward. 1995. Effector functions of antibody and CD8+ cells in resolution of rotavirus infection and protection against reinfection in mice. Virology 214:387-397.
437. McNeal, M. M., R. L. Broome, and R. L. Ward. 1994. Active immunity against rotavirus infection in mice is correlated with viral replication and titers of serum rotavirus IgA following vaccination. Virology 204:642-650.
438. McNeal, M. M., and R. L. Ward. 1995. Long-term production of rotavirus antibody and protection against reinfection following a single infection of neonatal mice with murine rotavirus. Virology 211:474-480.
439. Medina, L. V., J. D. Fortman, R. M. Bunte, and B. T. Bennett. 1994. Respiratory disease in a rat colony: identification of CAR bacillus without other respiratory pathogens by standard diagnostic screening methods. Lab. Anim. Sci. 44:521-525.
440. Mendes, E. N., D. M. Queiroz, F. E. Dewhirst, B. J. Paster, S. B. Moura, and J. G. Fox. 1996. *Helicobacter trogonum* sp. nov., isolated from the rat intestine. Int. J. Syst. Bacteriol. 46:916-921.
441. Meshorer, A. 1969. Hexamitiasis in laboratory mice. Lab. Anim. Care 19:33-37.
442. Metcalf, J. B., M. Lederman, E. R. Stout, and R. C. Bates. 1989. Natural parvovirus infection in laboratory rabbits. Am. J. Vet. Res. 50:1048-1051.
443. Meyer, J. M., A. Neely, A. Stintzi, C. Georges, and I. A. Holder. 1996. Pyoverdin is essential for virulence of *Pseudomonas aeruginosa*. Infect. Immun. 64:518-523.
444. Miconet, I., T. Roger, M. Seman, and M. Bruley-Rosset. 1995. Critical role of endogenous Mtv in acute lethal graft-versus-host disease. Eur. J. Immunol. 25:364-368.
445. Mikazuki, K., T. Hirasawa, H. Chiba, K. Takahashi, Y. Sakai, S. Ohhara, and H. Nenui. 1994. Colonization pattern of *Pasteurella pneumotropica* in mice with latent pasteurellosis. Jikken Dobutsu 43:375-379.
446. Millard, P. R., A. E. Wakefield, and J. M. Hopkin. 1990. A sequential ultrastructural study of rat lungs infected with *Pneumocystis carinii* to investigate the appearances of the organism, its relationships and its effects on pneumocytes. Int. J. Exp. Pathol. 71:895-904.
447. Minion, F. C., and K. Jarvill-Taylor. 1994. Membrane-associated hemolysin activities in mycoplasmas. FEMS Microbiol. Lett. 116:101-106.
448. Mitchell, B. M., A. Leung, and J. G. Stevens. 1996. Murine cytomegalovirus DNA in peripheral blood of latently infected mice is detectable only in monocytes and polymorphonuclear leukocytes. Virology 223:198-207.
449. Mixer, P. F., V. Camerini, B. J. Stone, V. L. Miller, and M. Kronenberg. 1994. Mouse T lymphocytes that express a gamma delta T-cell antigen receptor contribute to resistance to *Salmonella* infection in vivo. Infect. Immun. 62:4618-4621.
450. Miyata, H., M. Kishikawa, H. Kondo, C. Kai, Y. Watanabe, K. Ohsawa, and H. Sato. 1995. New isolates of pneumonia virus of mice (PVM) from Japanese rat colonies and their characterization. AADE Ed. J. 44:95-104.
451. Miyazaki, S., T. Matsumoto, K. Tateda, A. Ohno, and K. Yamaguchi. 1995. Role of exotoxin A in inducing severe *Pseudomonas aeruginosa* infections in mice. J. Med. Microbiol. 43:169-175.
452. Mo, X. Y., M. Sangster, S. Sarawar, C. Coleclough, and P. C. Doherty. 1995. Differential antigen burden modulates the gamma interferon but not the immunoglobulin response in mice that vary in susceptibility to Sendai virus pneumonia. J. Virol. 69:5592-5598.
453. Mo, X. Y., S. R. Sarawar, and P. C. Doherty. 1995. Induction of cytokines in mice with parainfluenza pneumonia. J. Virol. 69:1288-1291.
454. MocarSKI, E. S., M. Bonyhadi, S. Salimi, J. M. McCune, and H. Kaneshima. 1993. Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication. Proc. Natl. Acad. Sci. USA 90:104-108.
455. Mordelet-Dambrine, M., C. Danel, R. Farinotti, G. Urzua, L. Barritault, and G. J. Huchon. 1992. Influence of *Pneumocystis carinii* pneumonia on serum and tissue concentrations of pentamidine administered to rats by tracheal injections. Am. Rev. Respir. Dis. 146:735-739.
456. Morgan, M. S., and L. G. Arian. 1994. Serum antibody profiles of *Sarcoptes scabiei* infested or immunized rabbits. Folia Parasitol. (Prague) 41:223-227.
457. Morganti, L., M. P. Tampieri, R. Galuppi, and F. Menegali. 1992. Morphological and biochemical variability of *Microsporium canis* strains. Eur. J. Epidemiol. 8:340-345.
458. Mori, I., T. Hayashi, S. Kitazima, and H. Yamamoto. 1992. Binding of asparaginase to mouse monocytes. Int. J. Exp. Pathol. 73:585-592.
459. Morin, M. J., A. Warner, and B. N. Fields. 1996. Reovirus infection in rat lungs as a model to study the pathogenesis of viral pneumonia. J. Virol. 70:541-548.
460. Morissette, C., C. Francoeur, C. Darmond-Zwaig, and F. Gervais. 1996. Lung phagocyte bactericidal function in strains of mice resistant and susceptible to *Pseudomonas aeruginosa*. Infect. Immun. 64:4984-4992.
461. Morissette, C., E. Skamene, and F. Gervais. 1995. Endobronchial inflammation following *Pseudomonas aeruginosa* infection in resistant and susceptible strains of mice. Infect. Immun. 63:1718-1724.
462. Morner, T., R. Mattsson, M. Forsman, K. E. Johansson, and G. Sandstrom. 1993. Identification and classification of different isolates of *Francisella tularensis*. Zentralbl. Veterinarmed. Reihe B 40:613-620.
463. Morrey, J. D., R. W. Sidwell, R. L. Noble, B. B. Barnett, and A. W. Mahoney. 1984. Effects of folic acid malnutrition on rotaviral infection in mice. Proc. Soc. Exp. Biol. Med. 176:77-83.
464. Morse, S. S. 1987. Mouse thymic necrosis virus: a novel murine lymphotropic agent. Lab. Anim. Sci. 37:717-725.
465. Moskophidis, D., M. Bategay, M. van den Broek, E. Laine, U. Hoffmann-Rohrer, and R. M. Zinkernagel. 1995. Role of virus and host variables in virus persistence or immunopathological disease caused by a non-cytolytic virus. J. Gen. Virol. 76:381-391.
466. Mossman, K., C. Upton, R. M. Buller, and G. McFadden. 1995. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208:762-769.
467. Muller, W. J., C. L. Arteaga, S. K. Muthuswamy, P. M. Siegel, M. A. Webster, R. D. Cardiff, K. S. Meise, F. Li, S. A. Halter, and R. J. Coffey. 1996. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol. Cell. Biol. 16:5726-5736.
468. Nabarra, B., C. Desaynard, A. C. Wache, and M. Papiernik. 1996. Mouse mammary tumor virus production by thymic epithelial cells in vivo. Eur. J. Immunol. 26:2724-2730.
469. Nakane, A., A. Numata, Y. Chen, and T. Minagawa. 1991. Endogenous gamma interferon-independent host resistance against *Listeria monocytogenes* infection in CD4+ T-cell- and asialo GM1+ cell-depleted mice. Infect. Immun. 59:3439-3445.
470. Nakane, A., M. Okamoto, M. Asano, M. Kohanawa, and T. Minagawa. 1995. Endogenous gamma interferon, tumor necrosis factor, and interleukin-6 in *Staphylococcus aureus* infection in mice. Infect. Immun. 63:1165-1172.
471. Nakano, Y., T. Kasahara, N. Mukaida, Y. C. Ko, M. Nakano, and K. Matsushima. 1994. Protection against lethal bacterial infection in mice by monocyte-chemotactic and -activating factor. Infect. Immun. 62:377-383.
472. Naot, Y., S. Merchav, E. Ben-David, and H. Ginsburg. 1979. Mitogenic activity of *Mycoplasma pulmonis*. I. Stimulation of rat B and T lymphocytes. Immunology 36:399-406.
473. Naot, Y., R. Simon-Tou, and H. Ginsburg. 1979. Mitogenic activity of *Mycoplasma pulmonis*. II. Studies on the biochemical nature of the mitogenic factor. Eur. J. Immunol. 9:149-151.
474. Nathan, L., D. M. Twickler, M. T. Peters, P. J. Sanchez, and G. D. Wendel, Jr. 1993. Fetal syphilis: correlation of sonographic findings and rabbit infectivity testing of amniotic fluid. J. Ultrasound Med. 12:97-101.
475. National Research Council. 1991. Infectious diseases of mice and rats: a report of the Institute of Laboratory Animal Resources Committee on Infectious Diseases of Mice and Rats. National Academy Press, Washington, D.C.
476. Naughton, P. J., G. Grant, S. W. Ewen, R. J. Spencer, D. S. Brown, A. Pusztai, and S. Bardocz. 1995. *Salmonella typhimurium* and *Salmonella enteritidis* induce gut growth and increase the polyamine content of the rat small intestine in vivo. FEMS Immunol. Med. Microbiol. 12:251-258.
477. Naughton, P. J., G. Grant, R. J. Spencer, S. Bardocz, and A. Pusztai. 1996. A rat model of infection by *Salmonella typhimurium* or *Salmonella enteritidis*. J. Appl. Bacteriol. 81:651-656.
478. Neely, A. N., R. G. Miller, and I. A. Holder. 1994. Proteolytic activity and fatal gram-negative sepsis in burned mice: effect of exogenous proteinase inhibition. Infect. Immun. 62:2158-2164.
479. Nelson, J. B., and G. S. Tarnowski. 1960. An oncolytic virus recovered from Swiss mice during passage of an ascites tumour. Nature 188:866-867.
480. Netea, M. G., W. L. Blok, B. J. Kullberg, M. Bemelmans, M. T. Vogels, W. A. Buurman, and J. W. van der Meer. 1995. Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J. Infect. Dis. 171:393-399.
481. Newsome, P. M., and K. A. Coney. 1985. Synergistic rotavirus and *Escherichia coli* diarrheal infection of mice. Infect. Immun. 47:573-574.
482. Nichols, P. W., T. R. Schoeb, J. K. Davis, M. K. Davidson, and J. R. Lindsey. 1992. Pulmonary clearance of *Mycoplasma pulmonis* in rats with respiratory viral infections or of susceptible genotype. Lab. Anim. Sci. 42:454-457.
483. Nicholson, S. M., J. D. Peterson, S. D. Miller, K. Wang, M. C. Dal Canto, and R. W. Melvold. 1994. BALB/c substrain differences in susceptibility to

- Theiler's murine encephalomyelitis virus-induced demyelinating disease. *J. Neuroimmunol.* **52**:19–24.
484. Nicklas, W., V. Kraft, and B. Meyer. 1993. Contamination of transplantable tumors, cell lines, and monoclonal antibodies with rodent viruses. *Lab. Anim. Sci.* **43**:296–300.
485. Niemialowski, M. G., I. Spohr de Faundez, M. Gierynska, E. Malicka, F. N. Toka, A. Schollenberger, and A. Popis. 1994. The inflammatory and immune response to mousepox (infectious ectromelia) virus. *Acta Virol.* **38**:299–307.
486. Niilo, L. 1967. Acquired resistance to reinfection of rabbits with *Eimeria magna*. *Can. Vet. J.* **8**:201–208.
487. Nina, J. M. S., V. McDonald, R. M. A. Deer, S. E. Wright, D. A. Dyson, P. L. Chiodini, and K. P. W. J. McAdam. 1992. Comparative study of the antigenic composition of oocyst isolates of *Cryptosporidium parvum* from different hosts. *Parasite Immunol.* **14**:227–232.
488. Noble, R. L., R. W. Sidwell, A. W. Mahoney, B. B. Barnett, and R. S. Splendlove. 1983. Influence of malnutrition and alterations in dietary protein on murine rotaviral disease. *Proc. Soc. Exp. Biol. Med.* **173**:417–426.
489. Nunoya, T., M. Itabashi, S. Kudow, M. Hayashi, and M. Tajima. 1977. An epizootic outbreak of sialodacryoadenitis in rats. *Jpn. J. Vet. Sci.* **39**:445–450.
490. O'Callaghan, R. J., L. L. Engel, J. A. Hobden, M. C. Callegan, L. C. Green, and J. M. Hill. 1996. *Pseudomonas* keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. *Investig. Ophthalmol. Visual Sci.* **37**:534–543.
491. O'Donoghue, H. L., C. M. Lawson, and W. D. Reed. 1990. Autoantibodies to cardiac myosin in mouse cytomegalovirus myocarditis. *Immunology* **71**: 20–28.
492. Ogasawara, T., M. Emoto, K. Kiyotani, K. Shimokata, T. Yoshida, Y. Nagai, and Y. Yoshikai. 1994. Sendai virus pneumonia: evidence for the early recruitment of gamma delta T cells during the disease course. *J. Virol.* **68**:4022–4027.
493. Ohlinger, V. F., H. Bernd, G. Meyers, F. Weiland, and H.-J. Thiel. 1990. Identification and characterization of the virus causing rabbit hemorrhagic disease. *J. Virol.* **64**:3331–3336.
494. Ohnishi, Y., M. Yoshimura, and Y. Ueyama. 1995. Lactic dehydrogenase virus (LDHV) contamination in human tumor xenografts and its elimination. *J. Natl. Cancer Inst.* **87**:538–539.
495. Oleszak, E. L. 1994. Molecular mimicry between Fe receptors and viral antigens. *Arch. Immunol. Ther. Exp.* **42**:83–88.
496. Oleszak, E. L., J. Kuzmak, R. A. Good, and C. D. Platsoucas. 1995. Immunology of Theiler's murine encephalomyelitis virus infection. *Immunol. Res.* **14**:13–33.
497. Olsberg, C., A. Pelka, S. Miller, C. Waltenbaugh, T. M. Creighton, M. C. Dal Canto, H. Lipton, and R. Melvold. 1993. Induction of Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease in genetically resistant mice. *Reg. Immunol.* **5**:1–10.
498. Olson, R. D., D. L. Stevens, and M. E. Melish. 1989. Direct effects of purified staphylococcal toxic shock syndrome toxin 1 on myocardial function of isolated rabbit atria. *Rev. Infect. Dis.* **11**(Suppl. 1P):S313–S315.
499. O'Neill, H. C. 1991. Resistance to ectromelia virus infection in mice. Analysis of H-2-linked gene effects. *Arch. Virol.* **118**:253–259.
500. Orange, J. S., B. Wang, C. Terhorst, and C. A. Biron. 1995. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. *J. Exp. Med.* **182**:1045–1056.
501. Orange, J. S., S. F. Wolf, and C. A. Biron. 1994. Effects of IL-12 on the response and susceptibility to experimental viral infections. *J. Immunol.* **152**:1253–1264.
502. Osborn, J. E. 1982. Cytomegalovirus and other herpesviruses, p. 267–292. *In* H. L. Foster, H. D. Small, and J. G. Fox (ed.), *The mouse in biomedical research*, vol. II. Diseases. Academic Press, Inc., New York, N.Y.
503. Osterhaus, A. D. M. E., J. S. Teppema, and G. Van Steenis. 1982. Coronavirus-like particles in laboratory rabbits with different syndromes in the Netherlands. *Lab. Anim. Sci.* **32**:663–665.
504. Packham, D. K., T. D. Hewitson, J. A. Whitworth, and P. S. Kincaid-Smith. 1992. Glomerulosclerosis and hyalinosis in rabbits. *Pathology* **24**:164–169.
505. Pakandl, M., K. Gaca, F. Drouet-Viard, and P. Coudert. 1996. *Eimeria coecicola* Cheissin 1947: endogenous development in gut-associated lymphoid tissue. *Parasitol. Res.* **82**:347–351.
506. Pakes, S. P., and L. W. Gerrity. 1994. Protozoal diseases, p. 205–229. *In* P. J. Manning, D. H. Ringer, and C. E. Newcomer (ed.), *The biology of the laboratory rabbit*, 2nd ed. Academic Press, Inc., San Diego, Calif.
507. Parashar, K., M. J. Tarlow, and M. A. McCrae. 1992. Experimental reovirus type 3-induced murine biliary tract disease. *J. Pediatr. Surg.* **27**:843–847.
508. Parmely, M., A. Gale, M. Clabaugh, R. Horvat, and W. W. Zhou. 1990. Proteolytic inactivation of cytokines by *Pseudomonas aeruginosa*. *Infect. Immun.* **58**:3009–3014.
509. Parsons, R. J., and J. G. Kidd. 1936. A virus causing oral papillomatosis in rabbits. *Proc. Soc. Exp. Biol. Med.* **35**:441–443.
510. Pattison, M., F. G. Clegg, and A. L. Duncan. 1971. An outbreak of encephalomyelitis in broiler rabbits caused by *Nosema cuniculi*. *Vet. Rec.* **88**:404–405.
511. Pearce, B. D., S. C. Steffensen, A. D. Paoletti, S. J. Henriksen, and M. J. Buchmeier. 1996. Persistent dentate granule cell hyperexcitability after neonatal infection with lymphocytic choriomeningitis virus. *J. Neurosci.* **16**:220–228.
512. Pearson, D. J., and G. Taylor. 1975. The influence of the nematode *Syphacia obvelata* on adjuvant arthritis in rats. *Immunology* **29**:391–396.
513. Peck, R. M., G. J. Eaton, E. B. Peck, and S. Litwin. 1983. Influence of Sendai virus on carcinogenesis in strain A mice. *Lab. Anim. Sci.* **33**:154–156.
514. Peeters, J. E., P. Pohl, and G. Charlier. 1984. Infectious agents associated with diarrhoea in commercial rabbits: a field study. *Ann. Rech. Vet.* **15**: 335–340.
515. Pence, B. C., D. S. Demick, B. C. Richard, and F. Buddingh. 1991. The efficacy and safety of Chlorpyrifos (Dursban™) for control of *Myobia musculi* infestation in mice. *Lab. Anim. Sci.* **41**:139–142.
516. Percy, D. H., D. C. Auger, and B. A. Croy. 1994. Signs and lesions of experimental Sendai virus infection in two genetically distinct strains of SCID/beige mice. *Vet. Pathol.* **31**:67–73.
517. Percy, D. H., and S. W. Barthold. 1993. *Pathology of laboratory rodents and rabbits*. Iowa State University Press, Ames, Iowa.
518. Percy, D. H., M. A. Hayes, T. E. Kocal, and Z. W. Wojcinski. 1988. Depletion of salivary gland epidermal growth factor by sialodacryoadenitis virus infection in the Wistar rat. *Vet. Pathol.* **25**:183–192.
519. Percy, D. H., N. Karrow, and J. L. Bhasin. 1988. Incidence of *Pasteurella* and *Bordetella* infections in fryer rabbits: An abattoir survey. *J. Appl. Rabbit Res.* **11**:245–246.
520. Percy, D. H., K. L. Williams, and B. A. Croy. 1991. Experimental sialodacryoadenitis virus infection in severe combined immunodeficient mice. *Can. J. Vet. Res.* **55**:89–90.
521. Perlman, S., N. Sun, and E. M. Barnett. 1995. Spread of MHV-JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. *Adv. Exp. Med. Biol.* **380P**:73–78.
522. Petro, T. M., R. R. Watson, D. E. Feely, and H. Darban. 1992. Suppression of resistance to *Giardia muris* and cytokine production in a murine model of acquired immune deficiency syndrome. *Reg. Immunol.* **4**:409–414.
523. Pewe, L., G. F. Wu, E. M. Barnett, R. F. Castro, and S. Perlman. 1996. Cytotoxic T cell-resistant variants are selected in a virus-induced demyelinating disease. *Immunity* **5**:253–262.
524. Phelps, D. S., T. M. Umstead, R. M. Rose, and J. A. Fishman. 1996. Surfactant protein-A levels increase during *Pneumocystis carinii* pneumonia in the rat. *Eur. Respir. J.* **9**:565–570.
525. Pier, G. B., G. Meluleni, and J. B. Goldberg. 1995. Clearance of *Pseudomonas aeruginosa* from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies. *Infect. Immun.* **63**:2818–2825.
526. Pier, G. B., G. Meluleni, and E. Neuger. 1992. A murine model of chronic mucosal colonization by *Pseudomonas aeruginosa*. *Infect. Immun.* **60**:4768–4776.
527. Pinto, R. M., J. J. Vicente, D. Noronha, L. Goncalves, and D. C. Gomes. 1994. Helminth parasites of conventionally maintained laboratory mice. *Mem. Inst. Oswaldo Cruz.* **89**:33–40.
528. Pittet, J. F., S. Hashimoto, M. Pian, M. C. McElroy, G. Nitenberg, and J. P. Wiener-Kronish. 1996. Exotoxin A stimulates fluid reabsorption from distal airspaces of lung in anesthetized rats. *Am. J. Physiol.* **270**:L232–241.
529. Podwinska, J., and M. Chomik. 1992. Treponemal activity of anti-treponemal lymphotoxins and their relation to circulating immune complexes and autolymphocytotoxins. *FEMS Microbiol. Immunol.* **4**:345–351.
530. Podwinska, J., R. Zaba, M. Chomik, and J. Bowszyc. 1993. The ability of peripheral blood mononuclear cells of rabbits infected with *Treponema pallidum* to produce IL-2. *FEMS Immunol. Med. Microbiol.* **7**:257–264.
531. Pohlmeier, G., and F. Deerberg. 1993. Nude rats as a model of natural *Pneumocystis carinii* pneumonia: sequential morphological study of lung lesions. *J. Comp. Pathol.* **109**:217–230.
532. Pollock, J. L., and H. W. Virgin IV. 1995. Latency, without persistence, of murine cytomegalovirus in the spleen and kidney. *J. Virol.* **69**:1762–1768.
533. Polozowski, A. 1993. [Coccidiosis of rabbits and its control]. *Kokcydioza krowliow i jej zapobieganie. Wiad. Parazytol.* **39**:13–28.
534. Pomeroy, C., G. A. Filice, J. A. Hitt, and M. C. Jordan. 1992. Cytomegalovirus-induced reactivation of *Toxoplasma gondii* pneumonia in mice: lung lymphocyte phenotypes and suppressor function. *J. Infect. Dis.* **166**:677–681.
535. Pope, M., and I. Kotlarski. 1994. Detection of *Salmonella*-specific L3T4+ and Lyt-2+ T cells which can proliferate in vitro and mediate delayed-type hypersensitivity reactivity. *Immunology* **81**:183–191.
536. Powles, M. A., D. C. McFadden, L. A. Pittarelli, and D. M. Schmatz. 1992. Mouse model for *Pneumocystis carinii* pneumonia that uses natural transmission to initiate infection. *Infect. Immun.* **60**:1397–1400.
537. Prasad, P. A., A. V. Lakshmi, P. Suresh, and M. S. Bamji. 1991. Effect of respiratory infection on tissue riboflavin and flavin enzymes in mice. *Ann. Nutr. Metab.* **35**:19–24.
538. Price, P., S. D. Olver, M. Silich, T. Z. Nador, S. Yerkovich, and S. G.

- Wilson. 1996. Adrenality and the adrenocortical response of resistant and susceptible mice to acute murine cytomegalovirus infection. *Eur. J. Clin. Invest.* **26**:811–819.
539. Qin, L., W. M. Quinlan, N. A. Doyle, L. Graham, J. E. Sligh, F. Takei, A. L. Beudet, and C. M. Doerschuk. 1996. The roles of CD11/CD18 and ICAM-1 in acute *Pseudomonas aeruginosa*-induced pneumonia in mice. *J. Immunol.* **157**:5016–5021.
540. Rai, S. K., D. S. Cheung, M. S. Wu, T. F. Warner, and M. S. Salvato. 1996. Murine infection with lymphocytic choriomeningitis virus following gastric inoculation. *J. Virol.* **70**:7213–7218.
541. Ramirez, J. C., A. Fairen, and J. M. Almendral. 1996. Parvovirus minute virus of mice strain i multiplication and pathogenesis in the newborn mouse brain are restricted to proliferative areas and to migratory cerebellar young neurons. *J. Virol.* **70**:8109–8116.
542. Rani, M., R. K. Gupta, and S. Chhibber. 1990. Protection against *Klebsiella pneumoniae* induced lobar pneumonia in rats with lipopolysaccharide and related antigens. *Can. J. Microbiol.* **36**:885–890.
543. Reddick, R. A., and S. S. Lefkowitz. 1969. In vitro immune responses of rabbits with persistent adenovirus type 5 infection. *J. Immunol.* **103**:687–694.
544. Rehg, J. E., G. W. Lawton, and S. P. Pakes. 1979. *Cryptosporidium cuniculi* in the rabbit (*Oryctolagus cuniculus*). *Lab. Anim. Sci.* **29**:656–660.
545. Ren, K., J. D. Bannan, V. Pancholi, A. L. Cheung, J. C. Robbins, V. A. Fischetti, and J. B. Zabriski. 1994. Characterization and biological properties of a new staphylococcal exotoxin. *J. Exp. Med.* **180**:1675–1683.
546. Reperant, J. M., M. Naciri, S. Iochmann, M. Tilley, and D. T. Bout. 1994. Major antigens of *Cryptosporidium parvum* recognised by serum antibodies from different infected animal species and man. *Vet. Parasitol.* **55**:1–13.
547. Revets, H., D. Dekegel, W. Deleersnijder, J. De Jonckheere, J. Peeters, E. Leysen, and R. Hamers. 1989. Identification of virus-like particles in *Eimeria stiedae*. *Mol. Biochem. Parasitol.* **36**:209–215.
548. Richardson, M., A. Fletch, K. Delaney, M. DeReske, L. H. Wilcox, and R. L. Kinlough-Rathbone. 1997. Increased expression of vascular cell adhesion molecule-1 by the aortic endothelium of rabbits with *Pasteurella multocida* pneumonia. *Lab. Anim. Sci.* **47**:27–35.
549. Richter, C. B., K. L. Klingenberg, D. Hughes, H. S. Friedman, and D. I. Schenkman. 1990. D2 coryneforms as a cause of severe hyperkeratotic dermatitis in athymic nude mice. *Lab. Anim. Sci.* **40**:545.
550. Richter, C. B., J. E. Thigpen, C. S. Richter, and J. M. Mackenzie, Jr. 1988. Fatal pneumonia with terminal emaciation in nude mice caused by pneumonia virus of mice. *Lab. Anim. Sci.* **38**:255–261.
551. Riepenhoff-Talty, M., T. Dharakul, E. Kowalski, S. Michalak, and P. L. Ogra. 1987. Persistent rotavirus infection in mice with severe combined immunodeficiency. *J. Virol.* **61**:3345–3348.
552. Roberts, N. J. 1982. Different effects of influenza virus, respiratory syncytial virus, and Sendai virus on human lymphocytes and macrophages. *Infect. Immun.* **35**:1142–1146.
553. Roberts-Thomson, I. C., and R. F. Anders. 1984. Cellular and humoral immunity in giardiasis, p. 185–200. In S. L. Erlandsen and E. A. Meyer (ed.), *Giardia* and giardiasis. Plenum Press, New York, N.Y.
554. Rodák, L., B. Šmíd, L. Valíček, T. Veselý, J. Štěpánek, J. Hampl, and E. Jurák. 1990. Enzyme-linked immunosorbent assay of antibodies to rabbit haemorrhagic disease virus and determination of its major structural proteins. *J. Gen. Virol.* **71**:1075–1080.
555. Romia, S. A., A. Abu-Zakham, H. M. al-Naggar, R. A. Atia, and A. F. Abu-Shady. 1990. The course of *Giardia muris* infection in immunocompetent and immunocompromised mice. *J. Egypt. Soc. Parasitol.* **20**:721–728.
556. Rose, C. E., Jr., C. A. Juliano, D. E. Tracey, T. Yoshimura, and S. M. Fu. 1994. Role of interleukin-1 in endotoxin-induced lung injury in the rat. *Am. J. Respir. Cell. Mol. Biol.* **10**:214–221.
557. Ross, S. E., J. W. Simecka, G. P. Gambill, J. K. Davis, and G. H. Cassell. 1992. *Mycoplasma pulmonis* possesses a novel chemoattractant for B lymphocytes. *Infect. Immun.* **60**:669–674.
558. Roth, E. J., B. Kurz, L. Liang, C. L. Hansen, C. T. Dameron, D. R. Winge, and D. Smotkin. 1992. Metal thiolate coordination in the E7 proteins of human papilloma virus 16 and cottontail rabbit papilloma virus as expressed in *Escherichia coli*. *J. Biol. Chem.* **267**:16390–16395.
559. Roths, J. B., A. L. Smith, and C. L. Sidman. 1993. Lethal exacerbation of *Pneumocystis carinii* pneumonia in severe combined immunodeficiency mice after infection by pneumonia virus of mice. *J. Exp. Med.* **177**:1193–1198.
560. Rozalska, B., and T. Wadstrom. 1994. Role of antibodies against fibronectin-, collagen-binding proteins and alpha-toxin in experimental *Staphylococcus aureus* peritonitis and septicaemia in neutropenic mice. *Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis.* **281**:495–501.
561. Rubins, J. B., D. Charboneau, C. Fasching, A. M. Berry, J. C. Paton, J. E. Alexander, P. W. Andrew, T. J. Mitchell, and E. N. Janoff. 1996. Distinct roles for pneumolysin's cytotoxic and complement activities in the pathogenesis of pneumococcal pneumonia. *Am. J. Respir. Crit. Care Med.* **153**:1339–1346.
562. Rubio, N., and C. Torres. 1991. IL-1, IL-2 and IFN-gamma production by Theiler's virus-induced encephalomyelitic SJL/J mice. *Immunology* **74**:284–289.
563. Ruedl, C., M. Fruhwirth, G. Wick, and H. Wolf. 1994. Immune response in the lungs following oral immunization with bacterial lysates of respiratory pathogens. *Clin. Diagn. Lab. Immunol.* **1**:150–154.
564. Sagher, F. A., J. A. Dodge, D. H. Simpson, and P. Evans. 1991. Kinetics of viral replication in experimental rotavirus infection: effects of high dietary fat. *J. Pediatr. Gastroenterol. Nutr.* **13**:83–89.
565. Sakaguchi, T., K. Kiyotani, M. Sakaki, Y. Fujii, and T. Yoshida. 1994. A field isolate of Sendai virus: its high virulence to mice and genetic divergence from prototype strains. *Arch. Virol.* **135**:159–164.
566. Sakai, K., T. Kohri, M. Tashiro, Y. Kishino, and H. Kido. 1994. Sendai virus infection changes the subcellular localization of tryptase Clara in rat bronchiolar epithelial cells. *Eur. Respir. J.* **7**:686–692.
567. Sakata, Y., T. Akaike, M. Suga, S. Ijiri, M. Ando, and H. Maeda. 1996. Bradykinin generation triggered by *Pseudomonas* proteases facilitates invasion of the systemic circulation by *Pseudomonas aeruginosa*. *Microbiol. Immunol.* **40**:415–423.
568. Salim, A. F., A. D. Phillips, and M. J. Farthing. 1990. Pathogenesis of gut virus infection. *Baillieres Clin. Gastroenterol.* **4**:593–607.
569. Salim, A. F., A. D. Phillips, J. A. Walker-Smith, and M. J. Farthing. 1995. Sequential changes in small intestinal structure and function during rotavirus infection in neonatal rats. *Gut* **36**:231–238.
570. Sansing, W. A., J. J. Killion, and G. M. Kollmorgen. 1977. Evaluation of time and dose in treating mammary adenocarcinoma with immunostimulants. *Cancer Immunol. Immunother.* **2**:63–68.
571. Sasahara, T. 1990. The immunobiological properties expressed in vitro and in vivo of *Salmonella enteritidis*-induced murine T cell lines. *Kitasato Arch. Exp. Med.* **63**:107–118.
572. Sato, K., Y. Inaba, Y. Miura, S. Tokuhisa, and M. Matumoto. 1982. Isolation of lapine rotaviruses in cell cultures. *Arch. Virol.* **71**:267–271.
573. Sato, Y., H. K. Ooi, N. Nonaka, Y. Oku, and M. Kamiya. 1995. Antibody production in *Syphacia obvelata* infected mice. *J. Parasitol.* **81**:559–562.
574. Schagemann, G., W. Bohnet, I. Kunstýř, and T. Friedhoff. 1990. Host specificity of cloned *Spironucleus muris* in laboratory rodents. *Lab. Anim.* **24**:234–239.
575. Schauer, D. B., and S. Falkow. 1993. The *eae* gene of *Citrobacter freundii* biotype 4280 is necessary for colonization in transmissible murine colonic hyperplasia. *Infect. Immun.* **61**:4654–4661.
576. Schauer, D. B., N. Ghorri, and S. Falkow. 1993. Isolation and characterization of "Flexispira rappini" from laboratory mice. *J. Clin. Microbiol.* **31**:2709–2714.
577. Schauer, D. B., B. A. Zabel, I. F. Pedraza, C. M. O'Hara, A. G. Steigerwalt, and D. J. Brenner. 1995. Genetic and biochemical characterization of *Citrobacter rodentium* sp. nov. *J. Clin. Microbiol.* **33**:2064–2068.
578. Schjns, V. E., C. M. Wierda, M. van Hoesij, and M. C. Horzinek. 1996. Exacerbated viral hepatitis in IFN-gamma receptor-deficient mice is not suppressed by IL-12. *J. Immunol.* **157**:815–821.
579. Schneemilch, H. D. 1976. A naturally acquired infection of laboratory mice with *Klebsiella* capsule type 6. *Lab. Anim.* **10**:305–310.
580. Schoeb, T. R., M. M. Juliana, P. W. Nichols, J. K. Davis, and J. R. Lindsey. 1993. Effects of viral and mycoplasmal infections, ammonia exposure, vitamin A deficiency, host age, and organism strain on adherence of *Mycoplasma pulmonis* in cultured rat tracheas. *Lab. Anim. Sci.* **43**:417–424.
581. Schreiber, M., and G. McFadden. 1994. The myxoma virus TNF-receptor homologue (T2) inhibits tumor necrosis factor-alpha in a species-specific fashion. *Virology* **204**:692–705.
582. Schunk, M. K., D. H. Percy, and S. Rosendal. 1995. Effect of time of exposure to rat coronavirus and *Mycoplasma pulmonis* on respiratory tract lesions in the Wistar rat. *Can. J. Vet. Res.* **59**:60–66.
583. Schuster, G. S., G. B. Caughman, and N. L. O'Dell. 1991. Altered lipid metabolism in parvovirus-infected cells. *Microbios* **66**:143–155.
584. Schuurman, H.-J., E. B. Bell, K. Gärtner, H. J. Hedrich, A. K. Hansen, B. C. Kruijt, P. de Vrey, R. Leyten, S. J. Maeder, R. Moutier, U. Mohnle, J. Vankerkom, R. Boot, R. Broekhuizen, J. Dormans, H. van Herck, P. G. C. Hermans, J. Hoekman, J. van der Logt, M. van Wiik, J. G. Vos, and L. F. M. van Zutphen. 1992. Comparative evaluation of the immune status of congenitally athymic and euthymic rat strains bred and maintained at different institutes: 1. Euthymic rats. *J. Exp. Anim. Sci.* **35**:16–32.
585. Seeger, W., R. G. Birkemeyer, L. Ermert, N. Suttorp, S. Bhakdi, and H. R. Duncker. 1990. Staphylococcal alpha-toxin-induced vascular leakage in isolated perfused rabbit lungs. *Lab. Invest.* **63**:341–349.
586. Segovia, J. C., J. A. Bueren, and J. M. Almendral. 1995. Myeloid depression follows infection of susceptible newborn mice with the parvovirus minute virus of mice (strain I). *J. Virol.* **69**:3229–3232.
587. Sell, S., and J. Salman. 1992. Demonstration of *Treponema pallidum* in axons of cutaneous nerves in experimental chancres of rabbits. *Sex. Transm. Dis.* **19**:1–6.
588. Senkevich, T. G., E. V. Koonin, and R. M. Buller. 1994. A poxvirus protein with a RING zinc finger motif is of crucial importance for virulence. *Virology* **198**:118–128.
589. Shah, J. S., W. Pieciak, J. Liu, A. Buharin, and D. J. Lane. 1996. Diversity

- of host species and strains of *Pneumocystis carinii* is based on rRNA sequences. Clin. Diagn. Lab. Immunol. 3:119-127.
590. Shakhov, A. N., H. Wang, H. Acha-Orbea, R. J. Pauley, and W. Z. Wei. 1993. A new infectious mammary tumor virus in the milk of mice implanted with C4 hyperplastic alveolar nodules. Eur. J. Immunol. 23:2765-2769.
 591. Shames, B., J. G. Fox, F. Dewhirst, L. Yan, Z. Shen, and N. S. Taylor. 1995. Identification of widespread *Helicobacter hepaticus* infection in feces in commercial mouse colonies by culture and PCR assay. J. Clin. Microbiol. 33:2968-2972.
 592. Shanks, N., S. Larocque, and M. J. Meaney. 1995. Neonatal endotoxin exposure alters the development of the hypothalamic-pituitary-adrenal axis: early illness and later responsiveness to stress. J. Neurosci. 15:376-384.
 593. Shanley, J. D. 1991. Murine models of cytomegalovirus-associated pneumonitis. Transplant. Proc. 3(Suppl 3):12-16.
 594. Sharpe, A. H., and B. N. Fields. 1985. Pathogenesis of viral infections. Basic concepts derived from the reovirus model. N. Engl. J. Med. 312:486-497.
 595. Shellam, G. R. 1994. The potential of murine cytomegalovirus as a viral vector for immunosuppression. Reprod. Fertil. Dev. 6:401-409.
 596. Shellito, J., S. Nelson, and R. U. Sorensen. 1992. Effect of pyocyanine, a pigment of *Pseudomonas aeruginosa*, on production of reactive nitrogen intermediates by murine alveolar macrophages. Infect. Immun. 60:3913-3915.
 597. Sherry, B., C. J. Baty, and M. A. Blum. 1996. Reovirus-induced acute myocarditis in mice correlates with viral RNA synthesis rather than generation of infectious virus in cardiac myocytes. J. Virol. 70:6709-6715.
 598. Shoji-Darkye, Y., T. Itoh, and N. Kagiyama. 1991. Pathogenesis of CAR bacillus in rabbits, guinea pigs, Syrian hamsters, and mice. Lab. Anim. Sci. 41:567-571.
 599. Simaljakova, M., J. Buchvald, and B. Olexova. 1989. *Microsporium canis*-Infektion beim Kaninchen mit Ubertragung auf den Menschen. Mycoses 32:93-96.
 600. Skea, D. L., and B. J. Underdown. 1991. Acquired resistance to *Giardia muris* in X-linked immunodeficient mice. Infect. Immun. 59:1733-1738.
 601. Shifka, M. K., and R. Ahmed. 1996. Long-term antibody production is sustained by antibody-secreting cells in the bone marrow following acute viral infection. Ann. N. Y. Acad. Sci. 797P:166-176.
 602. Small, J. D. 1984. Rodent and lagomorph health surveillance—quality assurance, p. 709-723. In J. G. Fox, B. J. Cohen, and F. M. Loew (ed.), Laboratory animal medicine. Academic Press, Inc., San Diego, Calif.
 603. Small, J. D., L. Aurelian, R. A. Squire, J. D. Strandberg, E. C. Melby, Jr., T. B. Turner, and B. Newman. 1979. Rabbit cardiomyopathy associated with a virus antigenically related to human coronavirus strain 229E. Am. J. Pathol. 95:709-730.
 604. Small, J. D., and R. D. Woods. 1987. Relatedness of rabbit coronavirus to other coronaviruses. Adv. Exp. Med. Biol. 218:521-527.
 605. Smith, A. L., R. O. Jacoby, E. A. Johnson, F. Paturzo, and P. N. Bhatt. 1993. In vivo studies with an "orphan" parvovirus of mice. Lab. Anim. Sci. 43:175-182.
 606. Sorden, S. D., and W. L. Castleman. 1995. Virus-induced increases in bronchiolar mast cells in Brown Norway rats are associated with both local mast cell proliferation and increases in blood mast cell precursors. Lab. Invest. 73:197-204.
 607. Sorkness, R., R. F. Lemanske, Jr., and W. L. Castleman. 1991. Persistent airway hyperresponsiveness after neonatal viral bronchiolitis in rats. J. Appl. Physiol. 70:375-383.
 608. Soulez, B., F. Palluault, J. Y. Cesbron, E. Dei-Cas, A. Capron, and D. Camus. 1991. Introduction of *Pneumocystis carinii* in a colony of SCID mice. J. Protozool. 38:123S-125S.
 609. Soulsby, E. J. L. 1982. Helminths, arthropods and protozoa of domesticated animals, 7th ed. p. 660-661. Lea & Febiger, Philadelphia, Pa.
 610. Span, A. H., G. Grauls, F. Bosman, C. P. van Boven, and C. A. Bruggeman. 1992. Cytomegalovirus infection induces vascular injury in the rat. Atherosclerosis 93:41-52.
 611. Stachan, R., and Kunstýř, I. 1983. Minimal infectious doses and prepatent periods in *Giardia muris*, *Spiroplasma muris*, and *Trichomonas muris*. Zentralbl. Bakteriell. Mikrobiol. Hyg. Ser. A 256:249-256.
 612. Stals, F. S., G. Steinhoff, S. S. Wagenaar, J. P. van Breda Vriesman, A. Haverich, P. Dormans, F. Moeller, and C. A. Bruggeman. 1996. Cytomegalovirus induces interstitial lung disease in allogeneic bone marrow transplant recipient rats independent of acute graft-versus-host response. Lab. Invest. 74:343-352.
 613. Standiford, T. J., R. M. Strieter, M. J. Greenberger, and S. L. Kunkel. 1996. Expression and regulation of chemokines in acute bacterial pneumonia. Biol. Signals 5:203-208.
 614. Stanley, N. F. 1974. The reovirus murine models. Prog. Med. Virol. 18:257-272.
 615. Steele, T. A., and D. C. Cox. 1995. Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine. Cancer Biother. 10:307-315.
 616. Steffan, A. M., C. A. Pereira, A. Bingen, M. Valle, J. P. Martin, F. Koehren, C. Royer, J. L. Gendrait, and A. Kirm. 1995. Mouse hepatitis virus type 3 infection provokes a decrease in the number of sinusoidal endothelial cell fenestrae both in vivo and in vitro. Hepatology 22:395-401.
 617. Steffen, M. J., and J. L. Ebersole. 1992. Effects of aging on exocrine immune responses to *Mycoplasma pulmonis*. Mech. Aging Dev. 66:131-147.
 618. Steiner, D. A., E. W. Uhl, and M. B. Brown. 1993. In utero transmission of *Mycoplasma pulmonis* in experimentally infected Sprague-Dawley rats. Infect. Immun. 61:2985-2990.
 619. Stellrecht-Broomhall, K. A. 1991. Evidence for immune-mediated destruction as mechanism for LCMV-induced anemia in persistently infected mice. Viral Immunol. 4:269-280.
 620. Stevens, E. J., C. M. Ryan, J. S. Friedberg, R. L. Barnhill, M. L. Yarmush, and R. G. Tompkins. 1994. A quantitative model of invasive *Pseudomonas* infection in burn injury. J. Burn Care Rehabil. 15:232-235.
 621. Stevenson, M. M., T. K. Kondratieva, A. S. Apt, M. F. Tam, and E. Skamene. 1995. In vitro and in vivo T cell responses in mice during bronchopulmonary infection with mucoid *Pseudomonas aeruginosa*. Clin. Exp. Immunol. 99:98-105.
 622. Stone, B. J., and V. L. Miller. 1995. *Salmonella enteritidis* has a homologue of *tolC* that is required for virulence in BALB/c mice. Mol. Microbiol. 17:701-712.
 623. St. Pierre, Y., E. F. Potworowski, and G. F. Lussier. 1987. Transmission of mouse thymic virus. J. Gen. Virol. 68:1173-1176.
 624. Strake, J. G., M. J. Mitten, P. J. Ewing, and J. D. Alder. 1996. Model of *Streptococcus pneumoniae* meningitis in adult rats. Lab. Anim. Sci. 46:524-529.
 625. Streilein, J. W., J. A. Shaddock, and S. P. Pakes. 1981. Effects of splenectomy and Sendai virus infection on rejection of male skin isografts by pathogen free C57BL/6 female mice. Transplantation 32:34-37.
 626. Stringer, J. R. 1993. The identity of *Pneumocystis carinii*: not a single protozoan, but a diverse group of exotic fungi. Infect. Agents Dis. 2:109-117.
 627. Suckow, M. A., C. E. Chrisp, and N. T. Foged. 1991. Heat-labile toxin-producing isolates of *Pasteurella multocida* from rabbits. Lab. Anim. Sci. 41:151-156.
 628. Sukhar, V. V., and V. S. Uraleva. 1992. The C antigen of *Francisella tularensis*. Mikrobiol. Zh. 54:42-46. (In Russian.)
 629. Sukura, A., T. Soveri, and L. A. Lindberg. 1991. Superiority of methylprednisolone over dexamethasone for induction of *Pneumocystis carinii* infection in rats. J. Clin. Microbiol. 29:2331-2332.
 630. Suzuki, S., K. Komase, H. Matsui, A. Abe, K. Kawahara, Y. Tamura, M. Kijima, H. Danbara, M. Nakamura, and S. Sato. 1994. Virulence region of plasmid pNL2001 of *Salmonella enteritidis*. Microbiology 140:1307-1318.
 631. Sveen, K., and N. Skaug. 1992. Comparative mitogenicity and polyclonal B cell activation capacity of eight oral or nonoral bacterial lipopolysaccharides in cultures of spleen cells from athymic (nu/nu-BALB/c) and thymic (BALB/c) mice. Oral Microbiol. Immunol. 7:71-77.
 632. Sydora, B. C., B. D. Jamieson, R. Ahmed, and M. Kronenberg. 1996. Intestinal intraepithelial lymphocytes respond to systemic lymphocytic choriomeningitis virus infection. Cell. Immunol. 167:161-169.
 633. Szalai, A. J., D. E. Briles, and J. E. Volanakis. 1995. Human C-reactive protein is protective against fatal *Streptococcus pneumoniae* infection in transgenic mice. J. Immunol. 155:2557-2563.
 634. Szalai, A. J., D. E. Briles, and J. E. Volanakis. 1996. Role of complement in C-reactive-protein-mediated protection of mice from *Streptococcus pneumoniae*. Infect. Immun. 64:4850-4853.
 635. Taguchi, F., A. Yamada, and K. Fujiwara. 1979. Asymptomatic infection of mouse hepatitis virus in the rat. Arch. Virol. 59:275-279.
 636. Tahara, S., C. Bergmann, G. Nelson, R. Anthony, T. Dietlin, S. Kyuwa, and S. Stohlmann. 1993. Effects of mouse hepatitis virus infection on host cell metabolism. Adv. Exp. Med. Biol. 342P:111-116.
 637. Takashima, K., K. Tateda, T. Matsumoto, Y. Iizawa, M. Nakao, and K. Yamaguchi. 1997. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 65:257-260.
 638. Takashima, K., K. Tateda, T. Matsumoto, T. Ito, Y. Iizawa, M. Nakao, and K. Yamaguchi. 1996. Establishment of a model of penicillin-resistant *Streptococcus pneumoniae* pneumonia in healthy CBA/J mice. J. Med. Microbiol. 45:319-322.
 639. Takeuchi, A., and K. Hashimoto. 1976. Electron microscopy study of experimental enteric adenovirus infection in mice. Infect. Immun. 13:569-580.
 640. Tamura, Y., S. Suzuki, and T. Sawada. 1992. Role of elastase as a virulence factor in experimental *Pseudomonas aeruginosa* infection in mice. Microb. Pathog. 12:237-244.
 641. Tanabayashi, K., and R. W. Compans. 1996. Functional interaction of paramyxovirus glycoproteins: identification of a domain in Sendai virus HN which promotes cell fusion. J. Virol. 70:6112-6118.
 642. Tang, H. B., E. DiMango, R. Bryan, M. Gambello, B. H. Iglewski, J. B. Goldberg, and A. Prince. 1996. Contribution of specific *Pseudomonas aeruginosa* virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection. Infect. Immun. 64:37-43.
 643. Tashiro, M., Y. Beppu, K. Sakai, and H. Kido. 1996. Inhibitory effect of pulmonary surfactant on Sendai virus infection in rat lungs. Arch. Virol. 141:1571-1577.

644. Thale, R., U. Szepan, H. Hengel, G. Geginat, P. Lucin, and U. H. Koszinowski. 1995. Identification of the mouse cytomegalovirus genomic region affecting major histocompatibility complex class I molecule transport. *J. Virol.* **69**:6098–6105.
645. Theiss, J. C., G. D. Stoner, and A. K. Kniazeff. 1978. Effect of reovirus infection on pulmonary tumor response to urethane in strain A mice. *J. Natl. Cancer Inst.* **61**:131–134.
646. Thorns, C. J., C. Turcotte, C. G. Gemmell, and M. J. Woodward. 1996. Studies into the role of the SEF14 fimbrial antigen in the pathogenesis of *Salmonella enteritidis*. *Microb. Pathog.* **20**:235–246.
647. Thouless, M. E., R. F. DiGiacomo, and B. J. Deeb. 1996. The effect of combined rotavirus and *Escherichia coli* infections in rabbits. *Lab. Anim. Sci.* **46**:381–385.
648. Thulin, J. D., M. S. Kuhlenschmidt, and H. B. Gelberg. 1991. Development, characterization, and utilization of an intestinal xenograft model for infectious disease research. *Lab. Invest.* **65**:719–731.
649. Thulin, J. D., M. S. Kuhlenschmidt, M. D. Rolsma, W. L. Current, and H. B. Gelberg. 1994. An intestinal xenograft model for *Cryptosporidium parvum* infection. *Infect. Immun.* **62**:329–331.
650. Thunert, A., L. C. Jonas, S. Rehm, and E. Sickel. 1985. Transmission and course of Tyzzer's disease in euthymic and thymus aplastic nude Han:RNU rats. *Z. Versuchstierk.* **27**:241–248.
651. Tino, M. J., and J. R. Wright. 1996. Surfactant protein A stimulates phagocytosis of specific pulmonary pathogens by alveolar macrophages. *Am. J. Physiol.* **270**:L677–L688.
652. Tishon, A., A. Salmi, R. Ahmed, and M. B. Oldstone. 1991. Role of viral strains and host genes in determining levels of immune complexes in a model system: implications for HIV infection. *AIDS Res. Hum. Retroviruses* **7**:963–969.
653. Toka, F. N., I. S. De Faundez, M. Gierynska, and M. G. Niemialowski. 1996. The cytosolic free Ca²⁺ in ectromelia (mousepox) virus stimulated cytotoxic T lymphocytes. *Viral Immunol.* **9**:159–167.
654. Tomita, N., R. Morishita, J. Higaki, S. Tomita, M. Aoki, T. Ogihara, and Y. Kaneda. 1996. In vivo gene transfer of insulin gene into neonatal rats by the HVJ-liposome method resulted in sustained transgene expression. *Gene Ther.* **3**:477–482.
655. Torres-Rodriguez, J. M., M. A. Dronza, J. Rossell, and N. Madrenys. 1992. Incidence of dermatophytoses in rabbit farms in Catalonia, Spain, and its repercussion on human health. *Eur. J. Epidemiol.* **8**:326–329.
656. Toth, L. A., and J. M. Krueger. 1990. Somnogenic, pyrogenic, and hematologic effects of experimental pasteurellosis in rabbits. *Am. J. Physiol.* **258**:R536–R542.
657. Tripp, R. A., S. Hou, A. McMickle, J. Houston, and P. C. Doherty. 1995. Recruitment and proliferation of CD8+ T cells in respiratory virus infections. *J. Immunol.* **154**:6013–6021.
658. Tropea, F., L. Troiano, D. Monti, E. Lovato, W. Malorni, G. Rainaldi, P. Mattana, G. Viscomi, M. C. Ingletti, M. Portolani, et al. 1995. Sendai virus and herpes virus type 1 induce apoptosis in human peripheral blood mononuclear cells. *Exp. Cell Res.* **218**:63–70.
659. Tsuchimori, N., R. Hayashi, A. Shino, T. Yamazaki, and K. Okonogi. 1994. *Enterococcus faecalis* aggravates pyelonephritis caused by *Pseudomonas aeruginosa* in experimental ascending mixed urinary tract infection in mice. *Infect. Immun.* **62**:4534–4541.
660. Tsunoda, I., and R. S. Fujinami. 1996. Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. *J. Neuropathol. Exp. Neurol.* **55**:673–686.
661. Tsutsui, Y. 1995. Developmental disorders of the mouse brain induced by murine cytomegalovirus: animal models for congenital cytomegalovirus infection. *Pathol. Int.* **45**:91–102.
662. Tsutsui, Y., A. Kashiwai, N. Kawamura, S. Aiba-Masago, and I. Kosugi. 1995. Prolonged infection of mouse brain neurons with murine cytomegalovirus after pre- and perinatal infection. *Arch. Virol.* **140**:1725–1736.
663. Tucek, C. L., C. Desaynard, and M. Papiernik. 1993. A kinetic study on the deletion of thymic, peripheral, and gut-associated V beta 6+ T cells in an Mls-1b BALB/c colony infected with an exogenous mouse mammary tumor virus. *J. Immunol.* **151**:759–766.
664. Turinsky, J., B. P. Bayly, and D. M. O'Sullivan. 1991. 1,2-Diacylglycerol and ceramide levels in rat liver and skeletal muscle in vivo. *Am. J. Physiol.* **261**:E620–E627.
665. Tyler, K. L., M. A. Mann, B. N. Fields, and H. W. Virgin IV. 1993. Protective anti-reovirus monoclonal antibodies and their effects on viral pathogenesis. *J. Virol.* **67**:3446–3453.
666. Uetsuka, K., H. Nakayama, and N. Goto. 1996. Hepatitogenicity of three plaque purified variants of hepatotropic mouse hepatitis virus, MHV-2 in athymic nude mice. *Exp. Anim.* **45**:183–187.
667. Uhlir, J. 1991. Humoral and cellular immune response to *Psoroptes cuniculi*, the rabbit scab mite. *Vet. Parasitol.* **40**:325–334.
668. Uhlir, J. 1993. Isolation and partial characterization of an immunogen from the mite, *Psoroptes cuniculi*. *Vet. Parasitol.* **45**:307–317.
669. Umehara, K., M. Hirakawa, and K. Hashimoto. 1984. Fluctuation of antiviral resistance in the intestinal tracts of nude mice infected with a mouse adenovirus. *Microbiol. Immunol.* **28**:679–690.
670. Urano, T., K. Noguchi, G. Jiang, and K. Tsukumi. 1995. Survey of *Pseudomonas aeruginosa* contamination in human beings and laboratory animals. *AADE Ed. J.* **44**:233–239.
671. Utermohlen, O., A. Dangel, A. Tarnok, and F. Lehmann-Grube. 1996. Modulation by gamma interferon of antiviral cell-mediated immune responses in vivo. *J. Virol.* **70**:1521–1526.
672. Utsumi, K., T. Maeda, H. Tatsumi, and K. Fujiwara. 1978. Some clinical and epizootiological observations of infectious sialoadenitis in rats. *Exp. Anim.* **27**:283–287.
673. Utsumi, K., K. Maeda, Y. Yokota, S. Fukagawa, and K. Fujiwara. 1991. Reproductive disorders in female rats infected with sialodacryoadenitis virus. *Jikken Dobutsu* **40**:361–365.
674. Vacha, J., V. Znojil, M. Pospisil, J. Hola, and I. Pipalova. 1994. Microcytic anemia and changes in ferrokinetics as late after-effects of glucan administration in murine hepatitis virus-infected C57BL/10ScSnPh mice. *Int. J. Immunopharmacol.* **16**:51–60.
675. Vail, E. L., and G. F. Auguston. 1943. A new ectoparasite (Acarina: Cheyletidae) from domestic rabbits. *J. Parasitol.* **29**:419–421.
676. Van Arman, G. G., and W. C. Campbell. 1975. Anti-inflammatory activity of thiabendazole and its relation to parasitic disease. *Texas Rep. Biol. Med.* **33**:303–311.
677. Van den Dobbelen, G. P., K. Brunekreef, H. Kroes, N. van Rooijen, and E. P. van Rees. 1993. Enhanced triggering of mucosal immune responses by reducing splenic phagocytic functions. *Eur. J. Immunol.* **23**:1488–1493.
678. Van der Poll, T., A. Marchant, C. V. Keogh, M. Goldman, and S. F. Lowry. 1996. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. *J. Infect. Dis.* **174**:994–1000.
679. Van der Veen, J., and A. Mes. 1973. Experimental infection with mouse adenovirus in adult mice. *Arch. Gesamte Virusforsch.* **42**:235–241.
680. Van Nie, R., and J. Hilgers. 1976. Genetic analysis of mammary tumor induction and expression of mammary tumor virus antigen in hormone-treated ovariectomized GR mice. *J. Natl. Cancer Inst.* **56**:27–32.
681. Van Ogtrop, M. L., H. F. Guiot, H. Mattie, and R. van Furth. 1991. Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins. *Antimicrob. Agents Chemother.* **35**:976–982.
682. Varga, I. 1982. Large-scale management systems and parasite populations: coccidia in rabbits. *Vet. Parasitol.* **11**:69–84.
683. Venkatesan, P., R. G. Finch, and D. Wakelin. 1993. MHC haplotype influences primary *Giardia muris* infections in H-2 congenic strains of mice. *Int. J. Parasitol.* **23**:661–664.
684. Venkatesan, P., R. G. Finch, and D. Wakelin. 1996. Comparison of antibody and cytokine responses to primary *Giardia muris* infection in H-2 congenic strains of mice. *Infect. Immun.* **64**:4525–4533.
685. Venkatesan, P., R. G. Finch, and D. Wakelin. 1997. A comparison of mucosal inflammatory responses to *Giardia muris* in resistant B10 and susceptible BALB/c mice. *Parasite Immunol.* **19**:137–143.
686. Verleye, M., I. Heulard, J. R. Stephens, R. H. Levy, and J. M. Gillardin. 1995. Effects of citrulline malate on bacterial lipopolysaccharide induced endotoxemia in rats. *Arzneimittelforschung* **45**:712–715.
687. Villafuerte, R., C. Calvete, C. Gortazar, and S. Moreno. 1994. First epizootic of rabbit hemorrhagic disease in free living populations of *Oryctolagus cuniculus* at Doñana National Park, Spain. *J. Wildl. Dis.* **30**:176–179.
688. Virgin, H. W., IV, M. A. Mann, and K. L. Tyler. 1994. Protective antibodies inhibit reovirus internalization and uncoating by intracellular proteases. *J. Virol.* **68**:6719–6729.
689. Virgin, H. W., IV, and K. L. Tyler. 1991. Role of immune cells in protection against and control of reovirus infection in neonatal mice. *J. Virol.* **65**:5157–5164.
690. Vitovec, J., and M. Pakandl. 1989. The pathogenicity of rabbit coccidium *Eimeria coecicola* Cheissin, 1947. *Folia Parasitol. (Prague)* **36**:289–293.
691. Vogels, M. T., W. M. Eling, A. Otten, and J. W. van der Meer. 1995. Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor. *Antimicrob. Agents Chemother.* **39**:1744–1747.
692. Vogels, M. T., I. J. Lindley, J. H. Curfs, W. M. Eling, and J. W. van der Meer. 1993. Effects of interleukin-8 on nonspecific resistance to infection in neutropenic and normal mice. *Antimicrob. Agents Chemother.* **37**:276–280.
693. Vogels, M. T., E. J. Mensink, K. Ye, O. C. Boerman, C. M. Verschuere, C. A. Dinarello, and J. W. van der Meer. 1994. Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection. *J. Immunol.* **153**:5772–5780.
694. Vogtsberger, L. M., H. H. Harroff, G. E. Pierce, and G. E. Wilkinson. 1986. Spontaneous dermatomycosis due to *Microsporum canis* in rabbits. *Lab. Anim. Sci.* **36**:294–297.
695. Vonderfecht, S. L., A. C. Huber, J. J. Eiden, L. C. Mader, and R. H. Yolken. 1984. Infectious diarrhea of infant rats produced by a rotavirus-like agent. *J. Virol.* **52**:94–98.
696. Vonderfecht, S. L., and J. K. Schemmer. 1993. Purification of the IDIR strain of group B rotavirus and identification of viral structural proteins. *Virology* **194**:277–283.
697. Waggle, K. S., C. T. Hansen, J. R. Ganaway, and T. S. Spencer. 1981. A

- study of mouse strain susceptibility to *Bacillus piliformis* (Tyzzer's disease): the association of B-cell function and resistance. *Lab. Anim. Sci.* **31**:139–142.
698. Wajjwalku, W., M. Takahashi, O. Miyaishi, J. Lu, K. Sakata, T. Yokoi, S. Saga, M. Imai, M. Matsuyama, and M. Hoshino. 1991. Tissue distribution of mouse mammary tumor virus (MMTV) antigens and new endogenous MMTV loci in Japanese laboratory mouse strains. *Jpn. J. Cancer Res.* **82**:1413–1420.
699. Walmrath, D., M. Scharmann, R. Konig, J. Pilch, F. Grimminger, and W. Seeger. 1993. Staphylococcal alpha-toxin induced ventilation-perfusion mismatch in isolated blood-free perfused rabbit lungs. *J. Appl. Physiol.* **74**:1972–1980.
700. Wang, J. S., and S. F. Tsai. 1991. Prevalence and pathological study on rabbit hepatic coccidiosis in Taiwan. *Proc. Natl. Sci. Council. Repub. China Part B* **15**:240–243.
701. Wang, S. D., K. J. Huang, Y. S. Lin, and H. Y. Lei. 1994. Sepsis-induced apoptosis of the thymocytes in mice. *J. Immunol.* **152**:5014–5021.
702. Wang, X., S. B. Jones, Z. Zhou, C. Han, and R. R. Fiscus. 1992. Calcitonin gene-related peptide (CGRP) and neuropeptide Y (NPY) levels are elevated in plasma and decreased in vena cava during endotoxin shock in the rat. *Circ. Shock* **36**:21–30.
703. Wang, Y., M. Burnier, B. Detrick, and J. J. Hooks. 1996. Genetic predisposition to coronavirus-induced retinal disease. *Investig. Ophthalmol. Visual Sci.* **37**:250–254.
704. Ward, J. M., M. R. Anver, D. C. Haines, J. M. Melhorn, P. Gorelick, L. Yan, and J. G. Fox. 1996. Inflammatory large bowel disease in immunodeficient mice naturally infected with *Helicobacter hepaticus*. *Lab. Anim. Sci.* **46**:15–20.
705. Ward, J. M., R. E. Benveniste, C. H. Fox, J. K. Battles, M. A. Gonda, and J. G. Tully. 1996. Autoimmunity in chronic active *Helicobacter hepaticus* of mice. Serum antibodies and expression of heat shock protein 70 in liver. *Am. J. Pathol.* **148**:509–517.
706. Ward, J. M., J. G. Fox, M. R. Anver, D. C. Haines, C. V. George, M. J. Collins, Jr., P. L. Gorelick, K. Nagashima, M. A. Gonda, R. V. Gilden, J. G. Tully, R. J. Russell, R. E. Benveniste, B. J. Paster, F. E. Dewhirst, J. C. Donovan, L. M. Anderson, and J. M. Rice. 1994. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel *Helicobacter* species. *J. Natl. Cancer Inst.* **86**:1222–1227.
707. Ward, R. L. 1996. Mechanisms of protection against rotavirus in humans and mice. *J. Infect. Dis.* **174**:S51–S58.
708. Watanaba, H. 1992. Study on lymphocyte-response in early stage of respiratory infection—a view point from experimental *Klebsiella pneumoniae* pneumonia. *Kansenshogaku Zasshi* **66**:696–708. (In Japanese.)
709. Watson, D. A., D. M. Musher, and J. Verhoef. 1995. Pneumococcal virulence factors and host immune responses to them. *Eur. J. Clin. Microbiol. Infect. Dis.* **14**:479–490.
710. Watson, G. L., and M. G. Evans. 1985. Listeriosis in a rabbit. *Vet. Pathol.* **22**:191–193.
711. Wei, Q., M. Tsuji, T. Takahashi, C. Ishihara, and T. Itoh. 1995. Taxonomic status of CAR bacillus based on the small subunit ribosomal RNA sequences. *Chin. Med. Sci. J.* **10**:195–198.
712. Weinberg, G. A., and P. J. Durant. 1994. Genetic diversity of *Pneumocystis carinii* derived from infected rats, mice, ferrets, and cell cultures. *J. Eukaryot. Microbiol.* **41**:223–228.
713. Weisbroth, S. H. 1979. Bacterial and mycotic diseases, p. 193–241. In H. J. Baker, J. R. Lindsey, and S. H. Weisbroth (eds.). *The laboratory rat*, vol. I. Academic Press, Inc., New York, N.Y.
714. Weisbroth, S. H. 1996. Post-indigenous disease: changing concepts of disease in laboratory rodents. *Lab. Anim.* **25**:25–33.
715. Weisbroth, S. H., and S. Scher. 1968. *Corynebacterium kutscheri* infection in the mouse. I. Report of an outbreak, bacteriology, and pathology of spontaneous infections. *Lab. Anim. Care* **18**:451–458.
716. Weisbroth, S. H., and S. Scher. 1970. Spontaneous oral papillomatosis in rabbits. *J. Am. Vet. Med. Assoc.* **157**:1940–1944.
717. Weiss, L. M., A. Cali, E. Levee, D. LaPlace, H. Tanowitz, D. Simon, and M. Wittner. 1992. Diagnosis of *Encephalitozoon cuniculi* infection by western blot and the use of cross-reactive antigens for the possible detection of microsporidiosis in humans. *Am. J. Trop. Med. Hyg.* **47**:456–462.
718. Welsh, R. M., C. L. O'Donnell, and L. D. Shultz. 1994. Antiviral activity of NK 1.1+ natural killer cells in C57BL/6 scid mice infected with murine cytomegalovirus. *Nat. Immun.* **13**:239–245.
719. Wesonga, H. O., and M. Munda. 1992. Rabbit encephalitozoonosis in Kenya. *Lab. Anim.* **26**:219–221.
720. Whitehouse, A., M. P. France, S. E. Pope, J. E. Lloyd, and R. C. Ratcliffe. 1993. *Spiroplasma muris* in laboratory mice. *Aust. Vet. J.* **70**:193.
721. Wicher, V., R. E. Baughn, C. Fuentealba, J. A. Shaddock, F. Abbruscato, and K. Wicher. 1991. Enteric infection with an obligate intracellular parasite, *Encephalitozoon cuniculi*, in an experimental model. *Infect. Immun.* **59**:2225–2231.
722. Wickham, L. A., Z. Huang, R. W. Lambert, and D. A. Sullivan. 1994. Sialodacryoadenitis virus infection of rat lacrimal gland acinar cells. *Adv. Exp. Med. Biol.* **350P**:193–196.
723. Wijburg, O. L., M. H. Heemskerk, A. Sanders, C. J. Boog, and N. Van Rooijen. 1996. Role of virus-specific CD4+ cytotoxic T cells in recovery from mouse hepatitis virus infection. *Immunology* **87**:34–41.
724. Wilberz, S., H. J. Partke, F. Dagnaes-Hansen, and L. Herberg. 1991. Persistent MHV (mouse hepatitis virus) infection reduces the incidence of diabetes mellitus in non-obese diabetic mice. *Diabetologia* **34**:2–5.
725. Williams, M. D., J. R. Wright, K. L. March, and W. J. Martin II. 1996. Human surfactant protein A enhances attachment of *Pneumocystis carinii* to rat alveolar macrophages. *Am. J. Respir. Cell. Mol. Biol.* **14**:232–238.
726. Willoughby, R. E. 1993. Rotaviruses preferentially bind O-linked sialylglycoconjugates and sialomucins. *Glycobiology* **3**:437–445.
727. Winkelstein, J. A., and A. J. Swift. 1975. Host defense against the pneumococcus in T-lymphocyte deficient, nude mice. *Infect. Immun.* **12**:1222–1223.
728. Winter, J. B., A. S. Gouw, M. Groen, C. Wildevuur, and J. Prop. 1994. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. *Transplantation* **57**:418–422.
729. Wirblich, C., G. Meyers, V. F. Ohlinger, L. Capucci, U. Eskens, B. Haas, and H. J. Thiel. 1994. European brown hare syndrome virus: relationship to rabbit hemorrhagic disease virus and other caliciviruses. *J. Virol.* **68**:5164–5173.
730. Witthaut, R., A. Farhood, C. W. Smith, and H. Jaeschke. 1994. Complement and tumor necrosis factor-alpha contribute to Mac-1 (CD11b/CD18) up-regulation and systemic neutrophil activation during endotoxemia in vivo. *J. Leukocyte Biol.* **55**:105–111.
731. Wolfer, J., B. Grahn, B. Wilcock, and D. Percy. 1993. Phacoclastic uveitis in the rabbit. *Prog. Vet. Comp. Ophthalmol.* **3**:92–97.
732. Wood, B. A., W. Dutz, and S. S. Cross. 1981. Neonatal infection with mouse thymic virus: Spleen and lymph node necrosis. *J. Gen. Virol.* **57**:139–147.
733. Wood, W. B., Jr. 1941. Studies on the mechanisms of recovery in pneumococcal pneumonia. I. The action of type specific antibody upon the pulmonary lesion of experimental pneumonia. *J. Exp. Med.* **73**:201–222.
734. Wrona, T., and J. P. Dudley. 1996. Major histocompatibility complex class II I-E-independent transmission of C3H mouse mammary tumor virus. *J. Virol.* **70**:1246–1249.
735. Xu, L., T. J. Wrona, and J. P. Dudley. 1996. Exogenous mouse mammary tumor virus (MMTV) infection induces endogenous MMTV sag expression. *Virology* **215**:113–123.
736. Yamaguchi, T., and H. Yamada. 1991. Role of mechanical injury on airway surface in the pathogenesis of *Pseudomonas aeruginosa*. *Am. Rev. Respir. Dis.* **144**:1147–1152.
737. Yamawaki, I., P. Geppetti, C. Bertrand, B. Chan, P. Massion, G. Piedimonte, and J. A. Nadel. 1995. Viral infection potentiates the increase in airway blood flow produced by substance P. *J. Appl. Physiol.* **79**:398–404.
738. Yokochi, T., Y. Fujii, I. Nakashima, J. Asai, M. Kiuchi, K. Kojima, and N. Kato. 1993. A murine model of experimental autoimmune lens-induced uveitis using *Klebsiella* O3 lipopolysaccharide as a potent immunological adjuvant. *Int. J. Exp. Pathol.* **74**:573–582.
739. Yolken, R. H., C. Ojeh, I. A. Khatri, U. Sajjan, and J. F. Forstner. 1994. Intestinal mucins inhibit rotavirus replication in an oligosaccharide-dependent manner. *J. Infect. Dis.* **169**:1002–1006.
740. Yoneda, K., and P. D. Walzer. 1981. Mechanism of pulmonary alveolar injury in experimental *Pneumocystis carinii* pneumonia in the rat. *Br. J. Exp. Pathol.* **62**:339–346.
741. Yonemitsu, Y., Y. Kaneda, R. Morishita, K. Nakagawa, Y. Nakashima, and K. Sueishi. 1996. Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. *Lab. Invest.* **75**:313–323.
742. York, I. A., and J. Thorsen. 1992. Evaluation of a subunit vaccine for bovine adenovirus type 3. *Am. J. Vet. Res.* **53**:180–183.
743. Yoshihara, S., B. Chan, I. Yamawaki, P. Geppetti, F. L. Ricciardolo, P. P. Massion, and J. A. Nadel. 1995. Plasma extravasation in the rat trachea induced by cold air is mediated by tachykinin release from sensory nerves. *Am. J. Respir. Crit. Care Med.* **151**:1011–1017.
744. Yoshimoto, T., H. Nagase, H. Nakano, A. Matsuzawa, and H. Nariuchi. 1996. Deletion of CD4+ T cells by mouse mammary tumor virus (FM) superantigen with broad specificity of T cell receptor beta-chain variable region. *Virology* **223**:387–391.
745. Zaidman, G. W., P. Coudron, and J. Piro. 1990. *Listeria monocytogenes* keratitis. *Am. J. Ophthalmol.* **109**:334–339.
746. Zeligs, B. J., J. D. Zeligs, and J. A. Bellanti. 1986. Functional and ultrastructural changes in alveolar macrophages from rabbits colonized with *Bordetella bronchiseptica*. *Infect. Immun.* **53**:702–706.
747. Zhang, S., H. S. Lillehoj, and M. D. Ruff. 1995. In vivo role of tumor necrosis-like factor in *Eimeria tenella* infection. *Avian Dis.* **39**:859–866.